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ABSTRACT
Glucocorticoids (GCs) regulate many physiological systems in the body and have potent
immunosuppressive and anti-inflammatory properties. In children prolonged
administration causes a reduction in growth, which is in part due to the direct effects they
have on the growth plate. This effect is dependent on the dose, duration and type of GCs
used.
This thesis consists of four major types of studies each utilising different models of
growth and chondrocyte biology, which in combination strengthens the understanding of
the effects of GC and growth factors on the growing skeleton.
The initial in vivo study showed that in children treated with Dexamethasone (Dex) or
Prednisolone (Pred) for Acute Lymphoblastic Leukaemia, the effects of Dex on body
composition were more apparent in that it was up to 18 times more potent at reducing
short term linear growth than Pred.
The ATDC5 chondrocyte cell line was fully characterised, which allowed a unique
opportunity to study GC effects on a homogeneous population of chondrocytes at the
chondrogenesis and terminal differentiation phases. The GCs caused a reduction in cell
number, cell proliferation and proteoglycan content whilst stimulating chondrocyte
differentiation. These effects were dose dependent and only observed during the
chondrogenesis phase when the cells are rapidly dividing. Furthermore these negative
effects could be partially reversed with the use of a GC receptor antagonist and completely
reversed with IGF-I.
These observations were further translated into increasingly physiological models of bone
growth. Foetal mouse metatarsal organ explants, where the three dimensional structure
and cell connections of the growing bone remain intact, again demonstrated that Dex and
IGF-I had opposite effects on bone growth. The length of the metatarsals at day 10 from
harvesting day length in the control, Dex and IGF-I bones was 50% ± 3, 42% ± 2,
xv
(p<0.05) 99.3% ± 5(p<0.05) respectively. In contrast to Dex the effects of IGF-I were
immediate. Most importantly, it was demonstrated for the first time in vitro that IGF-I
increased the size of the hypertrophic zone, as occurs in vivo, and this accounted for most
of the increase in metatarsal length.
Prenatal administration of Dex caused a reduction in birth weight and length and this
difference was greater in the female mice. The growth restriction was associated with
elevated IGF-I and IGFBP-2 levels raising the possibility of a state of IGF-I insensitivity,
which may explain subsequent growth failure.
In conclusion, this thesis translated the clinical observation that Dex is more potent than
Pred at inhibiting linear growth and these effects are dependent on the dose and duration
of the GC exposure as well as the chondrocyte phenotype. These negative effects of GC
can be reversed by IGF-I administration.
xvi
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1.1 BACKGROUND TO THESIS
Glucocorticoids (GC) are used extensively in many childhood diseases, including
autoimmune and inflammatory conditions. It is estimated that 10% of children may
require some form of GC treatment during childhood (Warner, 1995). Their use has
undoubtedly led to improved survival of children with a number of chronic and life
threatening illnesses, albeit at the expense of adverse growth and skeletal development.
Children are prone to all the systemic effects of GC but additionally also show a
retardation in linear growth attributed to the effect of GC on the chondrocytes within the
growth plate. This is likely to be due to systemic, autocrine and paracrine effects.
1.2 BONE BIOLOGY
1.2.1 Bone
The word skeleton derives from the Greek word meaning 'dried up body', it is composed
of bones, cartilages, joints and ligaments accounting for 20% of the body mass. As well as
performing a vital role in body support, which is essential for locomotion it protects vital
organs such as the heart, lungs and brain and acts as a reservoir for minerals such as
calcium and phosphate that are made available for physiological requirements or
pathological disturbances. Bone is a complex tissue made up of living cells enmeshed in a
mineralised collagenous rich matrix. The inorganic mineral provides strength and resists
compression whereas the organic collagen fibres withstand tension and torsion
(Farquharson, 2003) such that the tensile strength of bone approaches that of cast iron, and
its capacity to absorb and release energy is twice that of oak, yet the weight of bone is
only one third that of steel (Martin & Burr, 1989). The bone marrow that lies within the




Most long bones have the same general structure. The diaphysis or shaft constitutes the
long axis of bone. This is constructed of a thick collar of compact bone surrounding the
medullary cavity. The ends of the diaphysis are expanded and termed the metaphysis and
in turn these are flanked by the proximal and distal epiphyses, which are the cartilaginous
portions of bone that ossify at puberty.
1.2.2 Bone Cells
There are three distinct type of cells found within bone: 1) the Osteoblasts which
synthesise and regulate the deposition and mineralisation of the extracellular matrix of
bone. These cells have a life span of up to 8 weeks in humans, during which time they lay
down osteoid; this includes proteoglycans, glycoproteins and collagen fibres. Eventually
they become trapped in their own calcified matrix, changing their phenotype and
developing into osteocytes. 2) Osteocytes, account for 90% of all cells in the adult
skeleton and although derived from osteoblasts are distinctly different in function. They
are regularly placed within the mineralised matrix and are connected with each other via
long slender cell processes, which provide much of the support network for the bones. 3)
Osteoclasts are derived from haematopoietic stem cells and their main feature is the
ability to absorb mineralised bone and cartilage. Osteoblasts and osteoclasts are involved
in the complex process of bone remodelling whereby old bone is replaced by newly
formed bone, thus allowing the bones to respond to and adapt to mechanical stresses and
repair any microdamage. It is estimated that it may take 4 to 5 years for bones to remodel
completely (Ott, 1996).
1.2.3 Bone Growth
Bones grow in two directions; through a cartilage template to increase their length
(longitudinal or endochondral growth), and through the formation of new bone on the
3
Chapter one Introduction
outer surfaces of existing bone to increase their width (appositional growth). This work
will focus on the endochondral process as it provides for the elongation of most of the
skeletal mass during growth and is ultimately connected with overall body growth.
The mechanisms of long bone growth are similar across many animal species. There are,
however, major variations in the growth rate between similar bones of different species,
bones of an individual animal and of the two growth plates within the same bone.
1.2,4 Embryonic Bone
Embryonic bone formation occurs through two distinct processes. Intramembranous
growth results in the formation of flat bones such as the cranium, mandible and scapula
whereas the process of endochondral growth accounts for the formation of long bones,
such as the tibia, femur and humerus.
Long bones of the skeleton first appear as limb buds and the earliest observable
morphological event in this process (between 10.5 and 12.5 days post-coitum in the
embryonic mouse) is the aggregation of committed, undifferentiated mesenchymal cells
into structures known as precartilage condensations. These cells differentiate into
chondrocytes and secrete extracellular matrix resulting in the formation of a cartilaginous
template of the future bone. Concomitant with this, other mesenchymal cells at the
periphery of the template differentiate to form a perichondrial sheath (Fig 1.1). This
primary bone collar is penetrated by blood vessels that gain access to the underlying
cartilage template, bringing elements that will form the bone marrow together with
osteoclasts that erode the internal calcified cartilage (Howell & Dean, 1992). Osteoclastic
resorption continues towards both ends of the template forming the primary ossification
centre with osteoblasts replacing the eroded cartilage with new lamellar bone. Around
birth in mammals a secondary ossification centre develops in the cartilage of the
epiphyseal region and a transverse flat disc of cartilage situated between the two centres of
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ossification forms the epiphyseal growth plate and assumes the specialised function of
elongation and growth during postnatal bone formation (Farquharson, 2003) (Fig 1.1).
1.2.5 Endochondral ossification
Longitudinal bone growth is a multistep process whereby the chondrocyte stem cells at the
ends of the long bones undergo an orderly series of events resulting in proliferation,
differentiation, hypertrophy and finally mineralisation, leading to the replacement of the
cartilage by bone. Undifferentiated progenitors within the reserve stem cell zone
differentiate into chondrocytes and progress through a proliferative phase. In the
proliferative zone, the cells have a flattened, oblate shape (Fig l.lf). Immediately after the
cessation of cell division the cells change to a spherical prolate form and undergo terminal
differentiation into hypertrophic chondrocytes, (Breur et al, 1994) where the chondrocytes
become more voluminous with increases in rough endoplasmic reticulum and Golgi
apparatus, reflecting increased matrix production (Buckwalter et al, 1986) (Fig l.lf).
Associated with this hypertrophic phenotype are increased membrane alkaline
phosphatase activity (ALP) and expression of collagen type X, chondrocalcin, osteonectin
and osteopontin as well as the down regulation of collagen type II expression. The volume
of hypertrophic chondrocytes is approximately 10 times larger than the volume of
proliferative chondrocytes, and chondrocyte height increases up to fivefold (in the
direction of growth) between the proliferative and hypertrophic zones (Hunziker et al,
1987). During terminal differentiation, mineralisation of the matrix surrounding the
hypertrophic chondrocytes occurs. Functionally the matrix changes to an environment
allowing vascular invasion (Buckwalter et al, 1983) and the hypertrophic chondrocytes
undergo apoptosis to leave lacunae separated by cartilaginous septae that become calcified
and form a scaffold for new bone formation. Histologically, the chondrocytes are arranged
in columns that parallel the longitudinal axis of the bone. Each column and each
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chondrocyte within a column are respectively separated by longitudinal and transverse
septa made up of a collagenous and proteoglycan rich extracellular matrix (Fig 1.1)
Consequently, the growth plate can be divided into several distinct zones containing
resting, proliferating, maturing and terminally differentiated hypertrophic chondrocytes
(Fig 1.1 g).
The contribution of individual growth plates to the growth rates of long bones varies
enormously. Human bones grow extremely slowly and the growth rate of the distal femur
has been estimated at 0.04 mm/day (Farquharson, 2003) to 0.22 mm/day in the rat and
0.39mm/day in the rabbit (Kember et al, 1976, 1983). The rate of bone growth attributed
to a specific growth plate is determined by a complex interplay of proliferative kinetics,
matrix production and hypertrophic chondrocyte enlargement (Breur et al, 1991). The
chondrocyte proliferation rate and the size of the proliferative pool correlate positively
with growth rates; cell duplication is more significant at faster rates of growth whereas
matrix synthesis is more significant at slower rates of growth. The final hypertrophic
volume and the rate of bone growth also correlate closely and have been shown to have a
positive linear relationship (Breur et al, 1991). This variation in hypertrophic cell volume
accounts for the different growth rates between species and also the different growth rates
that occur at the proximal and distal ends within the same long bone (Hunziker et al,
1987).
1.2.6 Matrix proteins
Collagen fibres are constructed primarily of fibrous proteins, which are a triple helix of
three polypeptide chains. These form strong rope like linear structures, that are insoluble
in water and very stable, thus ideally suited for providing mechanical support and tensile
strength. Whereas type I collagen is the most abundant protein in bone, collagen type II is
the principal structural protein of the growth plate cartilage. It interacts with collagen
6
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types IX and XI to form heterotypic fibrils that are distributed throughout the cartilage
matrix (Mwale et al, 2002). During chondrocyte maturation, collagen type II gene
expression decreases and the hypertrophic chondrocytes initiate the synthesis of collagen
type X - a protein unique to this cell type (Schmid & Linsenmayer, 1985). This collagen
type is a non-fibrillar, short chain collagen and it is thought to provide a structural role in
maintaining the organization and mechanical properties of the matrix (Chan & Jacenko,
1998). There are also a number of proteoglycans, of which aggrecan predominates, that
form a network that fills the space between the collagen fibrils in the matrix and non-
collagenous proteins such as osteopontin and osteonectin within the growth plate matrix
(Pacifici et al, 1990; Byers et al, 1992). As chondrocytes differentiate and hypertrophy,
simultaneous changes also occur within the extracellular matrix, furthermore the
chondrocytes must provide the correct extracellular network and establish cell-matrix
interactions to allow progressive differentiation. This observation is consistent with a
change from aggrecan to decorin and biglycan synthesis during normal chondrocyte
maturation (Bianco et al, 1990).
7
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Endochondrol bone formation: a) mesenchymal cells condense to become chondrocytes;
b) the chondrocytes proliferate and the central ones become hypertrophic c) the
perichondrial cells adjacent to the hypertrophic chondrocytes become osteoblasts and form
a bone collar. These then direct the formation of mineralised matrix and attract blood
vessels; d) formation of primary spongiosa; e) osteoblasts of the bone collar become
cortical bone, whereas those in the primary spongiosa are the precursors of trabecular
bone. Chondrocytes continue to proliferate, lengthening the bone; f) secondary
ossification centre forms through cycles of chondrocyte hypertrophy, vascular invasion
and osteoblast activity. The proliferating chondrocytes arrange themselves into orderly
columns and the haematopoetic marrow expands into the marrow space; g)
photomicrograph of a growth plate illustrating the columnar appearance of the
proliferating chondrocytes and the prolate morphology of the hypertrophic chondrocytes.
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1.2.7 Programmed cell death
The fate of the terminally differentiated hypertrophic chondrocyte is unclear. In growing
rats it has been calculated that 8 hypertrophic chondrocytes (including their associated
matrix) are eliminated from each column of cells every day (Hunziker et al, 1987).
Evidence suggests that terminally differentiated chondrocytes either re-differentiate into
bone cells (Cancedda et al, 1995), proliferate with one daughter chondrocyte dying and
the other becoming an osteoblast (Roach et al, 1995) or undergo the widely accepted route
of programmed cell death (Farnum & Wilsman, 1987; Gibson et al, 1995).
1.3 REGULATION OF GROWTH
Longitudinal bone growth is controlled by an intricate complex of systemic and local
mediators that interact to regulate the activities of the growth plate chondrocytes.
Receptors for growth hormone (GH), insulin-like-growth factor-I (IGF-I), thyroid
hormones, GCs, oestrogens and androgens have all been detected in growth plates in
various species, indicating that they may have direct effects on growth after birth. In
addition these systemic hormones may exert their effects on growth plate chondrocytes by
influencing the expression and or activity of locally acting growth factors such as Indian
hedgehog (Ihh), parathyroid hormone related peptide (PTHrP), bone morphogenetic
proteins (BMPs) and fibroblast growth factors (FGFs). Some of the important systems are
discussed in more detail below.
1.3.1 Regulation of Growth Via The GH and IGF-I axis,
a) The original somatomedin hypothesis
In 1957 Salmon & Daughaday demonstrated that GH may have indirect effects on linear
growth and proposed the 'original somatomedin hypothesis', which postulated that GH
controls growth by stimulating the liver production of a circulating substance
9
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(somatomedin), which reaches it target tissues of bone and cartilage to convey the growth
signals (Fig 1.2a). At this point somatomedin was an unknown substance, only discovered
later during studies looking at the effects of pituitary hormones on somatic growth. They
demonstrated that the hypophysectomised rats had markedly reduced radioactivity uptake
into the epiphyseal cartilage (Murphy et al, 1956) but this was reversed by in vivo
injections of purified bovine GH. However this positive effect of GH could not be
demonstrated in vitro and it was postulated that an intermediary growth factor or
endocrine hormone might be involved. This was given further credit when serum from
normal rats increased the radioactivity uptake whereas there were minimal effects from the
serum of hypophysectomised rats. Again GH treatment of hypophysectomised rats
restored the normal growth promoting activities. The term 'somatomedin' was coined to
reflect the ability of the substance to mediate the effects of GH (Daughaday et al, 1972)
and finally to IGF-I when its structure was established (Rinderknecht & Humbel, 1978).
b) The dual effector theory
The discovery that IGF-I is expressed in almost all tissues (D'Ercole et al, 1980) led to the
theory that IGF-I also had autocrine/paracrine effects. It was shown that GH
administration to hypophysectomised rats increased IGF-I expression in numerous non-
hepatic tissues and it was thought that its expression may be regulated by GH (Low et al,
1987 & 1988). Furthermore Isaksson et al (1982) demonstrated that a direct injection of
GH into the growth plates of hypophysectomised rats resulted in a significant increase in
longitudinal bone growth but no effect in the contralateral limb, thus also indicating a
local effect of GH. This was supported by the observation that GH was found to increase
IGF-I mRNA expression in growth plate chondrocytes and that the growth promoting
effects of locally administered GH was eliminated when an IGF-I antiserum was co-
infused with GH (Schlechter et al, 1986).
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This led to the proposition of the 'dual effector theory' in 1985 by Green et al who
postulated that GH had direct effects on the growth plate germinal zone to promote
chondrocyte differentiation and that GH also induces local IGF-I synthesis, which is
thought to stimulate the clonal expansion of chondrocyte columns in an
autocrine/paracrine manner (Fig 1.2b)
c) Current Theories
Recent studies have revealed a greater complexity to the endocrine GH/IGF-I system. Up
to six Insulin-like Growth Factor Binding Proteins (IGFBPs) have been identified, which
bind IGFs in the circulation, thus prolonging their half lives (Firth & Baxter, 2002). By
removing IGF-I from the circulation, they can modulate the function of IGFs in either an
inhibitory or a stimulatory manner. The endocrine role of IGF-I is still unclear as liver
specific IGF-I deletion in mice show normal growth (Yakar et al, 1999). Additionally the
relative contribution of both direct and indirect GH action on bone growth remains
uncertain. Current theories indicate that GH stimulates locally produced IGF-I to induce
growth and regulates the bound and free concentrations of IGF-I in the circulation which




Figure 1.2. The Somatomedin Hypothesis





























a) The original somatomedin hypothesis proposed
that GH from the pituitary gland controls growth by
stimulating the liver production IGF-I
(somatomedin).
b) Subsequently it was discovered that IGF-I is
expressed in most tissues and has autocrine/paracrine
effects, thus the dual effector theory proposes that
GH has direct and indirect (via IGF-I) effects on
bone growth.
c) However the situation is more complex as mice
with liver IGF-I gene deletion (IGF-I-/-) have normal
growth and development. Current theories suggest
that GH stabilises the ternary IGF binding complex
(IGFBP-3 & acid labile subunit (ALS)) that stabilises
IGF-I in serum. There is evidence to indicate that GH
stimulates locally produced IGF-I to induce growth
and regulates the bound and free concentrations of
IGF-I in the circulation. Thus the concentration of
free IGF-I may be involved in the endocrine control





IGF-II is a single chain 67 amino acid peptide that like IGF-I shares a significant
homology with insulin (Blundell & Humbel, 1980). As well as a paracrine role it is
secreted by the liver and has mitogenic and metabolic properties. Its major role appears to
be in underpinning foetal growth, with subsequent postnatal effects being less clearly
defined. All of its actions are mediated through the IGF-I receptor, with no signal
transduction through the IGF-II receptor (Czech, 1989). However the IGF-II receptor
plays an important role in the degradation of IGF-II. Inactivation of IGF-II-R expression
in mice by gene targeting results in foetal overgrowth, skeletal abnormalities and perinatal
death due to the overexposure of foetuses to IGF-II (Lau et al, 1994; Ludwig et al, 1996).
e) IGFBPs
Although IGF-I and IGF-II are important regulators of growth and metabolism their action
is positively or negatively regulated by up to six IGFBPs. The IGFBPs comprise a family
of 6 related proteins that interact with high affinity with IGF-I and compete with IGF-I
receptors for their binding and thus influence mitogenesis, differentiation and cell survival
(Firth et al, 2002). They were initially identified as carrier proteins for IGF-I and IGF-II
activity. Their presumed function was to protect IGF peptides from degradation and
clearance, increase the half life of the IGFs and deliver them to appropriate tissue
receptors. However it is now apparent that they have IGF-I dependent and independent
actions on cell growth (Firth et al, 2002; Ferry et al, 1999).
In the circulation the IGFs are present in a complex of 150kDa, composed of one molecule
of IGF-I or II, a 85kDa acid-labile subunit (ALS), and IGFBP-3. A smaller proportion of
the IGFs are associated with other IGFBPs and less than 1% is found in free form
(Rajaram et al, 1997).
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The precise role of individual IGFBPs is still unknown due to their complexity of actions
and their regulation but they are expressed in a tissue specific manner and have different
affinities for the IGFs. IGFBP-1 in particular inhibits IGF-I dependent cell growth and
differentiation and is involved in reproduction, foetal growth and brain development.
1GFBP-2 is the second most abundant binding protein in the circulation and also appears
to inhibit the action of IGF-I. Overexpression of IGFBP-3 leads to organomegaly, while
IGFBP-4 is most abundant in bones. IGFBP-6 is distinct as it has a preferential affinity for
IGF-II. (Schnieder et al, 2000). In reality the full interactions of these high affinity
IGFBPs and their modulation of the IGF dependent and independent effects remains to be
fully unravelled. An additional layer of complexity exists with the reporting of at least
four low affinity IGF binders - termed IGFBP related proteins (IGFBP-rP) (Baxter et al,
1998).
f) Prenatal and postnatal growth
Variation in human foetal growth occurs from around 16 weeks gestation. Excluding
chromosomal and genetic disorders, the dominant cause of growth retardation in mid and
late gestation relates to a diminished supply of nutrients or oxygen whereas the genetic
differences in body size are almost entirely related to maternal factors (Gluckman & Pinal
2003; Gluckman, 1986; Robson, 1978).
IGF-I and II levels increase longitudinally throughout pregnancy (Gohlke et al, 2004).
IGF-II is more important for embryonic growth, while IGF-I is the dominant foetal growth
regulator in late gestation. In contrast to the postnatal situation, GF1 has little effects on
IGF-I regulation as the GH receptors (GHR) are only expressed at very low levels in the
foetal tissues (Oliver et al, 1996). Insulin has a major effect on growth and size at birth,
predominantly during the third trimester when it stimulates foetal lipogenic activity,
including a rapid accumulation of adipose tissue (Lifshitz & Botero, 2003). None the less
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its somatogenic actions are also mediated through stimulating IGF-I release (Fowden et al,
1989). The IGF-I gene appears to be more responsive to nutritional change and thus the
foetal IGF-I system is more sensitive to nutrient restriction than IGF-II. (Fowden et al,
1989) Similarly asphyxia also leads to a cessation of foetal growth and is associated with
a fall in foetal IGF-I levels and altered IGFBPs (Bennet et al, 2001).
After birth the infant shifts from a growth rate that is predominantly determined by
maternal factors to one that is increasingly related to his or her own genetic background.
During the period of early infantile growth the growth velocity is independent of the
endogenous GH, but continues to be dependent on nutrition and thyroid status. By early
childhood growth becomes dependent on GH, and at puberty the sex steroids provide the
acceleration in height velocity. However even the gonadal steroids require an intact GH.
IGF-I action for their growth promoting effects to be most effective (Grimberg & De Leon
2005).
1.3.2 Local Regulation ofGrowth
a) Parathyroid hormone and Indian Hedgehog
Parathyroid hormone (PTH) is an essential regulator of the circulating levels of calcium
and phosphate. It modulates the activities of cells in the intestine, kidney and bone. Both
PTH and a second member of the PTH family, parathyroid hormone related peptide
(PTHrP) bind and activate the common PTH/PTHrP receptor. They both cause
hypercalcaemia and hypophosphatemia but as PTHrP circulating levels are significantly
lower than PTH levels it is thought unlikely that PTHrP has any major role in maintaining
calcium homeostasis. The physiological roles for PTHrP are recognised to be numerous as
it is expressed by a wide variety of embryonic and adult tissues, and it is thought mainly to
act as an autocrine/paracrine factor. PTHrP alongside indian Hedgehog (Ihh) a paracrine
factor produced by prehypertrophic chondrocytes, promotes chondrocyte proliferation
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while inhibiting hypertrophic differentiation, a function performed as part of a negative
feedback loop. Ihh produced by prehypertrophic chondrocytes increases the expression of
PTHrP in the periarticular region. PTHrP then binds to PTH/PTHrP receptors expressed
on prehypertrophic chondrocytes (before their conversion to Ihh expressing cells) and
blocks their further differentiation. As the population of committed cells progresses to the
hypertrophic phenotype, they stop expressing Ihh, thereby attenuating the negative
feedback loop and allowing the further differentiation of uncommitted prehypertrophic
cells (Fig 1.3) (Farquharson, 2003). Mice missing the PTH/PTHrP receptor gene have a
growth plate morphology similar to that of mice that are homozygous for the ablation of
the PTHrP gene (Lanske et al, 1996) in that they show widespread accelerated
differentiation of chondrocytes and premature mineralisation resulting in a narrow growth
plate. In contrast, the phenotype of mice in which the PTHrP gene is over expressed is
characterised by a dramatic slowing down of the differentiation of chondrocytes and a
wider growth plate (Weir et al, 1996).
b) Fibroblast Growth Factors
The family of Fibroblast Growth Factors (FGFs) constitute at least 22 members that
interact with at least four FGF receptors (FGFR) and are the major regulators of
embryonic bone development (Szebenyi & Fallon 1999). FGF signalling is critical for
chondrocyte maturation and skeletal development during post-natal bone growth. They
have similar biological effects and interact with members of the FGF receptor family of
transmembrane tyrosine kinases to elicit their biological response. Both FGF-1 & 2 as
well as FGFR1, -2, and -3 are widely expressed in chondrocytes (Fig 1.3)(Jingushi et al,
1995, Peters et al 1992). Upregulation of FGF receptor signalling results in bone
abnormalities during endochondral growth, and is the basis of several genetic forms of
human dwarfism including achondroplasia, which is caused by an activating mutation of
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FGFR3 (Shiang et al, 1994). Conversely mice with an inactivating mutation of FGFR3
gene demonstrate increased longitudinal growth (Colvin et al, 1996).
c) Bone morphogenetic proteins / Transforming Growth Factor B
The family of Bone morphogenetic proteins (BMPs) is comprised of at least 15 members,
which are all part of the Transforming Growth Factor B (TGFB) superfamily. BMPs were
originally identified as important stimulators of bone formation but are now recognised as
important regulators of growth, differentiation and morphogenesis during embryology
(Reddi, 2001). The BMPs/TGFB and their receptors act as a signalling system both
dependently and independently of the Ihh/PTFIrP feedback loop at different levels during
embryonic bone formation (van der Eerden et al, 2003). However the hallmark of BMPs is
their ability to induce de novo bone formation in non-skeletal tissue of which the initial
stages are characterized by the stimulation of collagen type II and the formation of a
cartilaginous matrix (Urist, 1965). Data indicates that BMPs can regulate the complete
cascade of events in cartilage formation, which includes the differentiation of the
committed mesenchymal stem cells to the chondrocyte phenotype, their terminal
differentiation and the mineralisation of the cartilage matrix. More specifically, BMP4
and BMP6 have been implicated in mediating the effects of PTHrP in regulating the pace
of chondrocyte differentiation (Grimsrud et al, 1999; Farquharson et al, 2001).
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PTHrP is secreted from the perichondria! cells and proliferating chondrocytes, whilst Ihh
is released from the pre-hypertrophic chondrocytes. Together they stimulate proliferaton
and delay hypertrophic differentiation. Ihh also acts on perichondrial cells to convert these
into the osteoblasts of the bone collar. Growth plates of gene ablated mice show a thinner
proliferating layer and normal hypertrophic layer, suggesting that in the absence of PTHrP
differentiation is accelerated so chondrocytes undergo premature hypertrophy and
apoptosis. The FGFs are also involved in growth plate signalling and act to decrease
chondrocyte proliferation and to accelerate the differentiation of hypertrophic
chondrocytes into terminally differentiated chondrocytes. FGFR3 is predominantly




1.4 GH AND IGF-I RECEPTORS
1.4.1 GH Receptor
The GHR was first identified in 1987 by Leung et al, and is part of the class I cytokine
superfamily of receptors including erythropoietin, leptin and numerous interleukins
(Finidori, 2000).
Most of the pathways initiated by GH binding appear to require as a first step, the
activation of Janus Kinase 2 (Jak2), this then phosphorylates certain tyrosine residues of
the cytoplasmic domain of the receptor, and other molecules that are in the region of the
receptor-Jak2 complex. Signal transducers and activators of transcription-5 (Stat-5) play a
crucial part as an intracellular signalling molecule. In addition proliferation and gene
transcription signalling occurs via several other pathways including Ras/MAP Kinase
(mitogen activated protein), Insulin receptor substrates - IRS-l/IRS-2 and PI3-Kinase
pathways.
Growth hormone receptor knockout mice have reduced bone growth and reduction in
chondrocyte proliferation after 2 weeks of age, however this is almost completely reversed
by restoring the circulating IGF-I levels to normal indicating that GH induced postnatal
growth is probably due to an increase in circulating IGF-I levels (Sims et al, 2000).
1.4.2 IGF-I Receptor
The cellular actions of IGF-I are mediated by a receptor tyrosine kinase (IGF-IR), which
are expressed in a diverse range of tissues including chondrocytes and osteoblasts.
Binding of IGF-I to its receptor utilises a family of soluble receptors, known as insulin
receptor substrates (IRSs) to initiate a series of autophosphorylation events. Activation of
the type I IGF-I receptor (IGF-IR) on the surface of cells (De Meyts et al, 1994) leads to
intracellular signalling through two distinct signalling pathways, phosphatidylinositol 3-
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kinase (PI-3K) and p42/p44 mitogen-activated protein kinase (MAPK), leading to
proliferative and antiapoptotic effects.
Activation of PI-3K activity results in a series of intracellular downstream events, and
recruitment of other downstream signalling molecules such as Akt to the plasma
membrane. Signalling via this pathway is responsible for the cells resistance to
programmed cell death (Franke et al, 1997).
The MAPK pathway is strongly dependent on tyrosine phosphorylation steps.
Phosphorylated MAPK translocates to the nucleus where it further activates the genes
necessary for cell cycle progression and DNA replication. The activation of the ribosomal
kinase p70s6 can be a consequence of activation of both PI-3K and MAPK signalling and
represents a potential convergence point of IGF-I dependent mitogenic and antiapoptotic
signalling.
In neonatal mice IGF-IR deletion is lethal as they die of respiratory failure as well as
exhibiting severe growth retardation, delayed ossification and generalised organ
hypoplasia (Liu et al 1993).
1.5 GLUCOCORTICOIDS
1.5.1 Physiology
The adrenal cortex synthesises two classes of steroids; the corticosteroids (glucocorticoids
and mineralocorticoids) and the androgens. Glucocorticoids (GCs) influence most systems
in the body and are essential for normal function. They are secreted from the adrenal
cortex and in physiological doses, they help the body adapt to intermittent food intake by
regulating blood sugar and electrolytes, promoting gluconeogenesis, mobilising fats for
energy metabolism and depressing inflammatory and immune responses.
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Physiological GCs include Cortisol (hydorcortisone) which is the most predominant as
well as cortisone and corticosterone. Its secretion is regulated by ACTH from the pituitary,
which in turn is under the control of hypothalamic Corticotrophin Releasing Hormone
(CRH). Cortisol secretion displays a diurnal rhythm with highest levels in the morning.
Negative feedback by GC inhibits Adrenocorticotropic hormone (ACTH) secretion via
direct and indirect actions on the CRH neurons, but this feedback can be overridden in
response to stressful settings (Goodman & Gilman's, 2001).










From this structure various groups can be substituted to form synthetic compounds with
different degrees of GC or mineralocorticoid activity. Such that hydroxylation at the C16
position reduces mineralocorticoid activity, while alpha-fluoro-substitution at the C9
position increases mineralocorticoid activity.
The normal daily secretion of Cortisol is 10 - 30mg and the exogenous daily dose that
completely suppresses the cortex is 40-80mg of Hydrocortisone, or 10-20mg of
Prednisolone in adults. The relative potencies of the major steroid compounds are given










The Glucocorticoid Receptor (GCR) is a steroid hormone-activated transcriptional factor
that regulates, directly or indirectly, target genes involved in glucose homeostasis, bone
turnover, cell differentiation, lung maturation and inflammation (Reichardt et al, 2000). It
belongs to the nuclear receptor superfamily, which includes receptors for the
mineralocorticoids, oestrogens, progestins and androgens as well receptors for peroxisome
proliferators, Vitamin D and thyroid hormones.
The actions of GC are mediated at least in part via specific GCRs, which are ligand
dependent DNA-binding nuclear receptors and belong to the superfamily of
steroid/thyroid/retinoid/orphan receptors (Lazar, 1993). In 1985 the GCR was cloned by
Hollenberg et al, who described 2 forms of the human GCR, the active GCRa (777 amino
acids) and GCRB (742 amino acids). The a isoform of the GCR is expressed in
appreciable levels in all nucleated normal cells, consistent with the widespread effects of
GC on metabolism, differentiation and development. After ligand binding it is functionally
active. This is in contrast to GCRB which does not bind ligand and indeed may act as a




Like most nuclear receptors, GCR is a modular protein that is organised into three major
domains: an N-terminal activation function-1 domain (AF-1), which plays an important
part in gene regulation (Giguere et al, 1986), a central DNA binding domain, and a C-
terminal ligand binding domain (LBD). In addition to its role in ligand recognition, the
LBD contains a ligand-dependent activation function (AF-2) that is tightly regulated by
hormone binding.
In the absence of ligand, GCR is predominantly maintained in the cytoplasm as an inactive
multi-protein complex. This consists of two heat shock proteins 90 (hsp90) molecules plus
a number of other proteins including immunophilins p59 and calreticulin (Beato et al,
1996). Entry of GC into the cell and subsequent binding to the LBD of GCR leads to a
conformational change in the receptor. These associated proteins are shed on steroid
binding, allowing dimerisation and translocation of the receptor into the nucleus. Once
within the nucleus, the GCR binds DNA promoter elements known as GC response
elements to activate or repress a complex set of transcription factors depending on the
context of the target promoters (Jantzen et al, 1987; Beato et al, 1996 & 1989). In addition
GCR can also cross talk with other transcriptional factors such as nuclear factor-kB and
activator protein-1 (AP-1) to repress their gene activation activities. (McKay & Cidlowski
1999). Both the ligand-dependent activation and repression by GCR require the intact
function of the LBD. This GC mediated repression has been postulated to be a molecular
basis for the anti-inflammatory and immunosuppressive activities ofGC.
The presence of GCR has been demonstrated in human bone at different stages of life in
humans (Abu et al, 2000) as well as in mice (Masuyama et al, 1992). Mutations in the
GCR are associated with Cushings syndrome, autoimmune diseases and cancers (Werner
& Bronnegard 1996). Meanwhile GCR gene knockout studies have shown that mice
homozygous for a targeted disruption of the GC gene die within a few hours of birth due
to respiratory failure as a result of severely impaired lung development (Cole et al, 1995),
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while the few survivors have markedly elevated levels of ACTH and plasma
corticosterone.
1.5.3 Systemic Side Effects
GCs affect most systems within the body and these include; endocrine effects - Cushing
syndrome and obesity; musculoskeletal - myopathy and osteoporosis. This is partially due
to hypogonadism as the sex steroids normally contribute to maintenance of both muscle
and bone mass. Additionally steroids reduce the quality of trabecular bone resulting in an
increase fracture rate (Ralston, 1999); immune - immunosuppression; gastrointestinal -
peptic ulcer and haemorrhage; central nervous system - depression, raised intra-cranial
pressure; cataracts and delayed tissue healing, the latter due to dermal atrophy and reduced
remodelling of the skin. These systemic effects are dependent on the dose and duration of
GCs as well as the type of GC used such that Dex causes greater immunosuppression and
adrenal suppression (Hansen & Loriaux 1976; Hughes & Reid GF 1982, Kaspers et al,
1996). Unwanted effects with steroids are common with prolonged administration. These
effects may be minimised by locally acting agents such as inhalers, intra-articular injection
and topical preparations. The effects of GCs on growth and chronic disease are discussed
in more detail below.
1.5.4 Clinical uses for GC and Effect on Growth
GCs are used extensively in paediatric practice, often in the treatment of a number of
chronic inflammatory, autoimmune and neoplastic diseases. It is estimated that 10% of
children may require some form of GC at some point in their childhood (Warner 1995).
Impairment of childhood growth with an approximate cortisone dose of 1.5mg/kg/day was
first described over 40 years ago (Blodget et al, 1956). Osteopenia in children receiving a
Pred dose of less than 0.16mg/kg/day has also been reported (Avioli, 1993). The
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maintenance of growth and bone health is a complex process that can be influenced not
only by drugs, but also by the nutritional status of the patient and the underlying disease
processes.
The common clinical indications for GC and their contribution to growth problems is
summarised below.
a) Asthma, Eczema & Hayfever
The increasing incidence and prevalence of childhood atopy and the more widespread use
of inhaled steroid therapy for asthma prophylaxis probably account for the largest group of
children who are chronically exposed to steroids. Oral GC therapy in asthma is associated
with a delay in growth and puberty and there is some evidence to suggest that final height
may also be compromised (Allen et al, 1994). Systemic exposure to inhaled steroids may
be higher with metered dose inhalers and dry powder devices where 80% of the drug is
deposited in the oropharynx. Although earlier studies did not show a relationship between
inhaled steroids and growth, there is now good evidence that inhaled steroids can
temporarily slow growth and alter bone and collagen turnover. The magnitude of this
effect may be influenced by the dose delivery system as well as the systemic
bioavailability of the inhaled steroid used (Shaw et al, 1997). This effect may be most
pronounced over the first few weeks of treatment (Doull et al, 1998). Long term studies
are difficult due to a number of confounding factors including the plethora of drugs,
delivery systems, compliance and disease severity but there is no clear evidence that final
height is compromised following inhaled GC therapy in children with asthma. Some
intranasal GCs such as budesonide have a very high level of systemic absorption when
applied directly to the nasal mucosa and short and intermediate term studies of children on
intranasal steroids such as budesonide and beclomethasone also show a deterioration in
growth velocity (Edsbacker et al, 1985). Like asthma, there is some suggestion that the
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effects of these intranasal steroids may be dose dependent and that the newer forms of
intranasal steroids may not have these adverse growth effects (Pedersen, 2001).
Assessment of short-term growth during topical steroid treatment for eczema has also
been studied but the results have been up till now, inconclusive (Heuck et al, 1998).
b) Inflammatory Bowel Disease
Longitudinal studies show that the growth velocities of children in the year preceding
diagnosis are reduced and growth retardation frequently complicates the clinical course in
children (Markowitz et al, 1993). In children with inflammatory bowel disease, retardation
of growth and skeletal maturation are widely reported and may be related to disease
activity as well as to its treatment (Savage et al, 1999). Vertebral fractures have also been
described in children with Crohn's disease with a short or absent history of steroid usage
(Cowan et al, 1995, Semeao et al, 1997). A cross-sectional study of bone mineralisation
using dual energy x-ray absorptiometry showed evidence of osteopenia even when
corrected for sex, height, weight and puberty (Cowan et al, 1997). In this study, the bone
status was related to steroid usage but had no relationship to disease activity. In a
longitudinal study of 55 children, uncorrected total body bone mineral density SDS
correlated negatively to cumulative steroid dosage and positively to body mass index
(Boot et al, 1998). A reduction in bone mineral density of the lumbar spine, femoral neck
and radius may be more prominent in children with Crohn's disease and those children
who are of a pubertal or post pubertal age. The introduction of budesonide enemas for
treatment of distal colitis has also been reported to be associated with suppression of




Impaired linear growth is one of the major complications of childhood-onset chronic renal
failure and its treatment. Final height may be less than the third percentile in 50% of
children who enter end stage renal failure in childhood. Children with a history of renal
insufficiency who receive GC may grow more slowly, have a poorer bone mineralisation
status and may not respond satisfactorily to Vitamin D replacement compared to those
who do not receive GC (Chesney et al, 1998). The prolonged use ofGC is also associated
with growth failure and reduced bone mineral density in other chronic renal disease such
as nephrotic syndrome. Here it is not clear whether intermittent GC therapy over a number
of years has an adverse effect on growth and final height (Lettgen et al, 1994; Saha et al,
1998). Post transplant, the cumulative GC dosage may be inversely related to the change
in relative height, however the GC also have less inhibitory effects on growth velocity,
without compromising graft function, when given on alternate days (Schaefer et al, 1990;
Jabs et al, 1996).
d) Arthritis
GC are widely used for treating chronic connective tissue diseases in children and as with
other inflammatory conditions there is considerable overlap between the inflammatory
process and steroid induced effects on bone health. A failure to develop adequate bone
mineralisation is virtually universal in children with Juvenile Idiopathic Arthritis (JIA) and
is characterised by a failure of bone formation, with a subsequent failure to undergo the
normal increase in bone mass during puberty. These negative effects on bone may be
increased if the child was on steroids (Cassidy & Hillman 1997; Kotaniemi et al 1998).
Other studies have not shown any statistical significance of the cumulative dose of
corticosteroids on growth although they did note a reduction in the growth velocity during
the first year of treatment which was more apparent in the polyarticular group (Saha et al,
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1999). It does appear that good control of disease activity in systemic onset JIA can be
achieved by high dose alternate day Pred with minimal side effects and that GC effects
can also be reversed after lowering the dosage in other autoimmune conditions (Kimura et
al, 2000; Conti et al, 1996).
e) Acute Lymphoblastic Leukaemia
GC have been a mainstay of the therapy for children with acute lymphoblastic leukaemia
(ALL). Dex is now replacing Pred as the drug of choice because it is reported to have a
greater lymphocytotoxicity and higher CNS penetration. Recent studies have shown that
bone mineralisation status as assessed by bone mineral density, corrected as well as
uncorrected for body size, may be adversely affected at completion of treatment (Halton et
al, 1996; Arikoski et al, 1999). The fracture incidence during ALL treatment was reported
to be as high as 39% and this was confirmed by Strauss et al (2001) who have shown a 5-
year cumulative incidence of 28% for fractures and 7% for osteonecrosis with a median
follow-up of over 7 years (Halton et al, 1996; Strauss et al, 2001). Older, pubertal stage,
the male sex and Dex have been shown to be independent risk factors for fractures and
reduced bone mineralisation. Previous studies have shown alterations in bone turnover and
short-term growth of children during ALL treatment and that these changes were most
marked during periods of intensive chemotherapy and high dose systemic GC
administration (Crofiton et al, 1998; Ahmed et al, 1999).
j) Prenatal GC treatment
Newborns born small for gestational age (SGA) are at increased risk of significant health
issues in later life as it not only affects infant mortality and morbidity, but may also
predispose individuals to coronary heart disease, diabetes, hypertension and stroke in
adults (Barker et al, 1989). Traditionally Intrauterine Growth Retardation (IUGR) has
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been defined as a birthweight less than 2500g which ignores gestational age and
population factors. Therefore the term SGA corrects for gestational age and various
criteria based on centiles or standard deviations.
The foetus may be exposed to elevated levels of GC most commonly to decrease the
incidence of respiratory distress syndrome and thus improve survival in infants born
prematurely (Liggins & Howie, 1972). However there is controversy over the risk-benefit
ratio of prenatal GCs for various re-treatment strategies if preterm delivery does not occur
within one week after the initial dose. Although early postnatal GCs decrease the
incidence of bronchopulmonary dysplasia and facilitate extubation, they do have short-
term adverse effects such as gastrointestinal bleeding and perforation, hyperglycaemia,
hypertension, growth failure in the long term and an increased incidence of cerebral palsy
(Halliday et al, 2003). Prenatal GC have also been used in the deliberate suppression of
the adrenal gland in the prenatal treatment of pregnancies with a female foetus affected
with congenital adrenal hyperplasia (CAH), however there remains the potential for long
term effects (Matthews, 2000). Furthermore women with CAH on maintenance treatment
with hydrocortisone, Dex or Pred during their pregnancies may have infants with a lower
birth weight (Krone et al, 2001).
Foetal GC levels are lower than maternal levels (Beitens et al, 1973) and the foetus is
normally protected to some degree from maternal GC by the presence of the placental
barrier enzyme, 11B-HSD type 2, which catalyses the rapid metabolism of active Cortisol
to inactive cortisone (Brown et al, 1996). However this enzyme is not a complete barrier
to maternal GC (Benediktsson et al, 1997) and deficiency of this enzyme such as with
protein restriction leads to a greater exposure of maternal GCs to the developing rat
(Langley-Evans et al, 1996). Similarly mutations of the 11B-HSD gene in humans are also
associated with a very low birth weight (Dave-Sharma et al, 1998).
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1.5.5 Pathophysiology of Glucocorticoid induced growth retardation
a) Systemic Effects on growth
GCs interfere with several regulatory mechanisms all of which lead to growth retardation
(Fig 1.4). They impact on the GH/IGF-I axis; whereas short term administration of GCs
stimulate GH and IGF-I secretion (Veldhuis et al, 1992) high dose GC therapy can
attenuate the physiological GH secretion by down-regulating the ghrelin receptors leading
to decreased GH releasing hormone and thus an increase in somatostatin tone (Kaji et al,
2001). Additionally GCs reversibly impairs the GH response in stimulation tests
(Pantelakis et al, 1972; Hughes et al, 1999) and prevent the induction ofGHR and IGF-IR
expression by GH and IGF-I in chondrocytes (Jux et al, 1998), although it has been shown
that GC per se increase the GHR mRNA expression in liver, growth plate and osteoblasts
(Canalis, 1998; Heinrichs et al, 1994).
The sex hormones also exert significant effects on skeletal development. Testosterone
stimulates growth by increasing the amplitude of GH pulses as well as a direct action on
cartilage. Oestrogens have a biphasic response; at low levels they stimulate GH secretion,
IGF-I and growth and at high levels play a critical role in bone maturation and epiphyseal
fusion at puberty. GC may impair the attainment of peak bone mass and delay growth
through alterations in gonadal function at the level of the pituitary and through direct
effects on the gonads. Studies in adults show that GC therapy may be associated with
testosterone deficiency as well as reversible gonadotrophin deficiency (Kamischke et al,
1998; Sakakura et al, 1975). In vitro evidence suggests that GC impair the action of
Follicle Stimulating Hormone, thus reducing oestrogen secretion (Hsueh & Erickson,
1978). Adrenal inactivity during chronic GC exposure may also lead to reduced levels of
other sex steroids such as androstenedione and oestrogen (Crilly et al, 1978) (Fig 1.4).
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Figure 1.4. Mechanisms ofGC induced bone loss and growth retardation.
Paracrine IGF-I in growth plate









































Figure 1.5. Time course marker gene expression during differentiation of ATDC5 cells.
Total RNA was isolated on the indicated day in culture and analysed by slot blot. Values
expressed as a percent of the highest hybridisation intensity for each mRNA.
Rat type II collagen cDNA (—) Rat PTH/PTHrP receptor (—)
Human aggrecan cDNA (—■) Mouse type X collagen cDNA (—)
Initial elevation of type II collagen mRNA followed by an increase in the aggrecan
mRNA. Expression of the PTH/PTHrP receptor gene occurs in close association with
early chondrogenesis. Thereafter these three mRNA levels decline as the cells proceed to
the hypertrophic stage which is associated with an elevation of type X collagen; which is
not detected in the proliferating or undifferentiated ATDC5 cell.










Robson et al, 1998; Gabrielsson et al, 1995; Unterman & Philips, 1985). In vitro studies
indicate that Dex reduces basal chondrocyte proliferation in a dose dependent manner as
well as inhibiting the proliferative effects of GH and 1GF-I (Jux et al, 1998). While low
dose GCs are required to maintain basal GHR expression and the differentiation of cells
(Pal et al, 1992; Salles et al, 1994), high dose GC impair the actions of GH and IGF-I on
the proliferative chondrocytes. Furthermore, the GCs cause a dose dependent decrease in
GH stimulated IGF-I secretion. Jux et al showed that Dex decreases GHR mRNA content
in chondrocytes and inhibits the homologous upregulation of GHR expression (Jux et al,
1998).
Although GHR and IGF-IR expression by GH and IGF-I in chondrocytes is restricted by
GC, it has also been shown previously that GC increase GHR mRNA expression in the
liver and growth plate (Jux et al, 1998, Heinrichs et al, 1994). However, in patients treated
with GCs, serum IGF-I levels may not be altered while the bioactivity is (Caufriez &
Copinschi, 1986). This would indicate another level of control involving the IGFBPs that
may be disrupted by GC (Price et al, 1992; Smink et al, 2002).
1.6 CATCH UP GROWTH
Catch up growth (CUG) is defined as growth velocity (cm/yr) greater than the median for
chronologic age and gender (Reiter & Rosenfeld, 1998). CUG, which was first reported by
Prader et al in 1963, and is typically an early post natal process that occurs in most infants
born SGA during the first 6 months and is complete by 2 years of age (Karlberg et al,
1997). However within this group infants born premature may take longer to catch up than
the full term SGA (Hokken-Koelega et al, 1995). Approximately 10% of children born




Height is also an indicator of chronic disease in children as shown in a decreased growth
rate in children diagnosed with chronic illnesses (Markowitz et al, 1993). Frequently GCs
are used in the treatment ofmany childhood illnesses, which along with the inflammatory
process compounds the reduction in growth. However upon cessation of the insult,
including discontinuation of GC, this group of children also undergo a period of
accelerated linear growth.
Two methods for the mechanism underlying CUG have been proposed. Initially Tanner
(1963) proposed a neuroendocrine model, which adjusts the growth rate to an age
appropriate set point. He suggested that the CNS contained a 'sizostat', which would sense
a mismatch in growth and adjust the release of specific molecules accordingly. The
evidence for this theory appears to be weakening and it is now apparent that CUG is also
partially regulated by a mechanism intrinsic to the growth plate. This was demonstrated by
Baron el al, (1994) who administered Dex directly into the growth plate of rabbits. A 77%
reduction in the growth rate of 5-week rabbit limbs was noted in the proximal tibial
growth plates infused with Dex. Following cessation of Dex, catch up growth was
observed in the affected growth plate only and not in the contralateral tibia. Ultimately this
corrected approximately half the deficit indicating that CUG cannot be explained by
central mechanisms alone. It is postulated that this is due partly to a delay in growth plate
senescence by Dex (Gafni et al, 2001). After the removal of the GC, the growth plate may
be less senescent and therefore proliferate more rapidly than expected for age leading to
catch up growth.
1.7 CHONDROCYTE MODELS
Human chondrocytes would be an ideal method to standardise the study of chondrocyte
growth and regulation, however they are difficult to obtain, vary according to the
condition and age of the patients and it is often difficult to isolate a sufficient number of
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cells. To avoid this problem human immortalized chondrocyte cell lines were established
to permit investigations in a standardized manner. Some human chondrocyte cell lines
include the retroviral-mediated transfection of primary rib chondrocytes - T/C-28a, from
which the C-28/12 and T/C-28a4 cell lines were derived (Goldring et al, 1994). However
even though they express genes for chondrocyte differentiation and undergo proliferation
they show less evidence for matrix synthesis and differentiation (Finger et al, 2003). This
lack of a multistep differentiation capacity is also an issue for animal derived chondrocyte
cell lines (Grigoriadis et al, 1988).
Other investigators have continued to utilise primary chondrocytes from various sources
including rats and chicks, but as well as creating difficulty in comparing results across
species, the chondrocytes are also at different stages of differentiation. Thus these
heterogeneous population of cells may behave differently from a homogenous population
of cells (Robson et al, 1998; Jux et al, 1998; Farquharson et al, 2001).
To circumvent these problems, the experiments in this thesis started primarily with a
newer chondrocyte cell line which undergoes the complete chondrocyte cell differentiation
process and worked towards utilising increasingly physiological models to study the
effects of GC on growth plate chondrocytes, thus incorporating organ culture and in vivo
models.
1.7.1 ATDC5 chondrocyte cell line
Studies to date have explored the effect of GC and growth factors on a heterogeneous
population of chondrocytes comprising a mixture of maturational phenotypes (Robson et
al, 1998; Koedam et al, 2000; Jux et al, 1998). The disadvantage with this approach is that
it is not clear which population of chondrocytes are most affected by the GC effects.
Although a few cell lines are known to be chondrogenic (Grigoriadis et al, 1990; Bernier
& Goltzman et al, 1993), there is no report of any cell line that undergoes the complete
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differentiation process as it has been difficult to generate stable cell lines that express the
phenotype of chondrocytes that is uniformly maintained.
More recently the murine ATDC5 chondrocyte cell line has been shown to undergo the
temporal sequence of events that occur during longitudinal bone growth in vivo and
thereby provide a good model to study the molecular mechanisms underlying regulation of
endochondral bone formation (Atsumi et al, 1990; Shukunami et al, 1997) (Fig 1.5). This
ATDC5 cell line was isolated from a teratocarcinoma stem cell line AT805 on the basis of
chondrogenic potentials in the presence of insulin (Atsumi et al, 1990). Subsequently it
was shown that in the presence of insulin, the line undergoes the early phase of
differentiation to chondrocytes to form cartilage nodules that increase in size due to
proliferation. The late phase differentiation of the cell line is characterised by an increase
in cell volume as well as a marked increase in ALP activity. Here the hypertrophic cells
appeared in the centre of cartilage nodules in association with type X collagen gene
expression and a dramatic elevation in ALP activity in culture, (Shukanami et al, 1997)
both of which are implicated in the mineralisation of cartilage (McLean et al, 1987; Wu et
al, 1989). With increasing time in culture these hypertrophic ATDC5 chondrocytes
undergo the process of mineralisation which is visible macroscopically; at this point ALP
activity starts to decline. Mineralisation appears to be a prerequisite for vascular invasion
into cartilage during endochondral bone formation. Although not essential, the addition of
ascorbic acid resulted in increased levels of type X collagen expression which facilitated a
higher level of gene expression and maintenance of the hypertrophic phenotype
(Shukunami et al, 1997).
A time course marker of gene expression during ATDC5 proliferation and differentiation,
demonstrate an initial elevation in type II collagen, followed by an increase in aggrecan
mRNA expression, however these then decrease during the phenotypic conversion of
ATDC5 cells into hypertrophic cells which is associated with the induction of type X
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collagen gene expression (Fig 1.5). The type X collagen could not be detected in
undifferentiated cells or proliferating chondrocytes. This observation is compatible with
findings during differentiation of chondrocytes in vivo (Iyama et al, 1991 & 1994).
Thus, it has been established that the ATDC5 cells reproduce the orderly transition of all
differentiation stages; from a prechondrogenic stem cell line it undergoes proliferation,
early and late phase differentiation followed by mineralisation as observed during
endochondral bone formation (Shukunami et al, 1997). As the effects of GC and growth
factors could now be studied on a homogenous population of chondrocyte phenotypes it
was felt that the ATDC5 cell line would be a valuable model for elucidating the molecular
mechanisms that are disrupted during growth retardation.
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Figure 1.5. Time course marker gene expression during differentiation of ATDC5 cells.
Total RNA was isolated on the indicated day in culture and analysed by slot blot. Values
expressed as a percent of the highest hybridisation intensity for each mRNA.
Rat type II collagen cDNA (—) Rat PTH/PTHrP receptor (—■)
Human aggrecan cDNA (—) Mouse type X collagen cDNA (—)
Initial elevation of type II collagen mRNA followed by an increase in the aggrecan
mRNA. Expression of the PTH/PTHrP receptor gene occurs in close association with
early chondrogenesis. Thereafter these three mRNA levels decline as the cells proceed to
the hypertrophic stage which is associated with an elevation of type X collagen; which is
not detected in the proliferating or undifferentiated ATDC5 cell.










1.7.2 Foetal Mouse Metatarsal Culture.
The complex mechanisms of GC effects on growth plate chondrocytes may be studied
more closely by utilising more physiological and established chondrocyte models such as
the foetal mouse metatarsal model. Here the normal histological architecture of the bone
and the cell-cell interactions are maintained and therefore represent an excellent model to
gain a greater understanding of the effects of GC on linear bone growth. The metatarsals
are dissected at 18 days - 3 days prior to full gestation; as the foetal metatarsal is grown in
serum free culture, direct measurements of total length, mineralising zone length and
width can be taken.
The foetal mouse metatarsal explant culture is a highly physiological model for studying
growth as the growth rate of foetal bones in culture is similar to that found in vivo whereas
bones harvested postnatally from 2-day-old rats arrest in culture after 2-days in vitro
(Scheven & Hamilton 1991). Recent studies indicate that mouse metatarsals may not show
this growth arrest if harvested postnatally (Macrae et al, 2006). In 15-day-old mouse
metatarsals cultured in serum free conditions, endochondral ossification, proceeded in a
normal, though slower manner. After 6 days in culture, the developmental stage of the 15-
day-old metatarsals resembled that of day 17 in vivo (Haaijman et al, 1997). Thus rapid
development occurs in the metatarsal rudiments between days 15 and 17. At 15 days
gestation the metatarsal rudiments consist of a core of weakly metachromatic cartilage
surrounded by mesenchymal cells of the early perichondrium. Chondrocyte hypertrophy
and matrix mineralisation are not yet present. In foetal mouse metatarsals mRNA
expression patterns have shown that type I collagen is expressed by cells of the connective
tissue and osteogenic lineage. Type II collagen is a general marker for the chondrogenic
lineage (Devlin et al, 1988; Hayashi et al, 1986) and type X collagen is a marker of the
hypertrophic chondrocyte differentiation (Gibson & Flint, 1985). At day 17, endochondral
ossification has reached a stage characterised by a zone of mineralised hypertrophic
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cartilage in the centre of the rudiment. A thin bone collar lines the mineralised centre
where type II collagen was expressed. Type X collagen mRNA was not yet expressed in
day 15 metatarsals, but by day 17 a large area of type X mRNA expression was present,
demarcating the hypertrophic chondrocytes in the centre of the rudiment. Type X collagen
disappeared again in the area of calcified cartilage (Haaijman et al, 1997). All this data
suggests that cultured metatarsals possess an intrinsic differentiation capacity to undergo
endochondral ossification in a normal albeit a slower manner in the absence of serum
(Haaijman et al, 1997).
Postnatally, the ratio of the mineralising zone to the cartilaginous proliferating and
hypertrophic zones increases and thus there is reduced potential for overall growth. At 18
days the metatarsals display a small central core of mineralised cartilage juxtaposed on
both sides to a translucent area representing the hypertrophic chondrocytes. The
proliferating chondrocytes are situated at both the proximal and distal ends of the
metatarsals (Fig 1.6).
Figure 1.6. Foetal Metatarsal Culture: A metatarsal cultured for 4 days is shown. This
displays a central core of mineralised cartilage, flanked with the lucent zones of








A few studies have utilised the foetal organ explants to investigate the actions of GC, GH
and IGF-I in this model system (Picherit et al, 2000, Scheven & Hamilton 1991, Coxam et
al, 1996) but none has looked at the interactions of these drugs and hormones at the
molecular and histological level.
Thus in contrast to cell culture studies, the metatarsal explant model in serum free medium
allows GC and hormonal effects on growth and cartilage differentiation to be studied in
greater detail, as the heterogeneous population of cells allows interactions to occur
between cells and the extracellular matrix in the morphogenetically patterned way that
replicates the in vivo process.
1.7.3 Prenatal GC exposure
Impaired foetal growth can be caused by a number of foetal, maternal, placental, and
demographic factors but in up to 40% of SGA cases, no cause for growth restriction can
be identified (Wollmann, 1998). Prenatal exposure to GC is known to cause growth
restriction in most mammalian species including humans. (Mosier et al, 1982; Reinisch et
al, 1978). Indeed, human IUGR is associated with elevated maternal and foetal levels of
endogenous GC (Goland et al, 1993), and these levels are more likely to be elevated in
those who fail to display catch-up growth (Economides et al, 1988; Clark et al, 1996;
Cianfarani et al, 2003). It is unclear whether the raised GC levels in the foetus per se have
a direct effect at the level of the growth plate chondrocyte.
SGA mice can be produced by the administration of prenatal Dex by subcutaneous
injections of lOOpg/kg Dex for the last 6 days (14-20) of pregnancy (Nyirenda et al,
1998). This can cause a 15-20% IUGR without foetal loss or alterations in the length of
gestation. The extent of reduction in birth weight is similar to that observed by
investigators using other rodent models of IUGR such as bilateral uterine artery ligation
and protein restriction (Mosier et al, 1982; Harrel et al, 1995). In pregnant sheep,
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Betamethasone administered in single or multiple doses causes a decrease in body weight
in the offspring with increasing effects after multiple doses (Jobe et al, 1998). Although
this model of SGA offspring has been utilised to demonstrate that prenatal GC exposure is
linked to conditions such as hypertension, hyperglycaemia and hyperinsulinaemia (Seckl,
2001) there is little work looking at the effect of prenatal GCs on developing bones.
42
Chapter one Introduction
1.8 AIMS OF THE THESIS
This thesis was designed to discover the mechanisms by which GCs induce growth
retardation in children, and subsequently to explore ways in which to ameliorate these
negative effects. This was undertaken by utilising and refining novel models of
longitudinal bone growth and to gain further insights into the molecular pathways that
may be disrupted by GCs.
The principal aims of this thesis are to:
1. Fully characterise the ATDC5 chondrocyte cell line to understand the key time
points in the chondrocyte life cycle that are affected by GCs.
2. Identify the cellular and molecular mechanisms underlying the adverse effects of
GCs on growth plate chondrocytes.
3. Determine the effects of GH and IGF-I and their ability to ameliorate the GC
effects in different growth plate models.
4. Study the effects of prenatal exposure to Dex on neonatal weight and length.
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CHAPTER 2
SHORT-TERM EFFECTS ON LINEAR GROWTH
AND BONE TURNOVER IN CHILDREN
RANDOMIZED TO RECEIVE PRED OR DEX.
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2. Short-term Effects On Linear Growth and Bone Turnover In Children
Randomized To Receive Pred or Dex.
2.1 Introduction
The functional effects of steroids on target tissues is difficult to predict and their use is
hampered in some individuals more than others because of side-effects such as growth
retardation, osteoporosis, hypertension, altered body composition and altered blood
glucose homeostasis. Alterations in growth and bone turnover, as assessed by knemometry
and markers of GH secretion and bone turnover, can also occur during relatively short
periods of GC therapy (Ahmed et al, 1999, Crofton et al, 1998). The onset and severity of
these GC induced effects may be dependent on the duration of therapy and the nature of
the steroid compound, and the comparative biological potency of the GC such as Dex and
Pred may be tissue specific (Orth & Kovacs, 1998). For instance, in children and young
adults with congenital adrenal hyperplasia, Dex may be about 25 and 80 times more
adrenal suppressive than Pred and hydrocortisone, respectively (Hansen & Loriaux, 1976,
Hughes & Read, 1982). Dex is also reported to be 4 times more potent at suppressing the
hypothalamo-pituitary-adrenal axis than Pred but it may be 16 times more
lymphocytotoxic than Pred (Kaspers et al, 1996). Dex also displays better CNS
penetration (Balis et al, 1987), and this feature has led to a randomised trial to look at its
efficacy in the treatment ofALL (Gaynon & Carel, 1999).
The relative potency of different GC on growth and bone turnover is unclear as there are
no in vivo studies in children. The current study was performed on children entering a
national trial of ALL therapy in which they were randomised to receive Pred or Dex as
part of induction of remission and continuing treatment. By accounting for possible
confounding factors such as other concurrent chemotherapy and the effects of the disease,
the randomisation process provided a suitable opportunity to compare the short-term
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effects of Pred and Dex on growth and bone turnover by the same methods as employed in
earlier studies (Ahmed et al, 1999, Crofiton et a\, 1998).
2.2 Subjects & Methods
a) Patients
All children presenting to a paediatric oncology centre with a diagnosis of ALL were
eligible for the study. Out of a total of 22 eligible children, one child was excluded
because of CNS disease at presentation and 2 children and their families declined
participation in the study. Nineteen children (eight boys, eleven girls) with a median age
of 5.9yrs (range, 2.6, 13yrs) were recruited.
b) Design
The children were entered into the national UK trial of ALL - MRC ALL97/99 and
randomized to receive Pred (40mg/m2, daily) or Dex (6.5mg/m2, daily) as induction
chemotherapy for 5 weeks (Table 2.1). The comparative doses of the GC were chosen
based on previous lymphocytotoxic data (Kaspers et al 1996). GC were also administered
as 5-day blocks in weeks 9 and 13. Brief details of the chemotherapy regimens are
outlined in Fig.2.1. Seventeen out of 19 children received either Group A or B
chemotherapy, which was determined by their age and white cell count at presentation.
The remaining 2 children received a more intensive regimen of chemotherapy as they
failed to remit over the first 4 weeks of induction therapy. Data from the first 4 weeks was
analysed up to 5 weeks in these children. The study was approved by the local research
ethics committee and informed consent was given by all parents and their children, where
appropriate.
c) Samples andAnthropometric Measurements
46
Chapter two Short Term Effects On Linear Growth After GC Exposure
Collection of blood samples coincided with vascular access for clinical management and
were performed every one to two weeks at approximately the same time in late morning
(Fig.2.1). Lower leg length was measured by knemometry at weekly intervals using the
random zero method (Ahmed et a\, 1995). The precision of the measurement was assessed
by calculating the technical error (TE), ie 1SD from the mean of a set of triplicate
measurements. The overall mean TE (+/- 1SD) was 0.15mm (0.13). Knemometry was
performed in 13 (6 Dex, 7 Pred) out of 19 children. The remainder of the children had a
median age of 3.1 years and were too young to cooperate with the measurements. Body
weight with undergarments was measured by an electronic scale.
d) IGF-I
IGF-1 concentrations were measured using a two-site immunoenzymometric (IEMA)
assay incorporating a sample pre-treatment to inactivate binding proteins
(Immunodiagnostic Systems Limited, Tyne and Wear, United Kingdom). The intra-assay
and inter-assay coefficients of variaton were <5% and <8%, respectively, over the sample
concentration range. The lower limit detection of the assay was 10 ng/ml.
e) Bone Markers
All samples were analysed in duplicate and samples from each patient were analysed in a
single run to minimise analytical variation. Bone Alkaline Phosphatase (bALP) was
measured in plasma by ELISA (Alkphase-B, Metra Biosystems Inc, Mountain View, CA,
USA). The sensitivity of the assay was 0.7U/1 and within-run and between-runs
coefficients of variation were <5% and <8%, respectively. Deoxypyridinoline crosslinks
(DPD) were measured in urine by ELISA (Pyrilink-D, Metra Biosystems Inc, Mountain
View, CA, USA). Assay sensitivity was l.lnmol/1 and within-run and between-runs
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coefficients of variation were <6% and <11%, respectively. The results were expressed in
relation to creatinine measured on the same urine sample.
2.3 Statistical Analyses
For the knemometry data, lower leg length velocity (LLLV) was calculated for each time
point by subtracting the LLL at that time point from that measured at the previous time
point, and dividing by the time interval (in weeks) between the two measurements. LLLV
was expressed as millimetres per week (mm/wk). Change in LLL was also expressed as a
percentage of the previous LLL. Body weight was expressed as a percentage change in
body weight from the pre-treatment body weight. Serum IGF-I, Bone ALP and urinary
DPD were expressed as absolute values as well as percentage change in IGF-I, bALP and
DPD (%IGF-I, %bALP, %DPD). The data were expressed as medians and ranges and
analysed using non-parametric tests. Comparison between groups was performed using the
Mann-Whitney U test and Spearman rank correlations were used to compare any
association between variables at each time point. Data were analyzed using SPSS software
v9.0.0 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel 97 SR-2 (Microsoft Corp,
Redmond, WA, USA).
2.4 Results
Lower Leg Length Velocity (LLL V)
At Wk 2 of therapy, median LLLV in the Dex group was -1.5mm/wk (range, -2.1, 0.7)
and significantly lower than the LLLV in the Pred group which was -0.1mm/wk (range -
0.28, 0.2) (p<0.05). During GC therapy, LLLV rose temporarily before falling by week 6
when GC therapy ended. In the Dex group, LLLV remained lower at week 8 (med LLLV,
-0.3mm/wk, r -1.3, 0) compared to LLLV in the Pred group at 0.3mm/wk (r, 0.2, 1.0)
(p<0.05). By weeks 12 and 16 of the chemotherapy protocol, LLLV was similar in both
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groups (Fig.2.2a). Mean LLLV between week 2 & 8 in the Dex and Pred groups were
-0.27mm/wk and 0.18mm/wk respectively. Compared to previous studies of healthy
children where the mean LLLV was 0.39mm/wk (1SD,0.12) (Ahmed el al, 1995), the
LLLV in the Dex and Pred groups were 5.7SD and 1.8SD below the mean.
Body Weight
During GC therapy, body weight showed an increase after week 2 and reached a peak in
both groups of children at week 6 (Fig. 2.2b). Although, the increase in weight from
baseline was generally greater in the Dex group, the difference did not reach statistical
significance until week 5 when the median change in weight from baseline in the Dex
group was twice that of the Pred groups at 17.5% (range 5 - 25) and 8.7% (range -3 - 18)
respectively (p<0.05). Children in the Dex group continued to remain at a higher level of
weight gain from baseline until week 16 when there weight gain became similar to that of
the Pred group (Fig. 2.2b). At Wks 2, 3, 4, 6 and 8, the percentage gain in weight was 1,
9.5, 1.6, 2.0 and 2.2 times higher in the Dex group than the Pred group, respectively.
Therefore, on average, percentage gain in weight was 3.1 times higher in the Dex group.
IGF-I
At presentation, median IGF-I level for the whole group was 83.5 pg/1 (31.8, 293); median
IGF-I level in the Pred and Dex groups were 69.3 pg/1 (33.8, 175) and 166 pg/1 (39, 293),
respectively (p=0.12). During the study period median IGF-I levels remained between
100 pg/1 and 150 pg/1 in the whole group and the absolute values were similar in the Pred
and Dex groups. However, in the Dex group, IGF-I levels fell much more markedly during
the period of steroid therapy and continued to remain lower than baseline (Fig.2.2c) At
weeks 4, 6 and 8, median change in IGF-I from baseline was lower in the Dex group than
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the Pred group at -16% (-45, -9) vs 19% (-50, 195), -3% (-58,43) vs 56% (-43, 146) and -
42% (-74, 3) vs 44% (-73, 415), respectively (p<0.05).
Bone Alkaline Phosphatase
At presentation median bALP concentration was low but similar in the Pred and Dex
groups at 37U/L (17, 159) and 46U/L (23, 69). From week 1 to week 3, change in bALP,
as median %bALP, was 72% (-8, 304) in the Pred group, whereas in the Dex group
%bALP was -1% (-28, 23) (p<0.005). By Wk 3 of therapy, median bALP concentration
was higher in the Pred group at 65U/L (36, 187) than in the Dex group at 39U/L (26, 60)
(p<0.05). By the end of Pred therapy at week 6, median bALP concentration had fallen to
a similar level in both groups (Fig 2.2d). By week 12 and 16, pooled bALP concentrations
had risen to a median value of 80U/L (36, 123) compared to a median pooled value of
44U/L (17, 187) between weeks 1 and 8 (p<0.005). At weeks 2, 3, 4, 6 and 8, bALP levels
were 1, 1.7, 1.4, 1.3 and 1.2 times lower in the Dex group than the Pred group,
respectively. Therefore, on average, bALP was 1.3 times lower in the Dex group than the
Pred group.
Deoxypyridinoline
At presentation, median DPD excretion was similar in the Pred and Dex groups at
22nmol/l (17, 38) and 20nmol/l (12, 26). DPD excretion fell in both groups reaching a
nadir between week 3 and 6 (Fig.2.2e). The percentage change of DPD in the Pred and
Dex group from week 1 to week 3 was -34% (-7, 14) and - 53% (-69, -6), respectively
(NS). By week 8, DPD excretion had started to rise more dramatically in the Pred group
such that the median DPD was 35nmol/l (10, 53) in the Pred group and 22 (9, 30) in the
Dex group (p<0.05). Subsequently, DPD excretion continued to rise but there was wide
variation during this recovery period (Fig.2.2e). At Wks 2, 3, 4, 6 and 8, DPD excretion
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was 1.4, 1.6, 1.4, 1.2 and 2.2 times lower in the Dex group than the Pred group,
respectively. Therefore, on average, DPD was 1.5 times lower in the Dex group than the
Pred group.
2.5 Discussion
Dex and Pred are two GCs that are commonly used in immunosuppressive therapy. As
Dex has a longer half-life, higher lymphocytoxicity and penetrates better into the CSF it
may be better suited for treatment in ALL (Gaynon & Carrel, 1999, Kaspers et al 1996,
Veerman et al, 1990). The improved CNS penetration may explain the finding of an
increased risk of neurocognitive late effects in those children who received Dex rather
than Pred during ALL treatment (Waber et a\, 2000). Besides ALL, there may be other
conditions where Dex may be a more efficacious than Pred but a lack of data on relative
efficacy as well as adverse effects of the two drugs has hindered an objective choice. By
evaluating a number of short-term physical and biochemical changes, this study attempted
to quantify the effects of Pred and Dex in children.
The changes documented in short-term growth and bone turnover in this study were
generally similar to a previous study of children undergoing treatment for ALL using Pred
during induction of remission (Ahmed et al, 1999, Crofton et al, 1998). By the end of the
induction period there was a reduction in short-term growth and suppression ofmarkers of
bone turnover.
The current study shows that at the dose used, Dex had a more profound suppressive effect
on bone turnover and short-term growth than Pred. Short-term growth as assessed by
knemometry and bone formation as assessed by bALP levels was less in the Dex group.
Similar changes were also observed in urinary DPD excretion, a marker of bone resorption
(Calvo et al, 1996). Not only did they fall further, bone formation and resorption remained
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two weeks of Pred was not observed in the group who received Dex. This paradoxical rise
in bALP has been attributed to premature maturation of osteoblasts and our data suggests
that this effect may be specific to Pred (Canalis, 1996, Stein et al, 1990). The rise and
subsequent fall in bALP emphasizes the importance of sequential measurements of bALP
during monitoring of GC effects on bone formation. These results showing an increased
potency of Dex are in keeping with the observation of an increased cumulative incidence
of fractures in those children who received Dex compared to Pred during ALL therapy
(Strauss et al, 2001).
GC induced changes in growth may be due to a combination of factors such as a
disruption in the GH-IGF-1 axis and direct effects on the growth plate (Robson, 1999).
High dose GC therapy alters pulsatility of GH secretion through an elevation of
somatostatin tone and may alter GH binding protein activity (Tonshoff et al, 1996,
Gabrielsson et al, 1995). Previous studies have suggested that a state of GH resistance
may exist in children undergoing ALL treatment (Crofton et al, 1998) and the current
study shows that Dex is more potent at depressing IGF-I levels than Pred. Absolute IGF-I
levels are age dependent and may be easier to assess following standardization for age as
well as standard deviation scores. However this standardization was not employed in this
study as the age range of children in the two randomized groups was similar and the aim
of the study was to assess the change in IGF-I levels over a short period of a few weeks.
GCs promote food consumption both directly and through stimulation of neuropeptide Y
and inhibition of corticotrophin releasing hormone release (Tataranni et al, 1996, Tempel
et al, 1994). Short-term changes in energy intake secondary to GC administration during
maintenance treatment in children with ALL have recently been reported by Reilly et al
(2001). This group did not show any significant differences in energy intake or weight
gain between Dex and Pred and this may have been due to the short, 5-day period of
steroid administration. Our study shows that the changes in weight gain were more
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marked in those children who were randomised to receive Dex for a longer period of 4
weeks.
Previous studies of short-term growth by knemometry have shown that changes in body
weight may independently influence lower leg length due to the action of gravity on the
soft tissues of the lower leg (Hermanussen et al, 1988, Ahmed et al, 1996). Previous
studies in a pregnant adult subject showed that an increase in body weight was associated
with a reduction in LLL until the subject developed dependent oedema at which point LLL
started to increase (Ahmed et al, 1996). Although changes in general body weight may-
explain the negative growth or actual shrinkage that was observed in some children,
weight changes cannot solely account for the observed LLLV differences between the two
groups as some of the major differences in LLLV between the Pred & Dex groups
preceded the major differences in body weight in the current study. Some of the early
shrinkage may be explained by ultrasound studies that show that systemic steroids therapy
may have an early water depleting effect on connective tissues and may lead to a reduction
in subcutis thickness (Schou et al, 2003). This water depleting effect may similarly affect
the growth plate which is susceptible to the effects ofGCs.
The Mann-Whitney U test was used to display the difference and thus the trend between
the medians for each group over the time. However there can be limitations to this
approach as the curve joining the means may not be a good descriptor for an individual as
it does not take into account the fact that different measurements at different time points
are from the same subject - thus each time point is analysed separately. Also successive
results are likely to be correlated to the significance level of the previous measurement. A
possible alternative approach would have been to utilise summary measures where the
summary of a response in the individual is identified and calculated for each subject prior
to undertaking statistical analysis (Matthews et al, 1990).
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Nineteen children were recruited into the study, and after randomisation 7 were left in the
Dex group. Although differences were detected in between Dex and Pred groups it is
possible that a type 1 error has occurred (that is a difference was detected between the
GCs when one did not exist). This could be circumvented by increasing the number of
subjects in each group. Likewise the chances of a type 2 error could also be minimised by
increasing the numbers in the groups, but this is often difficult if the condition is not
common in the population.
The dose of Pred (in milligrammes) was approximately 6 times that used of Dex and the
study shows that LLLV was about 3 times lower in the Dex group over the period of
treatment and the subsequent few weeks. Therefore as an estimate, between weeks 1 and 8
of the 5-week period of GC therapy, Dex was 18 times more potent at suppressing short-
term growth. Similar calculations estimate that Dex was 19 times more potent at raising
body weight and about 8 to 9 times more potent at suppressing bone turnover as assessed
by serum bALP concentration and urinary DPD excretion. After 8 weeks all the above
parameters, except change in body weight, were similar in the two groups. Thus although
GC dosing is based on anti-inflammatory activity, they can have variable potencies in
different tissues. Indeed blood samples from untreated ALL children also show a variation
in antileukaemic activity after exposure to GCs, with Dex displaying a 16 fold greater
effect on in vitro antileukaemic activity than Pred (Kaspers et al, 1996).
In summary, this study has attempted to quantify the relative effect of the two
corticosteroids, Dex and Pred on short-term growth and bone turnover. Compared to Pred,
Dex may be almost 20 times more potent at suppressing short-term growth and at raising
body weight and almost 10 times more potent at suppressing bone turnover. GC have a
variable effect on different parameters of growth and bone turnover and the intensity may
depend on the steroid used. Subsequent studies in this thesis have progressed to explore
the basic mechanisms by which GC impact growth.
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Table 2.1 ALL Randomisation
Details of Patients who were randomised to receive Prednisolone (Pred) or
Dexamethasone (Dex) as steroid therapy.
Pred Dex
N 12 7




Group A, B, C 7, 4, 1 4, 2, 1
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Figure 2.1
A flow diagram of chemotherapy schedule over the first 16 wks of MRC-ALL97/99 in
children receiving regimen A or B. Children entering the trial were randomized to receive
Dex or Pred. Drugs in the yellow area were only administered to Group A, drugs in the
grey shaded area were only administered to Group B and drugs in the open area were
administered to both groups. Drug doses and route of administration: Prednisolone (Pred),
2 2*2*
40mg/m /day, oral; Dexamethasone (Dex), 6.5mg/m /day, oral; Vincristine, 1.5mg/m , iv;
L-Asparaginase, 6000U/m2; Cytarabine Intrathecal (IT), <2yrs-30mg, 2yrs-50mg, >3yrs-
70mg; Methotrexate Intrathecal (IT), <2yrs-8mg, 2yrs-10mg, >3yrs-12mg; 6-
Mercaptopurine (6MP), 75mg/m2/day, oral; 6-Thioguanine (6TG), 40mg/m2/day, oral;
Daunorubicin, 25mg/m2, iv; Cytarabine (Ara-C), 75mg/m2/day, iv; Cyclophosphamide
1000mg/m2, iv.
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Figure 2.2
The effect of Pred (solid line) and Dex (broken line) on markers of bone growth and
turnover, (a) Lower Leg Length Velocity (LLLV, mm/wk), (b) Percentage change in body
weight from baseline, (c) Serum IGF-I concentration (IGF-I p.g/1), (d) Serum bone ALP
concentration (bALP, U/l) and (e) Urinary DPD excretion corrected for creatinine
excretion (DPD, nmol/l/creat, nmol/1) over the first 16 weeks of ALL97. GC therapy was
administered as induction of remission therapy for 4 weeks at full dose and for an
additional week as a tapering dose. GCs were also administered as 5-day blocks in Wk 9
and 13. The results are presented as median and 25th and 75th centile values and
measurements at any one time point in the two groups are clustered in pairs. * p <0.05.
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3.1 ATDC5 Characterisation
3.1.1 Introduction
The direct effects of GC on chondrocytes are not clearly understood and previous studies
that have examined the effect of GC on primary growth plate chondrocytes have been
unable to elucidate the effect of GC on the different stages of the chondrocyte life cycle
due to the heterogeneous mixture of maturational phenotypes (Robson et al, 1998,
Koedam et al, 2000).
This ATDC5 cell line was isolated from a teratocarcinoma stem cell line on the basis of its
chondrogenic potential. In the presence of insulin it was shown that the line undergoes the
early phase of differentiation and proliferation to chondrocytes (Atsumi et al, 1990). This
is associated with an initial elevation in type II collagen, which heralds the onset of a
chondrogenic lineage (Hayashi et al, 1986). The late phase differentiation of the cell line
is characterised by an increase in cell volume as well as a marked increase in ALP
activity; this was associated with type X collagen expression (Shukanami et al, 1996) both
of which are implicated in the subsequent mineralisation of cartilage (McLean et al, 1987;
Wu et al, 1989). With increasing time in culture these hypertrophic ATDC5 chondrocytes
undergo the process ofmineralisation, which is visible macroscopically.
The first phase of the study was to establish the temporal sequence of events that occur in
the maturational phenotypes of the ATDC5 chondrocyte cell line. Therefore to fully
characterise the cell line, the expression of markers of the phenotypes over time were
elucidated.
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3.1.2 Materials and Methods
a) Chondrocyte cell culture
The ATDC5 chondrocyte line was obtained from the RIKEN cell bank (Ibaraki, Japan)
and maintained as described by Atsumi et al (1990). Cells were cultured at a density of
2 . , .12000 cells per cm in multi-well plates (Costar, High Wycombe, UK) in maintenance
medium (DMEM/Hams' F12 (Invitrogen, Paisley, UK) supplemented with 5% Foetal Calf
o
Serum (FCS) (Invitrogen), lOug/ml human transferrin and 3 x 10" M sodium selenite
(Sigma, Poole, UK) until confluent (Day 6). Thereafter, differentiation was induced by the
addition of insulin (lOug/ml,Sigma) and ascorbic acid (20ug/ml) to the maintenance
medium (differentiation medium). Incubation was at 37°C in a humidified atmosphere of
95% air/5% CO2 and the medium was changed every second day.
b) Gene expression
For the determination of chondrocyte phenotype, cells were grown for up to 20 days as
above and RNA was extracted, reverse transcribed and analysed for collagen type II and
type X expression at Day 6, 8, 10, 13, 15, 17 and 20 by semi-quantitative RT-PCR. 18S
was utilized as the house keeping gene as it is not influenced by any treatments and it
gives an equal PCR band intensity in all preparations and time points.
c) RNA extraction
Total RNA was extracted from chondrocytes by repeated aspiration through a 25-gauge
syringe needle in 1.5 ml Ultraspec (Biotecx, Houston, TX). After extraction with
chloroform, RNA in the aqueous phase was precipitated with isopropanol and bound to
RNA Tack resin (Biotecx) following the manufacturer's protocol. After washing with 75%
ethanol, the RNA was eluted in lOOpl ribonuclease-free water (Houston et al, 1999). In
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each case the 260/280 ratio was 1.9-2.0, confirming the purity of the RNA. All
preparations were diluted to a concentration of 50 ng/pl and stored at -70 C.
d) Semiquanlative RT-PCR
Gene expression was analyzed by semiquantitative RT-PCR (Houston et al, 1999,
Farquharson et al, 1999, Jefferies et al, 2000). Aliquots of 500 ng RNA (or an equivalent
volume of water as a control) were reverse transcribed in 20-pi reactions with 200 ng
random hexamers and 200 U Superscript II reverse transcriptase using the Superscript
preamplification protocol (Invitrogen). PCR was performed in 20-pl reactions containing
cDNA equivalent to 10 ng RNA and 200 nM gene-specific primers in 11.1 x PCR buffer
(Jefferies et al, 1998) (Table 3.1). The cycling profile was 1 min at 92 C (first cycle, 2
min), 1 min at 55 C, and 1 min at 70 C. The number of cycles performed was carefully
titrated to ensure that the reactions were in the exponential phase. Reaction products were
analyzed on 1.5% agarose gels in the presence of ethidium bromide (250 pg/litre), and a
digital image of each gel was captured using a gel documentation system (Bio-Rad
Laboratories, Inc., Hemel Hempstead, UK).
3.1.3 Results
Temporal Expression ofchondrocyte phenotype specific markers.
Using gene specific primers (Table 3.1), collagen type II expression by the ATDC5 cells
was first noted after 10 days in culture indicating that the differentiation ofmesenchymal
cells to the chondrocyte phenotype (chondrogenesis) had occurred. Similarly, collagen
type X expression was noted from Day 15 onwards indicating that terminal differentiation
of the chondrocytes occurred from Day 10 to Day 15 (Fig 3.1). As anticipated 18S gave
similar band intensities at all time points confirming that the expression of the target genes
were real changes (Fig 3.1).
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The ATDC5 cells were in a confluent monolayer by day 6. In the presence of insulin the
cells underwent chondrogenic differentiation to form cartilage nodules. These cartilage
nodules continued to increase in size due to proliferation of the chondrocytes. A typical
nodule at day 12 is shown in Fig 3.2.
3.1.4 Discussion
Characterisation of the ATDC5 cell line revealed that type II collagen is expressed at 10
days, which is a general marker for chondrocyte lineage and indicates the presence of a
differentiated chondrocyte. Further differentiation and terminal differentiation is
characterised by expression of collagen type X by 15 days, indicating the presence of the
hypertrophic chondrocyte phenotype. If left longer in culture these chondrocytes would
then undergo mineralisation as seen in vivo (Shukunami et al, 1997). This is similar to
findings in chondrocyte populations in vivo where the type X collagen could not be
detected in undifferentiated cells or proliferating chondrocytes. (Iyama et al, 1994).
Subsequent experiments studied the effects of Dex and Pred during the periods leading up
to the expression of these maturation markers. This information is crucial as it allows the
study of two critical events during cartilage formation: the early differentiation of
committed mesenchymal cells into chondrocytes (chondrogenesis) and the terminal
differentiation of proliferating to hypertrophic chondrocytes (Cancedda et al, 1995).
Thus it was possible to study for the first time the effects ofGC on key points of cartilage
formation in a homogenous population of chondrocytes rather than previous studies which
have contained a phenotypically diverse population of primary chondrocytes (Robson et
al, 1998; Koedam et al, 2000).
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Table 3.1. Primer pairs used for specific gene analysis
Gene Primer Sequence Cycles Product Size (bp)
18S Unknown, purchased commercially
from Ambion
15 488
Collagen Type II TTAGAAAGGGGAGCACAGTCC(F) 35 323
TACACTGCCATGAAGCATGG(R)
Collagen Type X CAGAGGAAGCCAGGAAAGC (F) 32 330
GGTGTCCAGGACTTCCATAGC(R)
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Figure 3.1. Semiquantative RT-PCR analysis of the expression of chondrocyte marker
genes. Collagen type II is expressed from day 10 and collagen type X from day 15. 18S is
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Figure 3.2. Phase contrast micrograph of ATDC5 cells. Nodule formation was
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3.2 GC effects on Chondrogenesis and Terminal Differentiation
3.2.1 Introduction
The onset and severity of GC induced effects may be dependent on the duration of
therapy, the nature of the steroid compound, and the comparative biological potency of
GC such as Dex and Pred may be tissue specific (Orth & Kovacs, 1998). The initial study
in this thesis was the first to show the varying effects ofGC on bone growth and turnover,
demonstrating that Dex is more potent at suppressing short term linear growth than Pred in
children receiving treatment for Acute Lymphoblastic Leukaemia (Chapter 2).
This has been confirmed by in vitro studies looking at the joint effects of Dex and Pred on
bone and cartilage cells. In human osteoblasts cultured from bone biopsies of healthy
adults, Dex is more potent than Pred at inhibiting DNA synthesis (Kasperk et al, 1995) as
well as in animal studies where Dex was ten times more potent at reducing the
chondrocyte cloning ability than Pred (Robson et al, 1998).
GCs induce growth failure by a number of systemic effects, however it is apparent that
they also have direct effects on the growth plate (Baron et al, 1992). The aim of this study
was to ascertain the potencies of Dex and Pred on a number of parameters representing
chondrocyte growth; including proliferation, differentiation and proteoglycan synthesis.
These were done on a homogenous population of chondrocytes as characterised (Exp 3.1)
to assess GC effects on different maturational phenotypes; either during the proliferative
phase (chondrogenesis) or during the late differentiation phase (terminal
differentiation).
3.2.2 Materials and Methods
a) Chondrocyte cell culture
The ATDC5 chondrocyte line was maintained and cultured as described (3.1.2a).
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b) Chondrocyte number, proliferation, differentiation andmatrix production.
o n
Dex and Pred (Sigma) were added to the cells at a final concentration of 10" M, 10" M and
10"6M, in 0.01% ethanol and compared with control cultures which contained 0.01%
ethanol only. Collagen type II and collagen type X expression was first noted at 10 and 15
days respectively. The GC were added from Day 6 (chondrogenesis) or Day 11 (terminal
differentiation) for the 4 days leading up to the expression of these two chondrocyte
phenotypic markers.
The rate of chondrocyte proliferation was assessed by incubating the chondrocytes with
0.2uCi/ml of [3H]-thymidine (37MBq/ml; Amersham Pharmacia Biotech, Little Chalfont,
UK) for the last 18 hours of culture period and the amount of radioactivity incorporated
into trichloroacetic acid-insoluble precipitates measured (Farquharson et al, 1999).
Cell layers were rinsed with phosphate buffered saline (PBS) and lysed with 0.9% NaCl
and 0.2% Triton X-100 and centrifuged at 12000g for 15 min at 4°C. The supernatant was
assayed for protein content and ALP activity as a measure of cell number and chondrocyte
differentiation respectively. The protein content of the supernatant was measured using the
Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hemel-Hemstead, UK) based on the
Bradford dye binding procedure and gamma globulin was used as standard (Farquharson
et al, 1995). Enzyme activity was determined by measuring the cleavage of lOmM p-
nitrophenyl phosphate (pNPP) at 410nm. Total ALP activity was expressed as nmoles
pNPP hydrolysed/min/mg protein (Farquharson et al, 1999).
Proteoglycan synthesis was evaluated by staining with Alcian Blue as previously
described (Shukanami et al, 1997). In brief, cells were washed twice with PBS, fixed in
95% methanol for 20 minutes and, stained with 1% Alcian Blue 8GX (Sigma) in 0.1 HCL
overnight and rinsed with distilled water. Alcian blue stained cultures were extracted with
lml of 6M guanidine-HCL for 6 hours at room temperature and the optical density was
measured at 630 nm using a Jenway 6105 spectrophotometer.
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3.2.3 Statistical analysis
All experiments were performed at least twice. Data was analysed by analysis of variance.
All data are expressed as the mean ± sem of four observations within each experiment and
statistical analysis was performed using Statview (version 5.0.1). A p value of <0.05 was
considered to be significant.
3.2.4 Results
Effects ofGC on cell number andproliferation.
In comparison to control cultures the addition of Dex and Pred to cells during the
chondrogenic period (Days 6-10) caused a significant reduction in cell number (Table 3.
2). The reduction in cell number from control values for the Dex concentrations tested
were 10"8M (18.2%) 10'7M (33.3%) and 10"6M (31.8%) (p<0.05). The apparent plateau
noted at 10"7M for Dex was not seen with Pred, where a dose dependent reduction was
observed over the three concentrations tested: 10"8M (10.6%:NS), 10"7M (21.2%:p<0.05)
and 10"6M (30.3%:p<0.05). The mean reduction in cell number over the 3 concentrations
was 28% with Dex and 20% with Pred.
The effect ofDex and Pred on [3H]-thymidine uptake during the chondrogenesis period is
shown in Fig 3.3. Both GC caused a significant concentration dependent decrease in cell
proliferation from control values, Dex: 10"8M (11.7%) 10"7M (33.8%) and 10"6M (36.6%);
Pred: 10"8M (9.6%:) 10"7M (24.7%) and 10"6M (37%); (p<0.05). As was noted for cell
number, the apparent plateau noted at 10"7M for Dex was not seen with Pred, where a dose
dependent decrease was observed over the three concentrations tested. The mean reduction
over the three concentrations for Dex and Pred were 27% and 24% respectively. Dex at
10"7M was significantly more antiproliferative than Pred 10~7M. (p<0.05).
During the terminal differentiation phase (Days 10-15) Dex did not significantly alter cell
numbers when compared to control values (table 3.2), whereas Pred caused a significant
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reduction (p<0.05) at both 10"7M (14.1%) and 10"6M (10.9%). Cell proliferation rate in
control cultures was six fold less during the terminal differentiation phase than the
chondrogenic stage and the addition ofGC led to a significant suppression of proliferation
with Dex 10"8M (40.9%), 10"7M (24.1%) and 10"6M (40.3%) whereas a reduction in
proliferation by Pred was noted at 10"8M (26.3%), with a rise in proliferation at 10"6M
(p<0.05) (Fig 3.3).
Effects ofGC on proteoglycan production.
In comparison to control cultures during the chondrogenesis period, there was a
concentration dependent reduction in proteoglycan synthesis ranging from 42 to 50% with
Dex and 35 to 54% with Pred (Table 3.2). An apparent plateau was noted at 10"7M for Dex
which was not seen with Pred, where a dose dependent reduction was observed over the
three concentrations tested. Comparing Dex and Pred at equivalent concentrations, Dex at
10"7M caused a significantly greater fall in proteoglycans than Pred at 10"7M (p<0.05)
(Table 3.2). Over the three concentrations, Dex caused a mean reduction in proteoglycan
synthesis of 47% compared to 43% with Pred. No significant differences were noted
during terminal differentiation.
Effect on GC on chondrocyte differentiation.
The effect of GC on terminal chondrocyte differentiation as assessed by ALP activity is
shown in table 3.2. During chondrogenesis, enzyme activity in comparison to control
values was significantly increased with both Dex: 1(T8M (83%) 10"7M (118%) and 10"6M
(116%) and Pred: (39%) 10"7M (77%) and 10'6M (77%) (p<0.05). The mean elevation in
ALP with all concentrations of Dex and Pred are 106% and 62% respectively and at
equimolar concentrations of GC, Dex caused significantly larger increases in ALP than
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Pred. No significant differences in ALP activity were noted during the terminal
differentiation phase.
3.2.5 Discussion
Studies using rat chondrocyte cultures show that Dex and Pred both reduced cell
proliferation and colony formation and also that Dex was more potent than Pred at
equimolar concentrations (Dearden et al, 1986; Robson et al, 1998). This culture data is in
accord with the earlier in vivo observations where Dex appears to be more potent than
Pred at causing impairment of normal bone growth (Strauss et al, 2001).
This experiment used the ATDC5 chondrocyte cell line, as it displays less phenotypic
diversity than cultures containing a heterogeneous population of primary chondrocytes.
Furthermore, it allows the study of two critical events during cartilage formation: the early
differentiation of committed mesenchymal cells into chondrocytes (chondrogenesis) and
the terminal differentiation of proliferating to hypertrophic chondrocytes (Cancedda et al,
1995). Cell numbers were reduced by both Dex and Pred during the chondrogenesis
period, but little effect of both GC was noted during the terminal differentiation period.
GC may reduce cell numbers by mechanisms such as loss of proliferative activity,
increased apoptosis and cytostasis. This data strongly suggests that loss of proliferative
activity is, at least in part, responsible for the decrease in chondrocyte numbers by GC
treatment.
Cell proliferation rates and cell numbers were more greatly affected by Dex and Pred
during the chondrogenesis period when the chondrocytes were rapidly proliferating.
These results extend the data from cultures containing chondrocytes of various
maturational phenotypes (Robson et al, 1998) and are also in agreement with studies on
other bone cell types which indicate that Dex was more potent than Pred in reducing
osteoblast cell number and DNA synthesis (Kasperk et al, 1995, Davies et al, 2002).
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Davies and colleagues (2002) also reported that osteoblast precursor cells (HCC1) were
more chemosensitive to Dex than fully differentiated osteoblasts and together with our
present data, suggest that in bone cells, GCs exert their maximum effect at the cell
precursor stage. Over the three concentrations, Dex was also more potent than Pred as it
caused a 44% greater increase in ALP activity and greater reductions in proteoglycan
synthesis, cell number and cell proliferation. Annfeld (1992) also showed that Dex
treatment in rats, results in inhibition of both chondrocyte proliferation and cartilage
matrix production. The pro-differentiating effects of Dex are in agreement with studies
using costochondral cultures, in which Dex promoted ALP activity (Schwartz et al, 1995).
However the results are at variance with other studies where Dex lowered enzyme activity
in prehypertrophic chondrocytes but had minimal effects on hypertrophic or mineralising
chondrocytes (Robson et al, 2001). Although these results are in contrast to those
presented here, they do substantiate these and other observations that the response of
chondrocytes to Dex is dependent on their stage of differentiation (Yasuda et al, 1995).
This and subsequent chapters in the thesis use GC concentrations expressed in moles
rather than weight as in chapter 2. Historically pharmacological compounds have been
manufactured and tested according to the weight of the drugs, whereas biological
experimentation requires the knowledge of the amount of a substance present and is
referred to as moles. Thus Molarity (M) denotes the number of moles of a given substance
per litre of solution. The mole is useful in biological experiments because it allows
different substances to be measured in a comparable way as the number of particles is a
more useful unit in chemistry than mass or weight. Despite the variability in the
measurement units adopted worldwide, the International System of Units (SI) are now the
standard in Europe. However SI units are only available if an international standard is
present at that time. Such that in clinical practice measured Cortisol values are expressed in
SI units of mmol/1 (while Hydrocortisone is administered in weight units (mg)), whereas
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IGF-I levels are still given in weight units of ug/ml. It is obvious that there is a divergence
in measurement units between pharmacological and biological measurements. With
knowledge of the molecular weights of the GCs it is possible to convert between
millimoles and milligrams, however these figures then become unconventional and less
easy to interpret and compare in the light of published literature.
In conclusion, Dex and Pred reduce cell number, cell proliferation and proteoglycan
content whilst stimulating chondrocyte differentiation. The GCs have maximal effects
during chondrogenesis with minimal effects during terminal differentiation. Thus these
findings in the ATDC5 cell line may allow a more focused approach towards studying the
mechanisms underlying GC induced growth retardation.
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Table 3.2. GC effects on Chondrogenesis and Terminal Differentiation
Effect of Dex and Pred on cellular protein (cell number), proteoglycans and alkaline
phosphatase activity during chondrogenesis and terminal differentiation. All data
expressed as the mean ± sem, * - significantly different from control cultures (* p<0.05).
t = Dex cultures significantly different from equivalent dose of Pred (f p<0.05).
Chondrogenesis
10"8M 10"7M 10"6M
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Figure 3.3. Effect of Dex and Pred on cell proliferation as assessed by [3H]-thymidine
uptake during chondrogenesis and terminal differentiation phases. All data expressed as
the mean ± sem, * = significance compared to control (* p<0.05). f = significance level




















■Dex - chondrogenesis ■ Pred - chondrogenesis
Dex - terminal differentiation ♦ Pred - terminal differentiation
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3.3 Apoptosis
3.3.1 Introduction
Programmed cell death, or apoptosis was a term first coined by Kerr and colleagues in
1972, who observed that many dying cell types share the same characteristics; and
postulated that the process may be the result of an endogenous cell death programme
(Wyllieetal, 1980).
The human body is composed of approximately 1014 cells, each of which is capable of
undergoing apoptosis (Nicholson, 2000). Of these approximately 10 billion a day will die
to counteract the new cells that arise during mitosis (Hengartner, 2000). One of the
mechanisms central to the apoptotic process is via the caspases which are a group proteins
found in all species and elimination of these elements can slow or prevent apoptosis (Vaux
& Korsmeyer 1999; Kerr et al, 1972, Earnshaw et al, 1999).
Growth retardation after GC treatment could occur via several mechanism; primarily by
decreased proliferation of growth plate chondrocytes (Kember & Walker, 1971;
Annefield, 1992), delayed senescence of the growth plate chondrocytes, having undergone
fewer replications due to the inhibitory effect of Dex on cell proliferation (Gafni et al,
2001) or due to apoptosis.
Chrysis et al (2003) demonstrated that in rats treated for 7 days with Dex there was an
increase in apoptosis in both the proliferative and the hypertrophic chondrocytes,
accompanied by increased immunoreactivity for caspase-3. They observed an increased
number of apoptotic resting/early proliferative chondrocytes after Dex treatment, which
were rare in control animals but 18 fold higher after Dex treatment. Premature loss of
resting or early proliferative cells could diminish the growth potential in spite of increased
numbers of remaining replications of the chondrocytes (Chrysis et al, 2003). This
experiment tried to elucidate whether the inhibitory effects of Dex and Pred on
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chondrocyte proliferation in the previous experiment (Fig 3.3) were associated with
changes in the rate of apoptosis on the two chondrocyte maturational phenotypes.
3.3.2 Materials and Methods
a) Chondrocyte cell culture
The ATDC5 chondrocyte line was maintained and cultured as described (3.1.2a).
b) Apoptosis
Apoptosis of the cells was measured by APOPercentage Apoptosis Assay, (Biocolor Ltd,
Belfast, N.Ireland), which quantifies dye uptake by apoptotic cells only after the
translocation of phosphatidylserine to the outer surface of the cell membrane (Fadok et al,
1992). This kit were used according to the manufacturers instructions. Dex and Pred at
07 r
concentrations of 10" M, 10" M and 10" M were added to the cell cultures on Day 6 or Day
13 for a period of 24 hours. As a positive control, additional cells were incubated as above
with 5% ethanol.
3.3.3 Statistical analysis
Data was analysed by analysis of variance. All data are expressed as the mean ± sem of
four observations within each experiment and statistical analysis was performed using
Statview (version 5.0.1). A p value of <0.05 was considered to be significant.
3.3.4 Results
Using the APOPercentage Apoptosis Assay the number of apoptotic cells was higher in
the terminally differentiating chondrocytes in comparison to cultures in the
chondrogenesis phase. No evidence was detected for an effect of Dex and Pred on
apoptosis during the chondrogenesis phase (Fig 3.4a), however during terminal
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differentiation all Dex concentrations and Pred at 10"6M caused a significant decrease in
apoptotic cell numbers (p<0.05)(Fig 3.4b). Ethanol acted as a positive control and caused
an elevation in apoptosis (p<0.05).
3.3.5 Discussion
GC may impact on cell numbers by a combination of methods including loss of
proliferative activity, increased apoptosis and cytostasis. The previous data indicates that
an anti-proliferative effect, is at least in part, responsible for the decrease in chondrocyte
numbers by GC treatment. However no evidence of increased apoptosis was found, in this
cell line; this is in accordance with Jux et al (1998) whose studies entailed the use of
cultured rat chondrocytes primarily in the proliferative stage but is at variance with
Silvestrini et al (2000) who did show that hypertrophic chondrocytes of rats have an
increased apoptosis rate after high dose corticosterone exposure. Similarly in other bone
cells Pred causes an increase in osteoblast and osteocyte apoptosis, thus contributing to the
loss ofmature osteoblasts (Weinstein et al, 1998).
In the growth plate it is well recognised that apoptotic chondrocytes are most prevalent in
the terminally differentiated zone (Ohyama et al 1997; Chrysis et al 2003) and this is also
reflected in the ATDC5 cell line in this present study, which shows twice the apoptotic
activity during terminal differentiation compared to the chondrogenic phase. Interestingly,
Dex reduced apoptosis in the terminally differentiated cells whilst having no effect on the
chondrogenic phenotype, suggesting that GC control of chondrocyte apoptosis is
phenotype dependent. Alternatively it is possible that in this model, Dex and the highest
dose of Pred have caused an initial reduction in cell proliferation to such an extent that the
numbers of cells available for apoptosis are diminished. However this observation requires
further study.
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Figure 3.4. Effect of Dex and Pred treatment for 24 hours on the incidence of apoptosis
during a) chondrogenesis and b) terminal differentiation. No effects of the GC were
observed during the chondrogenesis phase, whereas all concentrations of Dex and Pred at
10"6M, caused a significant reduction in apoptosis during terminal differentiation (p<0.05).
Ethanol (5%) caused a significant elevation in apoptosis at both developmental time points
(p<0.()5).
a) Chondrogenesis
o 12 1 *
CO
Pred (M) Dex (M)
b) Terminal Differentiation
Pred (M) Dex (M)
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3.4 Glucocorticoid Receptor Antagonist
3.4.1 Introduction
Glucocorticoid hormones regulate physiological activity of almost all cell types in
mammals via the soluble GC receptor, which becomes activated in the presence of an
appropriate ligand.
These GC effects can be blocked by the addition ofRU486 (Mifepristone), which was the
first active antagonist to progesterone and GC that could be used in humans (Cadepond et
al, 1997). The main structural characteristic is the phenyl-aminodimethyl group grafted
onto the 1 IB-position of the steroidal skeleton, so that it has high affinity interactions with
a specific region of the receptor-binding pocket in the ligand-binding domain. RU486
binds with a high affinity to both the progesterone and GCR, but not the mineralocorticoid
receptor.
Following steroid binding, the receptors undergo a conformational change that is crucial
for receptor interaction with cellular targets. The antagonist binding seems to trigger a
transconformation of the hormone-binding domain that differs from that observed with
agonist binding. In vitro RU486 stabilises the hsp90 containing heteroligomeric complex
with the GCR (Lefebvre et al, 1988), thus impeding or slowing down the formation of the
activated receptor form and impairs nuclear transfer of the GCR in intact thymocytes
(Lefebvre et al, 1988). However these in vitro actions are still controversial (Pekki et al,
1994).
The aim in this experiment was to ascertain if the negative GC effects on the ATDC5 cell
line were mediated through the GC receptor. The chondrocyte proliferation rate was
assessed with GCR antagonist - RU486, Dex and both compounds in combination to
assess possible reversal of the antiproliferative effects ofDex.
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3.4.2 Materials and Methods
a) Chondrocyte cell culture
The ATDC5 chondrocyte line was maintained and cultured as described (3.1.2a). The
GCR antagonist (GCRA) was incubated at 3 concentrations (10"6, 10"8 and 10~10M) from
day 6 to ascertain independent effects on the ATDC5 cell line. Additionally these 3
concentrations of the GCRA were also co-incubated with Dex 10"6M to assess the effects
of chondrocyte proliferation.
b) Chondrocyte proliferation
The rate of chondrocyte proliferation was assessed by incubating the chondrocytes with
0.2uCi/ml of [3H]-thymidine for the last 18 hours of the culture period as described
(3.2.2b). The amount of radioactivity incorporated was measured during the chondrogenic
phase on day 9.
3.4.3 Statistical analysis
Data was analysed by analysis of variance. All data are expressed as the mean ± sem of
four observations within each experiment and statistical analysis was performed using
Statview (version 5.0.1). A p value of <0.05 was considered to be significant.
3.4.4 Results
RU486 had no effect on chondrocyte proliferation at the 10"6M, 10"8M or 10 I(IM (Fig
3.5). Similar to earlier experiments Dex 10"6M caused a 57% significant reduction in cell
proliferation compared to the control cultures (p<0.05). Dex combined with the two lower
o in*
doses of RU486 (10" and 10" M) did not reduce the anti-proliferative capability of Dex;
showing a significant 57% and 58% reduction in cell proliferation as compared to the
control group (p<0.05)
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However co-incubation of Dex with the higher concentration of RU486 at 10~6M, did
significantly reverse the Dex effects (p<0.05) towards but not back to control levels
ending in a 23% reduction from control levels (Fig 3.5)
3.4.5 Discussion
This experiment provides evidence that the effects of the GC are mediated through the GC
receptor. Dex as in the previous experiments reduces proliferation; this is partially
reversed by the higher concentration of GCRA and it is possible that complete reversal
may be achieved by higher doses of the GCRA. In vivo it has been shown that there is
discrepancy between the doses of the two compounds as 400mg of RU486 antagonises
lmg ofDex (Raux-Demay el al, 1995). The antiprogesterone activity in vivo is utilised in
obstretrics for voluntary early pregnancy termination (Cadepond et al, 1997) and the
antiglucocorticoid activity (Bertagna et al, 1984), eliminates the negative feedback of
Cortisol on ACTH, leading to increased ACTH and Cortisol secretion (Hermus et al, 1987).
But so far the only efficient treatment utilising the antiglucocorticoid effect of RU486 is
that ofCushings syndrome secondary to ectopic ACTH secretion or to adrenal carcinoma.
RU486 has been shown to have effects in many body systems, including reversal of Dex
induced muscle atrophy in rats (Konagaya et al, 1986) and in bone marrow it reversed B-
cell apoptosis induced by GC (Garvy et al, 1993). It has similar GC reversing actions in
osteoclasts (Wada et al, 1994). However there is scant data on chondrocyte effects,
although Di Battista et al, 1991, did demonstrate a complete reversal of Dex induced
suppression ofmetalloprotease synthesis in human chondrocytes.
This is the first documented study showing that chondrocyte proliferation in vitro can be
partly reversed by a GCRA, however in vivo it is possible that RU486 may have weak
agonist activity explaining why no clinical symptom of Cortisol deficiency is observed
after RU486 administration (Kling et al, 1993).
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Figure 3.5. GC and GCR Antagonist effects on cell proliferation.
Effect of Dex 10~6M and GCR Antagonist (RU486) on cell proliferation as assessed by
[ H]-thymidine uptake during chondrogenesis. Dex decreased cell proliferation (p<0.05),
whereas the GCRA had no significant effects on proliferation. During co-incubation of
Dex 10"6M with increasing concentrations of GCRA, the negative effects of Dex were
partially reversed towards control levels by GCRA at 10"6M. All data expressed as the
mean ± SEM, * = significance compared to control (* p<0.05). f = significance level
between Dex 10"6M and combined RU486 10"6M + Dex 10"6M (f p<0.05).
15
RU486 (M) RU486 (M) +
Dex 10"6M
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3.5 Receptor Expression and Reversal of GC effects
3.5.1 Introduction
GCs cause a decrease in cell proliferation and cell number and reduce matrix synthesis
while increasing differentiation. Although GC effects appear to be mediated through the
GCR the ATDC5 cell line was further characterised to ascertain the temporal expression
of the GCR. In addition IGF-IR receptor and GHR expression was also determined prior
to the treatment of the cell line with IGF-I and GH.
Initial data revealed that in the presence of insulin, IGF-I or GH did not have effects on
chondrocyte proliferation. Insulin is an important regulator of chondrocyte growth and the
ATDC5 cell line undergoes the full extent of chondrocyte proliferation, differentiation and
mineralisation in the presence of insulin (Atsumi et al, 1990). The insulin receptor and the
IGF-IR belong to the same subfamily of receptor tyrosine kinases and thus share a high
similarity of structure and intracellular signalling events. (Dupont & LeRoith, 2001). Thus
subsequent experiments were carried out in the absence of insulin in the culture medium
and restricted to the chondrogenic phase, as this is where the majority of the GC effects
were centred.
3.5.2 Materials and Methods
a) Gene expression
To determinate the onset of the expression
ATDC5 cells were grown for up to 16 days
reverse transcribed and analysed for receptor
semi-quantitative RT-PCR.
of the GC, GH and IGF-I receptors, the
as described (3.1.2b). RNA was extracted,
expression at Day 6, 9, 11, 13 and 16 by
b) RNA extraction and Semiquantative RT-PCR
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Total RNA, extracted from chondrocytes by repeated aspiration and gene expression was
analyzed by semiquantitative RT-PCR as described (3.1.2 c & d). PCR was performed in
20-pl reactions containing cDNA equivalent to lOng RNA and 200nM gene-specific
primers in 11.1 x PCR buffer (Jefferies et al 1998) (Table 3.3).
c) Chondrocyte cell culture
The ATDC5 chondrocyte line was maintained and cultured until confluent on day 6
(3.1.2a). Insulin (lOug/ml) was added into the culture medium at day 6 as before but in
subsequent experiments, insulin was not added into the standard culture medium when the
cell layer became confluent (Day 6). At day 6, Dex 10"6M was added to all wells and
Insulin (Bacham, St Helens, UK) and IGF-I (Bacham) was added to the Dex containing
wells at final concentrations of 50ng/ml, lOOng/ml and 500ng/ ml to obtain a dose
response. Further experiments were undertaken to ascertain the effects of IGF-I and GH
(Bacham), both at 1OOng/ml on chondrocyte proliferation in the presence of Dex 10"6M.
All experiments were undertaken in triplicate.
d) Chondrocyte proliferation
At day 8 the rate of chondrocyte proliferation was assessed by incubating the
chondrocytes with 0.2uCi/ml of [ H]-thymidine for the last 18 hours of the culture period
and the amount of radioactivity measured (3.2.2 b).
3.5.3 Statistical analysis
Data was analysed by analysis of variance. All data are expressed as the mean ± sem of
four observations within each experiment and statistical analysis was performed using
Statview (version 5.0.1). A p value of <0.05 was considered to be significant.
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3.5.4 Results
Temporal Expression ofGC, GH and IGF-I receptors.
Using gene specific primers (Table 3.3), the GC and IGF-I receptors are both expressed at
the first time point of 6 days. The GH receptor is expressed from day 9 onwards (Fig 3.6).
Chondrocyte Proliferation
Initial experiments in the presence of insulin containing medium failed to show any
difference in the rate of proliferation, with both IGF-I and GH at concentrations of
50ng/ml and 500ng/ml (Fig 3.7a,b).
In further experiments when insulin was omitted from the culture medium, Dex 10"6M
caused a significant decrease in proliferation (p<0.05). Dex cultured with insulin at
concentrations of 50, 100 and 500ng/ml showed there was no reversal of the Dex effects
on proliferation which remained significantly below control levels (p<0.05) (Fig 3.8).
However IGF-I at all three concentrations reversed the negative Dex effects with a peak
proliferation at a concentration of lOOng/ml (Fig 3.8). All three doses of IGF-I resulted in
proliferation rates greater than the control cultures (p<0.05).
The IGF-I dose response data was utilised to study the effects of IGF-I and GH on
chondrocyte proliferation (Fig 3.9). Dex and GH caused a decrease in proliferation
(p<0.05), whereas IGF-I alone or in combination with Dex, GH or both causes a
significant elevation in cell proliferation above control values (p<0.05).
3.5.5 Discussion
The ATDC5 cell line expresses both the GC and IGF-I receptors from the onset of the
chondrogenic phase whereas GHR expression appears towards the onset of terminal
differentiation. This may explain the lack of GH effects as these experiments were carried
out at day 8, alternatively it could have been a suboptimal GH concentration. Subsequent
87
Chapter three Cell Culture Studies
studies by another group have also confirmed that this cell line expresses the GCR
(Siebler et al, 2002).
The dose response data was very important for future experiments as it established that
IGF-I effects are maximal at lOOng/ml, with no additional benefit from increasing the
concentration. Although IGF-I reversed the antiproliferative effect of Dex and indeed
superseded the control values, increasing the dose of IGF-I to 500ng/ml did not result in a
further increase in cell proliferation, but caused a small reduction compared to IGF-I at
lOOng/ml. It is possible that there could be a downregulation in IGF-IR expression with
increasing doses of IGF-I, but this requires further study.
Insulin plays an essential part in the regulation of cartilage and bone metabolism
(Fitzsimmons et al, 2004; Torres et al, 2003). Both Insulin and IGF-I share similar
signalling pathways, therefore the standard insulin concentration (lOug/ml) used in the
culture of the ATDC5 cells may mask the IGF-I effects even at high doses of 500ng/ml.
This would then be the reverse of the in vivo situation where circulating IGF-I levels are
approximately 1000 times higher than insulin (Simpson et al, 1998). It could also be
argued that IGF-I is merely replicating the insulin effects, which was used as a standard
addition in earlier experiments; although this is possible we would then have expected to
see some reversal of the Dex effects with insulin. Similarly in vivo experiments indicate
that IGF-I is more important for growth as mice lacking insulin receptors show only slight
growth retardation at birth (Louvi et al, 1997), whereas IGF-IR null mice are extremely
growth retarded (Liu et al, 1993).
Thus it is apparent that GH and IGF-I effects in this experiment cannot be fully compared
to the initial Dex and Pred data as the lack of insulin in these experiments is a confounding
variable, but it is apparent that the proliferative properties of IGF-I are much greater than
Insulin at equivalent concentrations and that Dex has antiproliferative effects with or
without insulin and these are completely reversed by IGF-I.
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Table 3.3. Primer pairs used to study expression of GC, GH and IGF-I receptors.
Gene Primer Sequence Product Size (bpl




GHR CATTGGCCTCAACTGGACTT (F) 283
GACTTCGCTGAACTCGCTGT (R)
IGF-IR CACCGAGAACAACGAGTGCT (F) 366
GTCACCGAATCGATGGTTTT (R)
89
Chapter three Cell Culture Studies
Figure 3.6. Semiquantative RT-PCR analysis of the expression of the GC, GH and IGF-I
receptors. GC and IGF-I receptors are expressed from day 6, whereas the GH receptor is
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Figure 3.7. Chondrocyte proliferation with GH and IGF-I in the presence of insulin
containing medium as assessed by [3H]-thymidine at day 8 in the presence of a) GH and
IGF-I both at 50ng/ml, and b) GH and IGF-I both at 500ng/ml. All data expressed as the
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Figure 3.8. Effects of Dex 10"6M, Insulin and IGF-I (both at 50, 100 and 500ng/ml) on
chondrocyte proliferation as assessed by [3H]-thymidine uptake at day 8 in the
chondrogenesis period. Insulin was not a standard addition to the culture fluid. All data
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Figure 3.9. Effect of Dex 10"6M, GH and IGF-I (both at lOOng/ml) on cell proliferation as
assessed by [HI]-thymidine uptake at day 8 in the chondrogenesis period. Dex and GH
caused a significant reduction (p<0.05), whereas all IGF-I treatments cause a significant
elevation in proliferation (p<0.05). All data expressed as the mean ± SEM, * =









Cont Dex IGF-I GH IGF-I IGF-I GH GH
+ GH + Dex + Dex + Dex
+ IGF-I
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CHAPTER 4
ORGAN EXPLANT STUDIES
4.1 The influence of Glucocorticoids and Growth Factors on Metatarsal Growth:
Direct Linear Growth and Histomorphometry.
4.2 Metatarsal Chondrocyte Proliferation and Differentiation.
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4.1 The Influence Of Glucocorticoids And Growth Factors On Metatarsal Growth:
Direct Linear Growth And Histomorphometry.
4.1.1 Introduction
Most children who require systemic GCs also suffer from chronic inflammatory disease
and, in the clinical scenario it can be difficult to clearly assess the relative contribution of
disease and drugs on growth. In these children, maintenance of growth is a complex
process that is influenced by a number of different mechanisms that affect the GH/IGF-1
axis by disrupting GH secretion or altering GH/IGF-1 sensitivity (Allen et al, 1996).
The dual effector theory of GH/IGF-1 action at the growth plate proposes that GH acts
directly on germinal zone precursors of the growth plate to stimulate the differentiation of
chondrocytes and then amplify local IGF-I synthesis which, in turn, induces the clonal
expansion of chondrocyte columns in an autocrine/paracrine manner (Isaksson et al,
1987). Although liver derived IGF-I is the main determinant of serum IGF-I levels, it
appears not to be as important for postnatal growth as locally derived IGF-1 (Yakar et al,
1999 & 2002).
The complex effects and physiological mechanisms of GC on growth plate chondrocytes
are difficult to study solely in live animals where effects cannot be localised to specific
cell types. The foetal mouse metatarsal explant culture is a highly physiological model for
studying growth as the growth rate of foetal bones in culture is similar to that found in
vivo whereas bones harvested postnatally from 2-day-old rats arrest in culture after 2-days
in vitro (Scheven & Hamilton, 1991; Coxam et al, 1996). In addition, the metatarsal
culture model maintains cell-cell and eel I-matrix interactions and the direct assessment of
bone growth and histological architecture can be determined. By using the foetal mouse
metatarsal assay, the aims of the present studies were to obtain a clearer understanding of
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the cellular events underlying GC induced growth retardation and, in addition, determine
whether IGF-I and GH can ameliorate the effects of GC on bone growth.
4.1.2 Materials and Methods
a) Foetal metatarsal organ culture
The middle three metatarsals were aseptically dissected from 18 day old embyronic Swiss
mice. Bones were cultured at 37°C in a humidified atmosphere of 95% air/5% CO2
individually in 24 well plates (Costar, High Wycombe, UK) for up to 10 days. Each well
contained 300pl of a-MEM without nucleosides (Invitrogen, Paisley, UK) supplemented
with 0.2% BSA Cohn fraction V (Sigma, Dorset, UK), O.lmmol/L P-glycerophosphate
(Sigma), 0.05mg/ml L-ascorbic acid phosphate (Wako, Japan), 0.292mg/ml L-glutamine
(Invitrogen), 0.05mg/ml gentamicin (Invitrogen) and 1.25ug/ml fungizone (amphotericin
B) (Invitrogen). Dex (Sigma), IGF-I (Bacham, St. Helens, UK) and GH (Bacham), were
added at a final concentration of 10~6M, lOOng/ml and lOOng/ml, respectively, to the
cultured bones. The control and experimental groups contained 6 metatarsals each and the
experiment was repeated at least twice.
b) Morphometric analysis
Images were taken of the metatarsals every second day of culture using a digital camera
(COHU, San Diego, USA) attached to an Olympus M081 microscope. The total length of
the bone and width through the centre of the mineralising zone was determined using
Image Tool (Image Tool version 3.00, University of Texas Health Life Science Centre in
San Antonio). All results are expressed as a percentage change from harvesting length,
which was regarded as baseline to demonstrate the rate of growth over time. For the
determination of the size (in direction of longitudinal growth) within the growth region of
the distinct chondrocyte maturational zones the 4 and 10-day-old metatarsals were fixed in
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70% ethanol, dehydrated and embedded in paraffin wax (Haaijman et al, 1997). Wax
sections (10 pm in thickness) were reacted for ALP activity (Farquharson et al, 1992) for
the demarcation of the hypertrophic and proliferating zones. Serial sections were stained
with von Kossa and haematoxylin & eosin using standard protocols to identify the zone of
cartilage mineralisation. Images of the stained metatarsals were captured using Image tool
(University of Texas) and the size of the combined (distal and proximal) ALP negative
proliferating zone was determined (equation 1). Similarly, the size of the combined ALP
positive hypertrophic zone located at either side of the mineralising zone was determined
(equation 2). The size of the mineralising zone was determined directly from the von
Kossa stained sections. (1). Proliferating zone = total length - (hypertrophic zone +
mineralising zone), (2). Hypertrophic zone = (hypertrophic zone + mineralising zone) -
mineralising zone.
4.1.3 Statistical analysis
All data are expressed as the mean ± sem and statistical analysis was performed using an
analysis of variance (GenStat, Sixth Edition, VSN International Ltd). A p value of <0.05
was considered to be significant.
4.1.4 Results
All foetal mice metatarsals grew in culture and displayed a central core of mineralised
cartilage juxtaposed on both sides to a translucent area representing the hypertrophic
chondrocytes (Figs. 4.1 & 4.2b,c,d). Digital images were taken every second day and the
control metatarsal shown in Fig 4.1 demonstrates an increase in total length and the length
of the mineralising zone. The localisation ofALP reactivity within metatarsal sections was
restricted to the mineralising and hypertrophic chondrocytes and thus clearly delineated
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the boundary between the proliferating and hypertrophic zones (Fig. 4.2e) whereas von
Kossa staining was specific to the mineralising zone.
Longitudinal bone growth
All experiments were done on metatarsals from 18-day-old embryos that were cultured for
intervals for up to 10 days. Dex-treated bones paralleled control bone growth rate until
day 8 when their rate of growth decreased resulting in a total length that was significantly
reduced from controls at day 8 (p<0.05) and 10 (p<0.05), (Fig. 4.3a). IGF-I and combined
IGF-I+Dex-treated bones showed a rapid acceleration in growth from day 2 that was
significantly higher than the control group (p<0.05) and this increased growth rate was
maintained throughout the duration of the experiment. At day 10, mean increase from
baseline in total length of control, Dex, IGF-1 and IGFl+Dex bones was 50% ± 3, 42% ±
2, (p<0.05) 99.3% ± 5, (p<0.05) and 87% ± 4 (p<0.05), respectively. Compared to the
IGF-I treated bones, the length of the metatarsals treated with IGF-I+Dex was also
significantly lower at days 8 (p<0.05) and 10 (p<0.05). The ability of GH to directly
influence bone growth in this model system was also studied (Fig. 4.3b). In contrast to the
growth promoting effects of IGF-I (Fig. 4.3a), GH was found to have no significant effects
on total bone length as compared to control metatarsals.
In control bones there was a significant increase in the length of the mineralising zone by
day 6, and by day 10 the mean increase in length from baseline was 122% ± 2, (p<0.05)
(Fig 4.3c). The mineralising zone length of the IGF-I treated bones changed little
throughout the culture period and by day 10 it had only increased from baseline by a mean
of 10% ± 2 (p<0.05). Also by day 10 the length of the mineralising zone in the Dex-
treated metatarsals had increased by a mean of 79% ± 19% (p<0.05) from baseline,
significantly less than in the control metatarsals (p<0.05). The growth rate of the
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mineralising zone in the IGF-I+Dex treated metatarsals was also less than control and Dex
treated metatarsals with the mineralising zone length significantly decreased at day 6 (11%
± 5, p<0.05), day 8 (32% ± 8, p<0.05), and day 10 (33% ± 10; p<0.05) from the control
bones. Overall this data suggests the existence of an inverse relationship between the
length of the mineralisation zone and total bone length (Figs 4.3a & c).
The thickness of the control and Dex treated metatarsals did not change with time in
culture and were not significantly different from each other at any of the time points
examined (Fig. 4.3d). In comparison to the controls, both the IGF-I and IGF-I+Dex
treated bones were significantly thicker from day 4 (p<0.05) and 6, respectively (p<0.05).
At day 4, the thickness of the IGF-I treated bones was significantly different from the IGF-
I+Dex treated bones. At day 10, the thickness of the IGF-I and IGF-I+Dex treated bones
were respectively 51% + 10 (p<0.05) and 35% + 14 (p<0.05) greater than that of their
harvesting lengths.
With the exception of the results shown in Fig. 4.3b, the data presented in Figs 4.3a, c & d
(and all subsequent results in this chapter) were obtained from metatarsals of embryos
from the same mother. The differing growth rates shown in Figs 4.3a & b are likely to be
due to variability between the embryos selected for each experiment. The inhibition of
growth rate by Dex was observed in both studies.
Assessment ofchondrocyte maturational zone sizes
In many of the metatarsal rudiments the boundary between the proliferating and
hypertrophic zone of chondrocytes was difficult to delineate whilst in culture, therefore
measurements of the size of these individual maturational zones was performed on
histological sections of 4 and 10 day-old metatarsals. The lengths of the proliferating,
mineralising and hypertrophic zones are shown in (Table 4.1).
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Although Dex decreased and IGF-I increased the length of the proliferating zone these
changes did not reach statistical significance. However, IGF-I+Dex treatment resulted in a
significant increase in the length of the proliferating zone at day 4 (p<0.05), which was not
sustained by day 10. The length of the mineralising zone was significantly reduced with
all treatments at both time points (p<0.05) as compared to the controls. At day 4 there was
a 10% reduction with all treatments, this decrease became larger by day 10, with Dex,
IGF-I and IGF-I+Dex causing a 16, 51 and 42% reduction respectively in the length of the
mineralising zone as compared to the control bones (p<0.05). Dex caused a non¬
significant increase in the length of the hypertrophic zone at day 4 and 10. In contrast,
IGF-I led to a marked increase in the length of the hypertrophic zone at day 4 (98%
increase, p<0.05) which became more pronounced by day 10 (346% increase, p<0.05)
(Table 4.1, Figs 4.4 a & b). The combined effects of IGF-I+Dex were similar to IGF-I
exposure alone, resulting in a 74% and 233% increase in length at day 4 and day 10,
respectively (p<0.05) (Table 4.1). The size of the individual hypertrophic chondrocytes in
the 10-day IGF-I treated metatarsals was also much larger than those of the Dex treated
metatarsals (Figs 4.4c & d).
4.1.5 Discussion
The growing foetal chondrocytes undergo the three principal stages required for normal
foetal growth: proliferation, hypertrophy and mineralisation as shown in this study. The
foetal metatarsals have a relatively smaller mineralising zone than the newborn rodent and
thus the cartilaginous portions retain a greater capacity for chondrocyte proliferation and
hypertrophy; making them an ideal model to study growth plate effects.
The results unequivocally show that Dex and IGF-I have major and opposite effects on
longitudinal bone growth with IGF-I clearly reversing the growth inhibitory effects of
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Dex. However, the potential for Dex to inhibit bone growth was still present in the IGF-
I+Dex cultures where the growth rates did not match those of bones cultured with IGF-I
alone. Similar effects with other GC have previously been reported by Picherit et al, who
demonstrated that hydrocortisone induced growth retardation in foetal rat metatarsals
(Picherit et al, 2000).
The IGF-I stimulation in linear growth is similar to the results achieved by Scheven and
Hamilton (1991), however, these workers reported GH stimulatory effects on metatarsal
length, which is in contrast to the data of this present study. Whilst GH is well recognised
to stimulate longitudinal bone growth in vivo (Isaksson et al, 1982, Hunziker et al, 1994),
its effects in vitro are less clear (Lindahl et al, 1987; Ohlsson et al, 1994). Other studies
have strongly suggested that GH effects in vivo may be indirect and that IGF-I effects are
more pervasive in vitro (Vetter et al, 1986; Trippel et al, 1989).
A morphometric analysis was completed to further characterise the response of
metatarsals to both Dex and IGF-I with respect to the size of the individual maturational
zones within the growth plate. The reduction in length of the mineralisation zone with Dex
was consistent with metatarsals treated with hydrocortisone (Picherit et al, 2000).
However, the absence of an increase in the length of this zone following IGF-I is at
variance to others who have demonstrated an increase in mineralisation zone length with
IGF-I in a rat metatarsal model system (Coxam et al, 1996). Dex also led to a small, non¬
significant, increase in the length of the hypertrophic zone which is similar to the findings
of Smink and colleagues (2002) who demonstrated an increase in the hypertrophic zone
length in mice treated with Dex. They further postulated that this was a likely consequence
of an acceleration of the chondrocyte differentiation rate as observed in PTHrP null mice
(Kronenberg et al, 1997). Alternatively, due to the restriction of cartilage mineralisation,
the increased size of the hypertrophic zone may be in part be due to a simple build up of
non-mineralised hypertrophic chondrocytes. A similar, more pronounced process, may
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explain the more marked reduction in the mineralisation zone observed in the IGF-I
treated metatarsals. Additionally another non-significant difference was noted between
IGF-I and Dex on the proliferating zone length. It was deemed important to report these
trends as subsequent experimentation may confirm or refute these observations, thus
reducing the risk of a type 1 or type 2 errors.
In contrast to the effects ofDex, IGF-I rapidly stimulated linear bone growth by increasing
the size of the hypertrophic chondrocytes, thus increasing the length of this zone. Within
the maturational zones of the growth plate, the major effects of IGF-I were clearly on the
length of the hypertrophic chondrocyte zone and also the size of the cells within. This
result is in accord with the hypothesis that it is the size of the hypertrophic zone rather
than chondrocyte proliferative kinetics that is the single major determinant of bone growth
rate (Wilsman et al, 1996; Hunziker & Schenk, 1989). Although IGF-I is expressed by
chondrocytes situated in all maturational zones of the growth plate, IGF-I mRNA
expression is mainly restricted to the hypertrophic zone and the infusion of IGF-I into
hypophysectomised rats showed that IGF-I stimulated growth plate chondrocytes at all
stages of differentiation including those in the hypertrophic zone (Hunziker et al, 1994;
Smink et al, 2002; Reinecke et al, 2000).
The growth retardation in the IGF-I null mouse is associated with an attenuation of
chondrocyte hypertrophy and no significant changes in proliferation (Wang et al, 1999)
and this data further strengthens the hypothesis that the predominant role of IGF-I in
growth promotion is in augmenting chondrocyte hypertrophy. This effect of IGF-I can
reverse GC induced growth retardation but this apparent ameliorative effect results in an
alteration of the relative proportion of proliferative, hypertrophic and mineralised
chondrocytes.
In conclusion, this study shows that Dex and IGF-I have opposite effects on linear bone
growth. The effects of Dex were time dependent whereas IGF-I effects were immediate.
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Dex decreased skeletal mineralisation while IGF-I markedly stimulated chondrocyte
hypertrophy in favour of mineralisation and completely reversed Dex induced growth
retardation. However, the potential for Dex to inhibit bone growth was still present in the
IGF-I+Dex cultures where growth rates did not match those of bones cultured with IGF-I
alone. In addition, the IGF-I mediated improvement in growth was at the expense of
altering the balance between proliferating and hypertrophic chondrocytes within the
metatarsal. GH had no beneficial effect on metatarsal growth at the dose studied.
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Figure 4.1. Linear Metatarsal Growth in Culture: The same control bone grown for 10
days in culture is shown. Digital images were taken every two days of every bone and the
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Figure 4.2. Measurements of digital images of foetal mouse metatarsal bones in culture
with clearly delineated mineralising zones (b - d) were taken using a calibrated ruler (a).
These images demonstrate the harvesting day length (b) and the increased longitudinal
growth at day 4 (c). An IGF-I exposed metatarsal at day 10 is illustrated in (d). Section of
an IGF-I treated metatarsal at day 10 reacted for ALP activity showing staining within
both the mineralising (MZ) and hypertrophic zone (HZ). The proliferating zone (PZ) is
negative for ALP activity (e).
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Figure 4.3. Linear Metatarsal Growth after Dex, IGF-I and GH exposure (a) Dex at 10 M
caused a significant decrease in linear growth from 8 days, whereas IGF-I and IGF-I+Dex had
significant stimulatory effects from 2 days (b) Effects of GH lOOng/ml and Dex lO^M on total
length. GH had no significant effects on total length. Again Dex significantly decreased the
total length from day 8 (p<0.05). (c) Effects of Dex, IGF-I and IGF-I+Dex on the length of the
mineralised zone. In the control metatarsals, mineralisation increased from 4 days. All
treatments caused a significant reduction in mineralisation from day 6. IGF-I treated bones
were the least mineralised, whereas Dex and IGF-I+Dex effects were intermediate, (d) Effects
of Dex, IGF-I and IGF-I+Dex on metatarsal thickness. Both IGF-I and IGF-I+Dex caused a
significant increase in the metatarsal thickness from day 4 and 6 respectively. Results shown in
a, c and d were obtained from the same cultures whereas the data shown in b were from a
separate experiment. All data is expressed as the mean + SEM, * = significance compared to
control (* p<0.05). f = significance of IGF-I compared to IGF-I/Dex (f p<0.05). Dex 10"6M
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Figure 4.4. Histological assessment of chondrocyte hypertrophy (a -d) in metatarsals
treated with Dex and IGF-I. Haematoxylin & eosin stained sections of 10-day-old
cultures of control (a & c) and IGF-I (b & d) treated metatarsals. There is an increase in
the size of the hypertrophic zone of the IGF-I treated metatarsals (b) compared with
controls (a). The chondrocytes of the hypertrophic zone of the metatarsals in a & b are
shown in higher magnification in c & d. The chondrocytes juxtaposed to the von Kossa
positive mineralised cartilage are larger in the IGF-I treated (d) than in the control
metatarsals (c). Note the micrographs shown in figs a & b are taken at different
magnifications to accommodate the increased length of the IGF-I treated metatarsals. P -
proliferating chondrocytes; H - hypertrophic chondrocytes; dashed line (—) marks the
boundary between the proliferating and hypertrophic zones. Magnifications: a = bar 100
pm; b = bar 200 pm; c & d = 25 pm.
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Table 4.1. Lengths of the proliferating, mineralising and hypertrophic zones. Data
expressed in micrometers (pm) ± sem, * = significance compared to controls (* p<0.05).
Treatment Proliferating Zone Mineralising Zone Hypertrophic Zone
Day 4 Day 10 Day 4 Day 10 Day 4 Day 10
Control 140.4 ±3.0 122.6 ±7.0 53.7 ± 1.3 102.0 ±3.4 38.2 ± 1.7 36.7 ±4.4
Dex 129.0 ±2.4 120.3 ±4.2 48.5 ±1.9* 84.2 ± 7.4 * 42.6 ±4.0 40.2 ± 15.1
IGF-I 150.6 ±5.6 123.8 ±5.0 48.8 ± 1.5 * 49.3 ± 2.2 * 75.6 ± 1.4 * 163.4 ± 7.6 *
IGF-I+Dex 159.8 ± 8.9 * 137.0 ±4.7 48.5 ± 1.5 * 57.8 ±3.5 * 66.6 ±8.4 * 122.0 ± 3.1 *
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4.2. Metatarsal Chondrocyte Proliferation and Differentiation.
4.2.1 Introduction
Having established that Dex retards and IGF-I accelerated linear growth, this experiment
set out to ascertain mechanisms by which these two compounds could be having their
differential effects on chondrocyte proliferation and hypertrophy.
Undifferentiated progenitors within the reserve stem cell zone differentiate into
chondrocytes and progress through to the proliferative phase. However the perichondrium
and periosteum are now increasingly known to participate in the regulation of limb
growth, serving as potential sources of signalling molecules that are involved in
chondrocyte proliferation, maturation and hypertrophy (Colnot et al, 2004). The tissues
that give rise to the appendicular skeleton namely the cartilage and perichondrium are
derived from the same population of mesenchymal cells. During development some
mesenchymal cells begin to flatten, elongate and form the perichondrium, whereas cells in
the central condensation differentiate into chondrocytes to form the cartilage skeleton.
However the nature of the tissue interactions between the cartilage and perichondrium is
not well understood, as organ culture work has shown that removal of the perichondrium
results in an increase in chondrocyte proliferation and longitudinal growth in chick
embryonic bone (Long & Linsenmayer, 1998). Conversely in mice ex vivo models the
perichondrial removal resulted in growth arrest with little formation of trabecular and
periosteal bone (Colnot et al, 2004).
Although the previous data indicate that IGF-I is a powerful growth stimulatory and
proliferative agent, this metatarsal culture model allowed the direct localisation of the
proliferative effects of Dex and IGF-I to the cartilaginous growth plate or the
perichondrium. Additionally biochemical corroboration was sought of the observation that
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IGF-I has a three-fold increase in the length of the hypertrophic zone, by measuring the
alkaline phosphatase activity within the metatarsals.
4.2.2 Materials and Methods
a) Foetal metatarsal organ culture
The middle three metatarsals were aseptically dissected from 18-day old embyronic Swiss
mice and Dex and IGF-I were added at a final concentration of 10"6M and lOOng/ml,
respectively, to the same cultured bones as described in 4.1.2a.
b) Alkaline Phosphatase (ALP) enzyme activity
At the end of the culture period (day 10), ALP activity within the metatarsals was
determined as previously described (Deckers et al, 2001). Briefly, each metatarsal was
permeabilised in 100 pi of 10 mmol/L glycine (pH 10.5) containing 0.1 mmol/L MgC^,
0.01 mmol/L ZnCh and 0.1% Triton-X-100 by freeze-thawing three times. The extract
was assayed for ALP activity by measuring the rate of cleavage of 10 mM p-nitrophenyl
phosphate (pNPP). Total ALP activity was expressed as nmoles pNPP
hydrolysed/min/metatarsal. Each group contained 3 metatarsals and the experiment was
repeated at least twice.
c) Cell proliferation and dry weight determination
fH]-thymidine uptake.
On day 4 and 10 of culture [3H]-thymidine (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK) was added (final concentration 10 pCi/ml) to each metatarsal
culture for the last 6 hrs of culture. After washing in phosphate buffered saline (PBS) the
metatarsals were extracted in trichloroacetic acid (2 x 30 min), acetone (2 x 30 min), ether
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(3 x 30 min) and air dried overnight at room temperature. After the determination of dry
weight (Sartorious, micro Gottingen, Germany) the tissue was solubilised (NCS-II tissue
solubilizer, Amersham) and the DNA incorporated [ H]-thymidine was determined using a
scintillation counter (Haaijman et al, 1997). The cell proliferation data was expressed as
[3H]-thymidine (dpm)/metatarsal. Each group contained 3 metatarsals and the experiment
was repeated at least 2 times.
Histological assessment ofBromodeoxyuridine uptake.
Bromodeoxyuridine (BrdU) (Sigma) was added (final concentration 1 mg/ml) to the
culture medium of the metatarsals for the last 6 hrs of culture on day 4 and 10 as described
previously (Haaijman et al, 1997). At the end of the incubation period the tissue was
washed in Phosphate Buffered Saline (PBS) and fixed in 70% ethanol, dehydrated and
embedded in paraffin wax. Sections, 10 pm in thickness, were cut along the longitudinal
axis and chondrocyte nuclei with incorporated BrdU were detected using an indirect
immunofluoresence procedure as detailed (Farquharson et al, 1993). Briefly, sections
were denatured with 1.5 M HC1 for 30 min before incubation with an antibody to BrdU
(DAKO, Ely, Cambridgeshire, UK) diluted 1:50 in PBS for 1 h. After washing, the
sections were incubated for a further 1 h in FITC-labeled goat anti-mouse IgG (Sigma)
diluted 1:50 in PBS. The sections were finally mounted in PBS/glycerol (Citifluor, Agar
Scientific, Essex, UK). Sections were examined using a Leica BMRB fluorescent
microscope and the total number of BrdU positive chondrocytes within both the proximal
and distal growth regions was determined. BrdU labelled cells located to the
perichondrium were also counted. Three sections from each of 6 bones from each
treatment group at both time points were examined to obtain an aggregate value.
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4.2.3 Statistical analysis
All data are expressed as the mean ± sem and statistical analysis was performed using an
analysis of variance (GenStat, Sixth Edition, VSN International Ltd). A p value of <0.05
was considered to be significant.
4.2.4 Results
Dry weights
At days 4 and day 10 there was no significant difference between the weights of the
control and Dex treated metatarsals. They were, however, significantly lighter (p<0.05)
than the IGF-I and IGF-I+Dex treated bones, which were themselves similar in weight to
each other at both time points (Table 4.2).
Metatarsal ALP enzyme activity
The enlargement of the hypertrophic zone seen with IGF-I treatment after 10 days in
culture (from previous experiment; section 4.1.4 & Table 4.1) was further studied by
determining ALP activity in the metatarsals at the end of the culture period The ALP
activity (nmoles/hydrol/min/metatarsal) expressed as mean ± SEM was as follows;
Control 0.0187 ± 0.009
Dex 0.0117 ±0.009
IGF-I 0.038 ± 0.0061 *
IGF-I+Dex 0.026 ± 0.0044
= significance compared to controls (p < 0.05).
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In agreement, with the increase in hypertrophic zone length from the previous experiment
(Table 4.1; Fig 4.4b), IGF-I treatment resulted in significantly elevated levels of ALP
activity within the metatarsals (103% increase, p<0.05) compared to the control bones.
Combined IGF-I+Dex caused an increase and Dex treatment alone a reduction in ALP
activity, these two results were not, however, significantly different from the control
values.
Cell Proliferation: [3H]-thymidine incorporation & BrdU staining
The incorporation of [ H]-thymidine into the metatarsals was determined at days 4 and 10,
representing two distinct phases of varying growth rates. There was a tailing off in the
linear growth curve from day 6 in all bones (Fig.4.3a) and this was reflected in lower [3H]-
thymidine incorporation rate in the control metatarsals at day 10 (75131 ± 5864 dpm)
compared to the control bones at day 4 (98608 ± 6732 dpm), (Table 4.3). In comparison to
control bones, Dex treatment for 4 days resulted in a significant reduction (50%, p<0.05)
3 ...in [ H]-thymidine incorporation, whereas both IGF-I and IGF-I+Dex treatment resulted in
significant increases of 43 and 57%, respectively (p<0.05). After 10 days there was a
# 3
significant reduction in [ H]-thymidine incorporation in all treatment groups compared to
the control cultures (Table 4.3). However, this reduction, from control bone values, was
greater with Dex (80%, p<0.05) than that observed with IGF-I (64%, p<0.05) or IGF-
I+Dex (53%, p<0.05).
3 •To further refine the [ H]-thymidine uptake data, the localisation of the proliferating cells
(BrdU positive) was determined and quantified within both the growth plate and the
perichondrium (Figs 4.5 & 4.6).The total number of proliferating cells in all control
metatarsal groups was higher at day 4 than day 10, which is in agreement with the [3H]-
thymidine incorporation data and indicative of slower linear growth with time in culture
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(Table 4.3 and Fig 4.3a). Compared to day 4 control metatarsals, Dex significantly
reduced the number of BrdU positive cells located in the growth plate (42% decrease,
p<0.05) and perichondrium (76% decrease, p<0.05) and therefore also the total number of
dividing cells within the whole metatarsal (56% decrease, p<0.05), (Figs 4.5a, 4.6a & b).
In contrast, IGF-I treatment significantly increased the number of BrdU positive cells in
the perichondrium (76% increase, p<0.05) but not those within the growth plate (Figs 4.5a
& 4.6c). Combined IGF-I+Dex treatment had no significant effect on BrdU incorporation
in the perichondrium and growth plate compared to the control metatarsals at day 4 (Fig
4.5a).
Compared to day 10 control metatarsals (Fig. 4.6d), treatment with Dex alone (Fig. 4.6e),
or in combination with IGF-I, significantly reduced the number of BrdU positive cells
within the perichondrium (Dex: 96% decrease, p<0.05; IGF-I+Dex: 71% decrease,
p<0.05), (Fig. 4.5b). Similarly, treatment with IGF-I alone (Fig. 4.6f) or in combination
with Dex resulted in a reduction in BrdU positive cells within the growth plate
chondrocytes (IGF-I: 63% decrease, p<0.05; IGF-I+Dex: 57%, P<0.05) (Fig. 4.5b). No
cells out with the perichondrium and growth plates showed any BrdU positive staining.
These results indicate that in comparison to chondrocytes within the growth plate, the cells
within the perichondrium are more sensitive to stimulation by IGF-I during the period of
rapid growth (day 4) and inhibition by Dex at both time points.
4.2.5 Discussion
This study reveals that the Dex-induced reduction in total metatarsal length is likely to be
due to a reduction in chondrocyte proliferation as well as a reduction in the length of the
mineralising zone seen in the last experiment. This antiproliferative potential of Dex is in
agreement with the ATDC5 chondrocyte cell culture data as well as other investigators
(Robson et al, 1998).
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IGF-I rapidly stimulated the chondrocyte proliferation rate during the early phase of bone
growth, although this did not persist at 10 days. Scheven & Hamilton (1991) also
demonstrated that the increase in cell proliferation in metatarsals is not sustained with
IGF-I over time, which could indicate the rapid utilisation of endogenous growth factors
needed to support longitudinal growth. Metatarsals treated with IGF-I and Dex displayed
greater cell proliferation than IGF-I treatment alone. The synergistic effect of IGF-I and
Dex on cell proliferation has not been previously reported. It's clinical significance is
unclear but an upregulation of chondrocytes expressing IGF-I following GC exposure has
been reported previously and it is possible that IGF-I is an important local growth factor
that counteracts the effect of GC at the tissue level (Rooman et al, 1999; Borges et al,
1999; Smink et al, 2002).
In order to understand the cellular mechanisms underlying the opposite effects of Dex and
IGF-I on bone length the distribution of BrdU positive cells within metatarsals treated by
both Dex and IGF-I alone and in combination was analysed. The number of dividing cells
within the perichondrium was greatly reduced by Dex at both 4 and 10 days of culture. In
contrast, at 4 days, the number of BrdU positive cells was greater in the perichondrium of
IGF-I treated bones. Stimulation of cell proliferation was not observed in the IGF-I
treated 10-day-old metatarsals and this may be due to the observed slowing of growth in
these rapidly growing bones. In 4-day-old rapidly growing metatarsals, IGF-I completely
reversed the inhibitory effects of Dex on cell proliferation within the perichondrium and
growth plate. This reversal of the negative effects ofDex by IGF-I co-incubation was also
observed, albeit to a lesser extent, in the perichondrial cells of 10-day-old cultures. These
results extend the [ H]-thymidine incorporation data and also confirm the ability of IGF-I
to reverse the deleterious effects of Dex on cell proliferation. The observation that cell
proliferation within the perichondrium was more sensitive to inhibition by Dex and
stimulation by IGF-I than chondrocytes within the growth plate has previously not been
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recognised. The perichondrium is vital to the endochondral process through its role in
mediating the PTHrP-Ihh signalling cascade and it is possible that the marked Dex
induced inhibition of proliferation within cells of the perichondrium has a more direct
effect on the bone growth process (Kronenberg et al, 1997; Long & Linsenmayer 1998;
Maeda & Noda, 2003). Although high levels of IGF-I mRNA expression have been shown
in the perichondrium, there is no data on the effect of GC on the perichondrial cells
(Edmondson et al, 1995). The differential sensitivity of cells to Dex treatment within the
perichondrium and within the growth plate requires further study.
The IGF-I stimulated increase in the length of the hypertrophic zone was biochemically
confirmed by the elevation in ALP. It was of interest to note that the data from the
IGF+Dex treated cultures is consistent with the metatarsal length data where the presence
of Dex partially reduced the effects of IGF-I. In vivo daily IGF-I administration has also
been noted to raise the serum ALP, although this is mainly an indicator of osteoblastic
activity (Laron et al, 1991).
Endochondral bone growth is a dynamic process and studying different time points may
more accurately reflect this process. The data shows that Dex decreased and IGF-I
increased cell proliferation. This alteration in the proliferation rate by both Dex and IGF-I
was most marked within the cells of the perichondrium, with Dex having greater negative
effects on the perichondrial chondrocytes at both time points, whereas the marked initial
stimulatory effects of IGF-I on these chondrocytes were not sustained over time.
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Table 4.2. Dry weights (ug) of the metatarsal bones at day 4 and day 10. Data expressed
as mean ± sem, * = significance compared to controls (* p<0.05).
Treatment
Dry Weights (ug)
DAY 4 DAY 10
Control 34 + 3 84 ±2
Dex 33 ±2 82 ± 5
IGF-I 48 ±2 * 152 ±5 *
IGF-I+Dex 59 ±5 * 147 + 2* ;
Table 4.3. Cell Proliferation: Effect of Dex, IGF-I and IGF-I+Dex on [3H]-thymidine
uptake at day 4 and day 10. All data expressed as the mean ± sem, * = significance
compared to controls (* p<0.05).
Treatment
[3H]-thymidine (dpm)
DAY 4 DAY 10
Control 98608 ± 6732 75131 ±5864
Dex 49521 ±1124 * 15000+ 1612 *
IGF-I 140547 + 9821 * 27631 ± 2594 *
IGF-I+Dex 154941 +3695 * 35470+ 1339 *
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Figure 4.5. Effect of Dex, IGF-I and IGF-I+Dex on the number of BrdU positive cells
within the growth plate (black bars), the perichondrium (white bars) and the combined
number within the growth plate and perichondrium (hatched bars) at (a) day 4 and (b) day
10. Cell proliferation is higher at day 4 than day 10 with all treatments. At day 4 Dex
causes a significant reduction in cell proliferation in the growth plate and perichondrium
(p<0.05), whereas IGF-I increases the number of proliferating perichondrial cells
(p<0.05). By day 10, Dex sustains the decrease in cell proliferation, which is significant in
the perichondrium (p<0.05). Both IGF-I and IGF-I+Dex also cause a decrease in the
number of the positive immunofluorescent cells at this time point. All data expressed as
the mean ± sem, * = significance compared to controls (* p<0.05).
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Figure 4.6. Histological assessment of chondrocyte proliferation (a - f) in metatarsals
treated with Dex and IGF-1. BrdU labelled cells in control (a & d), Dex treated (b & e)
and IGF-I treated (c & f) metatarsals cultured for 4 (a - c) and 10 (d — f) days. Note the
decreased number of proliferating cells in the Dex treated metatarsals and in particular the
lack of staining within the perichondrium (b & e). Increased perichondrial staining is
observed in the 4-day-old IGF-I treated cultures.
Magnifications = bar 100 pm.
119




5.1 Potential for the ATDC5 Cells to Recover Following Dex Exposure.
5.2 Metatarsal Growth Following Variable Lengths of Dex Exposure.
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5.1 Potential for the ATDC5 Cells to Recover Following Dex Exposure
5.1.1 Introduction
Studies in children suggest that growth retardation following a short period of systemic
exposure to GC may be followed by a period of CUG and that alternate day therapy may
be less adverse for growth (Ahmed et al, 1999; Jabs et al, 1996). Catch-up growth has also
been observed in vivo following direct injection of GC into the growth plate of rabbits
(Baron et al, 1994).
GC induced growth retardation is caused by multiple intertwined factors, including direct
effects on the growth plate as demonstrated by Baron et al (1992, 1994) who showed a
77% reduction in growth rate of 5 week old rabbits who had Dex administered directly
into the growth plate. Following cessation of Dex, CUG was observed in the affected
growth plate only and this ultimately corrected half the growth deficit.
There are no in vitro studies looking at the potential for chondrocytes to undergo catch up
growth. In this study, the ATDC5 cell line was used to determine the effect of the GCs on
the ability of chondrocytes to recover following different intervals of GC exposure to
assess the potential for CUG. The ATDC5 chondrocyte cell line undergoes the temporal
sequence of events that occur during longitudinal bone growth in vivo (Atsumi et al, 1990;
Shukanami et al, 1997). As it had been fully characterised it was considered a useful
model to assess if cell recovery following Dex exposure was duration or cell phenotype
dependent.
5.1.2 Materials and Methods
a) Chondrocyte cell culture
The fully characterised ATDC5 chondrocyte line was set up and maintained as described
previously (3.1.2a).
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b) Recoveryfollowing GC exposure
For these experiments, a single concentration of Dex at 10"6M was used as it was noted to
have the most potent effects in earlier experiments. This dose was added to all cells when
confluent (Day 6) and subsequently replaced with differentiation medium without Dex
after 1, 3, 7 and 10 days (Recovery plates). Each time point was studied in quadruplicate.
All cultures were maintained for a total of 14 days along with a group that was exposed to
Dex for the total 14 days duration (no recovery period). Additional culture plates of Dex
(10"6M) treated cells and their respective controls (containing 0.01% ethanol) were
stopped at the allocated time points (Day 1, 3, 7 and 10) to assess the impact of Dex prior
to the period of recovery. Cell number, ALP activity and proteoglycan content were
determined as described previously (3.2.2b).
5.1.3 Statistical Analysis
All experiments were performed at least twice. Data was analysed by analysis of variance.
All data are expressed as the mean ± sem of four observations within each experiment and
statistical analysis was performed using Statview (version 5.0.1). A p value of <0.05 was
considered to be significant.
5.1.4 Results: ATDC5 recovery
Recoveryfollowing GC exposure
Exposure of the ATDC5 cells to Dex for one or more days resulted in lower cell numbers
(protein) on Day 14. These differences however did not reach statistical significance
unless the cells were exposed to Dex for all 14 days (p<0.05) (Fig 5.1a & b). There was a
significant reduction in proteoglycan content after 7, 10 and 14 days of GC exposure (Fig
5.1c). After the recovery period (Fig 5.Id), all Dex exposed cells showed a significant
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reduction in proteoglycan content (p<0.05). ALP activity was increased after Dex
treatment at all days compared to control cultures but this increase was statistically
significant only after 7 (65%) and 14 (148%) days of exposure (Fig 5.1e). After the
recovery period (Fig 5.If) ALP remained significantly elevated from day 10 (p<0.05).
5.1.5 Discussion
In growth failure, amelioration of the growth retarding insult results in a period of
supranormal linear growth described as CUG (Prader et al, 1963). Following cessation of
a unilateral infusion of Dex into rabbit tibial growth plates CUG was observed in the
affected growth plate but not in the contralateral tibia (Baron et al, 1992). It is postulated
that this is due partly to a delay in growth plate senescence by Dex (Gafni et al, 2001).
The ATDC5 cell line allowed the study of this recovery phenomenon in greater detail. No
differences were observed in proteoglycan content in the culture plates stopped prior to
recovery at 24 and 72 hours of treatment. Flowever after the recovery period a reduction in
proteoglycans was apparent at all treatment lengths. This would indicate that Dex-induced
suppression may take some time to manifest itself even though the stimulus for
suppression has been removed. Longer treatments with Dex of 7 and 10 days duration
showed unchanged levels of proteoglycans compared to the 14 day treated group and
indicates that within the timescale of this experiment the ability to recover after 7 days of
Dex treatment was limited. Longer periods of recovery allowed the ALP activity to
suppress back towards control levels, although after 10 days there was no further recovery
noted as compared to the 14 day Dex treated group. It cannot be ruled out however, that
longer periods of recovery could result in suppression of ALP activity back to control
levels. In vivo it is possible that catch up growth is never complete and merely falls below
the statistical detection limit of a study (Silverstein et al, 1997).
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In conclusion the ability to recover is related to the length of Dex exposure and possibly
the chondrocyte phenotype. This study suggests that the potential for recovery of different
events of the chondrocyte life cycle may vary.
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Figure 5.1. ATDC5 Recovery. Effect of Dex 10" M on protein (a & b): proteoglycans
(PG) (c & d) and ALP activity (e & f) either after a period of no recovery (a,c,e) or where
the dex treated cells were allowed to recover and assayed at 14 days (b,d,f). (a) Cell
numbers increase with time in culture. The only significant reduction is after 14 days Dex
treatment (p<0.05). (b) Shows a reduction in protein at all time points, which is only
significant at day 14 (p<0.05). (c) Shows an elevation in proteoglycans with time in the
control group, but a significant reduction in proteoglycans (p<0.05) from day 7 to day 10
in the Dex treated group as compared to their controls, (d) There is a significant reduction
in proteoglycan content with 1 day Dex treatment (p<0.05) and this is more pronounced
with longer periods of treatment (e) There is a gradual elevation in ALP activity
(nmoles/hydrol/min/mg/protein) at each time point with a significant elevation above the
respective control at days 7 and 14. (f) After the recovery period ALP activity remains
elevated which is significant at days 10 and 14 (p<0.05).
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5.2 Metatarsal Recovery and Alternate Days Dex Administration
5.2.1 Introduction
Clinically prevention ofGC induced growth retardation could be addressed in a number of
cases by judicious use of GC therapy. In addition alternate day GC therapy regimens are
also useful in reducing the steroid load without having significant adverse disease effects,
in conditions such as renal and liver transplant resulting in an improvement in final height
(Hasegawa et al, 2004; Diem et al, 2003; Hochberg, 2002).
As the foetal mouse metatarsal model was thought to be a more physiological model of
bone growth, a similar experiment as in the ATDC5 recovery (exp 5.1) was conducted to
ascertain discrepancies between recovery following different doses and durations of Dex
exposure. In addition to assessing total linear growth following different durations of Dex
it was possible to look at alternate day exposure to Dex in these metatarsals.
5.2.2 Methods and Materials
a) Foetal metatarsal organ culture
The middle three metatarsals were aseptically dissected from 18 day old embryonic Swiss
mice and cultured at 37°C in individual wells in serum free medium in a humidified
atmosphere of 95% air/5% CO2 as described (4.1.2a).
The foetal mouse metatarsals from one dam were grown in serum free culture. All groups
were studied in quadruplicate. One set of control bones was set up along with two sets of
metatarsals continuously exposed to Dex 10"6M and Dex 1CT8M for a total of 10 days.
These were used to compare the effects of the different Dex regimens below.
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b) Recovery experiment
On the harvesting day, Dex 10"6M was added in quadruplicate to the wells for a duration
of 1, 2, 4 or 6 days. After this allocated time Dex was removed and the metatarsal cultures
continued till day 10 to assess recovery.
c) Alternate Day Dex
Alternate day Dex exposure was studied using Dex concentrations of Dex 10"6M and Dex
o
10" M. Every day for a total of 10 days the metatarsals were either exposed to Dex or
washed once with serum free medium prior to maintaining them in Dex free medium for
that corresponding 24-hour period.
d) Morphometric analysis
Images were taken of the metatarsals every second day of culture using a digital camera
(COHU, San Diego, USA) and the total length of the bone determined using Image Tool
(Image Tool version 3.00, University of Texas Health Life Science Centre in San Antonio)
as described (4.1.2b).
5.2.3 Statistical Analysis
Results are expressed as a percentage change in total length from harvesting length. All
data are expressed as the mean ± sem and statistical analysis was performed using an
analysis of variance (GenStat, Sixth Edition, VSN International Ltd). A p value of <0.05
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The metatarsals exposed to 1, 2 and 4 days of Dex 10"6M and then allowed to recover till
day 10, were shorter by 3, 5 and 7% than the control group, but these differences were not
significant. However the groups given 6 days Dex (followed by a 4 day recovery period)
and continuous Dex for 10 days were 27 and 22% shorter respectively as compared to the
control metatarsals (Fig 5.2a).
Alternate Day Dex
Both continuous and alternate day Dex treatments resulted in a significant reduction in
total length at day 10 (p<0.05). By day 10 in the continuously treated Dex 10"6M and Dex
o
10" M groups there was a 22% and a 27% reduction in total length respectively when
compared to the control metatarsals (p<0.05). (Fig 5.2b).
The alternate day Dex groups at 10"6M and 10"8M lengthened by 42% ± 4.4 and 55% ± 4.0
from harvesting length. This represents a 32% and 11% reduction respectively from the
control group length at day 10.
o s
Although the Dex 10" M bones were shorter than the metatarsals exposed to Dex 10" M,
this difference was not significant. Likewise there was no significant difference between
• ft Q
continuous and alternate day Dex 10" M. However alternate day Dex 10" M treated bones
were significantly longer than their continuously treated counterparts (p<0.05).
5.2.5 Discussion
After short durations of Dex exposure the metatarsals did not show evidence of growth
retardation. However with longer durations of 6 days it is evident that the potential to
recover decreases. This may be a reflection of Dex duration or a crucial phenotype after
which recovery may not occur. It is also simply possible that there was less recovery time
compared to the metatarsals treated for a shorter duration. However if that was the case it
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would be anticipated that after a partial recovery period, the metatarsals would be longer
than their continuously treated counterparts, which was not the case here.
All metatarsals treated with alternate and continuous Dex were significantly shorter than
the control group. Dex at 10"6M did not demonstrate any significant differences between
o
the two groups. However at a lower GC dose, alternate day Dex 10 M did have
significantly longer lengths than the continuously treated cohort.
This experiment indicates that the growth-sparing effects of alternate day GC may be
dependent on dose as well as pattern GC of administration. This growth sparing effect of
alternate day steroids has not been observed by all investigators and it may be influenced
not only be the duration of therapy but also the underlying disease process and the sex of
the patient (Allen, 1996). In addition, most clinical reports refer to the use of Pred or
hydrocortisone whereas these studies employed the use of Dex, which has markedly more
potent effects on growth in vivo and in vitro as demonstrated in earlier experiments.
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Figure 5.2 a & b. Metatarsal Growth after variable patterns of Dex Exposure
a. Exposure for 1, 2, 4 and 6 days Dex 10"6M followed by period of recovery to day 10.
No significant difference in length is noted in the groups allowed to recover after 1, 2 and
4 days Dex treatment. There is a significant reduction in length after 6 days Dex and in the
continuously exposed group (p<0.05).
b. Effect of continuous and alternate day Dex 10"6M and Dex 10~XM on total length. Both







Cont Dex Dex Dex Dex Dex







cont Dex Dex Alt dex Alt dex
10"6M 10"8M 10"6M 10"8M
130
Chapter six Prenatal GC Exposure
CHAPTER 6
PRENATAL GLUCOCORTICOID EXPOSURE
6.1 Physical Measurements After Prenatal Glucocorticoid Exposure.
6.2 Circulating Levels of IGF-I, IGFBP-2 & Insulin levels after Prenatal
Glucocorticoid Exposure.
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6.1 Physical Measurements After Prenatal GC Exposure
6.1.1 Introduction
Dex reduced linear growth in foetal mouse metatarsals; further experiments assessed the
impact of prenatal GC exposure on the bones and growth ofmice exposed to Dex in utero.
Thus the following studies attempted to explore the underlying physical and biochemical
abnormalities in SGA.
SGA refers to the size of the infant at birth, whereas IUGR suggests diminished growth
velocity in the foetus as documented by intrauterine growth measurements and indicates
the presence of a pathophysiologic process occurring in utero that inhibits foetal growth. A
child who is born SGA has not necessarily suffered from IUGR, and infants who are born
after a short period of IUGR are not necessarily SGA (Lee et al, 2003). The underlying
pathophysiology of IUGR and the failure of CUG in some small-for-gestational-age SGA
infants is unclear. Although most SGA newborns catch up during the first 2 years of life,
about fifteen percent will display persistent growth failure (Albertsson-Wikland &
Karlberg, 1997) and the vast majority of these will remain short in later life, comprising
22% of adults with short stature (Karlberg et al, 1997).
Prenatal exposure to GC is known to cause growth restriction in most mammalian species
including humans (Mosier et al 1982; Reinisch et al 1978). Indeed, human IUGR is
associated with elevated maternal and foetal levels of endogenous GC (Goland et al,
1993), and these levels are more likely to be elevated in those who fail to display catch-up
growth (Economides et al, 1988; Clark et al, 1996; Cianfarani et al, 2002).
Administration of synthetic GCs to women at risk for premature delivery is an established,
evidenced-based intervention known to accelerate the rate of maturation of various foetal
organs, such as the lungs, heart, brain, liver, kidney, and gut. About 10% of pregnant
women in North America and Europe are treated with synthetic GCs between weeks 24
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and 34 of gestation to promote foetal lung maturation in foetuses at risk of being delivered
prematurely (NIH Consensus 1995; Matthews 2000). However, concerns remain about the
effect of repeated courses of prenatal Dex and betamethasone on the long-term growth
subsequently in childhood (Newnham & Moss, 2001). In rodents, antenatal exposure to
GC has been used as a model to study long term effects on a number of physical traits,
including hypertension, hyperglycaemia, hyperinsulinaemia, neuroendocrine responses
and anxiety-like behaviour (Seckl, 2001). Although there is a substantial amount of
literature on the postnatal effects of GC on murine growth (Smink el al, 2003),
surprisingly little is known of the prenatal effects of GCs on longitudinal growth at the
level of the growth plate and its relationship to biochemical markers ofGH action.
The current study was performed to investigate the feasibility of using the mouse as a
model for studying the effects ofprenatal GCs on linear growth.
6.1.2 Methods
aj Animals
Time-mated pregnant C57B1/6 mice were housed individually with free access to
laboratory chow and water. One group (n = 6) received subcutaneous injections of
100pg/kg Dex in 0.9% saline for the last 6 days (E14 - E20) of pregnancy whilst controls
(n = 8) were given vehicle injections (0.9% saline). At birth, pups were sexed and
weighed, and crown rump length (CRL) was determined using a digital calliper (Mahr
GmbH, Esslingen, Germany). The 6 Dex treated dams had 39 pups (20 males, 19 females)
and the eight control dams produced 51 pups (32 males, 19 females). A subset of the pups
(n = 24; non fasting), randomly chosen, was sacrificed by decapitation and trunk blood
obtained. In this subset (6 males and 6 females from three Dex treated mothers; 8 males
and 4 females from 3 control dams), tibiae were dissected out and their lengths measured
using digital callipers as described above. Additionally, 5 male pups from each group
133
Chapter six Prenatal GC Exposure
(Dex or control) were injected intraperitoneally with BrdU (2.5 mg/lOOg body weight) 1 h
before sacrifice. The tibiae from the BrdU injected mice were fixed in 70% ethanol for 24
hours, dehydrated and embedded in paraffin wax. The experimental protocol was
approved by the University of Edinburgh Animal Use Committee and the animals were
maintained in accordance with university guidelines for the care and use of laboratory
animals.
b) Chondrocyte proliferation
Wax sections, 10 jam in thickness, were cut along the longitudinal axis and chondrocyte
nuclei with incorporated BrdU were detected using an indirect immunofluoresence
procedure as detailed previously (Exp 4.2.2) (Farquharson et al, 1993). In brief, sections
were denatured with 1.5 M HC1 for 30 min before incubation with an antibody to BrdU
(DAKO, Ely, Cambridgeshire, UK) diluted 1:50 in phosphate buffered saline (PBS) for 1
h. After washing, the sections were incubated for a further 1 h in FITC-labeled goat anti-
mouse IgG (Sigma) diluted 1:50 in PBS. The sections were finally mounted in
PBS/glycerol (Citifluor, Agar Scientific, Essex, UK). Sections were examined using a
Leica BMRB fluorescent microscope and the total number of BrdU positive chondrocytes
within both the proximal and distal growth regions was determined. Two sections from
each bone from each treatment group were examined to obtain an aggregate value.
c) Growth plate and maturational zone widths
Wax sections were stained with haematoxylin & eosin, viewed under an Olympus M081
microscope and images of the growth plate were captured using a COHU digital camera.
The width of the growth plate and specific maturational zones were determined using
Image Tool as previously described (4.2.2b). Due to the absence of the secondary
ossification centre in 1-day-old bones the boundary at the top of the proliferating zone is
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not easy to determine. Therefore the growth plate was divided into two broad regions
referred to as proliferative and hypertrophic (Fig 6.1). The junction between the
proliferating and hypertrophic zone was easily identified by the abrupt change in
chondrocyte morphology. The cells within the proliferating zone have an oblate
morphology, which is in contrast to the prolate morphology of those within the
differentiating hypertrophic zone (Fig. 6.1). The width of the proliferative and
hypertrophic zones was presented as a percentage of the whole growth plate width in order
to take account of any possible obliqueness of sections. The growth plate width was
ascertained from 10 male mice (5 control, 5 Dex). Three sections from each bone from
each treatment group were examined to obtain the mean width of the growth plate.
6.1.3 Statistical analysis
Results of body weight, CRL and tibial length are expressed as mean ± sem. Body weight
and CRL of the pups exposed to Dex are presented as Standard Deviation Scores (SDS) to
examine the gender specific effect of prenatal Dex on growth. SDS for body weight or
CRL for each pup was calculated by using the equation (absolute value for that mouse
minus mean value for the control cohort of the same sex at same age) divided by one
standard deviation from the mean for the control cohort of the same sex at same age. Data
were analyzed using SPSS software vlO (SPSS Inc., Chicago, IL, USA) and Microsoft
Excel 2000 SR-2 (Microsoft Corp, Redmond, WA, USA).
6.1.4 Results
Body weight
The mean body weights in male and female pups were 1.377g ± 0.02 in the control group
and significantly greater than the pups from the Dex treated dams with a body weight of
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1.224g ± 0.02 (p<0.05) (Fig 6.2). The difference in body weight was seen in both male
(Dex treated, 1.270 ± 0.026g; control, 1.368 ± 0.026g; p<0.05) and female pups (Dex
treated, 1.175 ± 0.022g; control, 1.392 ± 0.034g; p<0.05). Flowever, the effect of Dex on
birth weight was more pronounced in female pups, with a mean body weight SDS of-1.46
± 0.65 compared to -0.66 ± 0.79 for the male mice (p<0.05). Five out of 19 (26%) female
pups but none of the male pups had a body weight less than -2SDS (Fig 6.3a,b).
Crown Rump Length
The mean CRL in the Dex-treated group was 27.90 ± 0.12mm, compared with 30.00 ±
0.21mm in the control group (p<0.001). The difference in CRL was observed in both
males (CRLs in Dex-treated group and control group were 28.20 ± 0.20mm and 29.90 ±
0.25mm, respectively; p<0.05), and females where CRLs were 27.60 ± 0.12mm and 30.20
± 0.36mm in the Dex-treated and control groups, respectively (p<0.05) (Fig 6.4). The
female Dex-treated pups had a mean CRL SDS of-1.59 ± 0.55 compared to -1.19 ± 0.37
in the male mice (not significant). Three out of 19 (16%) female pups but none of the male
pups had a CRL less than -2SDS of control mice. Although the effect of Dex was mostly
on CRL and body weight, 3 out of 20 (15%) male pups had a CRL of less than -1 SDS but
a normal weight (Fig.6.3a,b).
Tibial Length
Tibial lengths were measured in 12 Dex-treated (6 male) and 12 control (8 male) mice.
Although the body weight of this subset of Dex-treated (1.29 ± 0.04g) and control (1.34 ±
0.02g) groups was not significantly different (probably reflecting the relatively small
sample size), the mean CRL was lower in the former group (27.7 ± 0.2 mm) as compared
to 28.8 ± 0.3mm in the control (p<0.05). However, the mean tibial lengths in the Dex-
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treated and control groups were similar at 4.69 ± 0.08mm and 4.62 + 0.08mm,
respectively. Female mice had significantly shorter tibial lengths than males in both the
Dex-treated (4.53 ± 0.12mm versus 4.86 ± 0.08mm; p<0.05) and control (4.37 ± 0.09mm
versus 4.75 ± 0.08mm; p<0.05) groups.
Correlation between Body Weight & CRL and Body Weight & Tibial Length
There was an association between body weight and CRL in both the Dex-treated groups
(r,0.5; p<0.05) and the control groups (r,0.7: p<0.05) (Fig.6.3). Furthermore, in the
subgroup of Dex-treated and control mice which had detailed anthropometry, there was an
association with body weight and tibial length (r,0.7; p<0.001) (Fig.6.5). Flowever, there
was no significant relationship between CRL and tibial length in the smaller group of 12
mice, which had tibial length measurements.
Chondrocyte Proliferation and Lengths ofProliferating and Hypertrophic Zones
The length of the individual proliferating and hypertrophic zones were measured in 10
male mice (5 Dex-treated, 5 controls). In this subset, there was no statistically significant
difference between the body weights in the Dex-treated group (1.36 ± 0.03g) and the
controls (1.38 ± 0.03g). However, the Dex-treated group had significantly shorter CRLs
(28.2 ± 0.2mm) compared to the control group (29.3 ± 0.4mm) (p<0.05). The total width
of the growth plates was 91.9 ± 2.9pm and 86.5 ± 2.3pm in the Dex-treated and control
group, respectively (not significant). Mean proliferating zone length expressed as a
percentage of the growth plate width was similar at 81.7 ± 1.3% in the Dex-treated group
and 81.8 ± 1.1% in the controls. Similarly, the mean length of the hypertrophic zone was
18.3 ± 1.3% and 18.2% + 1.1 of the growth plate in the Dex-treated and control groups,
respectively (not significant). The number of proliferating chondrocytes was reduced in
137
Chapter six Prenatal GC Exposure
the pups exposed to prenatal Dex (111.5 ± 5.3) as compared to the control group (140.2 ±
37.1) but this was not significant.
6.1.5 Discussion
The results of the present study not only confirm that prenatal Dex exposure results in
growth retardation in the offspring but they also show that it has a greater effect on the
female offspring. The extent of reduction in birth weight was similar to that observed by
other investigators using other models of IUGR such as bilateral uterine artery ligation,
protein restriction, as well as prenatal GC exposure (Harrel & Tannenbaum, 1995;
Houdijk et al, 2000; Mosier et al, 1982).
Sexual dimorphism exists in a number of anthropometric measures at birth and it is
possible that these differences are established early during foetal life (Hindmarsh et al,
2002). Antenatal GC treatment in sheep produces greater lung maturation in females at
risk of preterm delivery (Kovar et al, 2001) and in guinea pigs alters the female foetal
hypothalamic-pituitary-adrenal (HPA) function (Dean & Matthews, 1999). The effects of
prenatal stress or GC exposure in programming the HPA axis have also been shown to be
sex-specific, with female rats displaying greater ACTH and corticosterone levels than their
male counterparts (McCormick et al, 1995). GC exposure in late gestation in the rat
permanently programs gender specific differences in adult cardiovascular and metabolic
physiology (O'Regan et al, 2004). Similarly an increased incidence of SGA in female
offspring has been reported in two population-based studies (Hediger et al 1998, Thomas
et al, 2000).
The underlying basis to the sexually dimorphic effect of prenatal GC on growth, with
female offspring being more severely affected, is unclear. A gender specific effect on
postnatal growth in 3-5 week old rats exposed to prenatal Dex has been reported before by
Swolin-Eide et al, (2002), where the investigators found an increase in CRL and long
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bone length in the male offspring but a decrease in the CRL of the female offspring; the
authors did not report any gender-specific differences in size at birth.
Despite a reduction in body weight and crown rump length in the whole cohort of pups, a
clear reduction in tibial length was not observed in this study. Furthermore in the
subpopulation of mice that had tibial lengths and histomorphometry performed no
significant differences in body weight were noted between the control and Dex-treated
groups despite a reduction of CRL in the latter. Future studies should include more
sensitive and accurate measurements of the rest of the axial skeleton by techniques such as
radiogrammetry as it is possible that calliper based measurement of the tibia may not
reveal small changes in the length of individual bones that may cumulatively be reflected
as reduced CRL. Our finding was similar to that of Mehta et al (2002) who did not find
any significant reduction in femoral or tibial length in sixteen mice with IUGR secondary
to maternal protein restriction. However, they did report an increase in the width of the
epiphyseal plate; whereas this study did not reveal any significant increase in the width of
the proliferative or hypertrophic zone of the growth plate. Although the number of
proliferating chondrocytes was reduced in the prenatal Dex exposed group, this finding
was not statistically significant.
Although sexual dimorphisms are well documented, the association with prenatal GC and
IUGR has not been previously recognised. This data shows that prenatal GC exposure
affects birth weight and length and that this effect is more marked in the female offspring.
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Figure 6.1. Photomicrograph of a tibial growth plate, depicting numerous chondrocytes
forming the proliferating zone (PZ) and the larger, prolate chondrocytes constituting the
hypertrophic zone (HZ).
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Figure 6.2. Effect of prenatal Dex exposure on body weight (g) in the combined, male
and female groups. All data expressed as the mean ± sem, * = significance compared to
control (* p<0.05).
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Figure 6.3. a) Relationship between body weight SDS and CRL SDS in the control
group. Correlation score 0.6 (p<0.05), 32 males, 19 females. And b) Dex exposed group.
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Figure 6.4. Effect of prenatal Dex exposure on Crown Rump Length (CRL) in the
combined, male and female groups. All data expressed as the mean ± sem. * =
significance compared to control (* p<0.05).
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Figure 6.5. Relationship between body weight (g) and mean tibial length (mm) in the
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6.2. Circulating Levels of IGF-I, IGFBP-2 & Insulin levels after Prenatal
GC Exposure
6.2.1 Introduction
After establishing the effect of prenatal Dex on the physical parameters of growth, this
study assesses the impact of prenatal Dex on the levels of circulating growth factors:
IGF-I, Insulin and IGFBP-2 in the same offspring.
GH, Insulin, IGF-I, IGF-II and their binding proteins play an important role in influencing
prenatal and postnatal growth (LeRoith et al, 2001). IGF-II is the dominant IGF during
early development and IGF-I becomes more important at a later stages, the growth
promoting effects of both factors are mediated through the IGF-I receptor (Gluckman et
al, 1992, Dechiara et al, 1990). Unlike Insulin, which acts predominantly on liver, muscle
and adipose tissue, ah foetal tissues express IGFs in early gestation. The activity of these
peptides is modulated by IGFBPs, which help localise IGFs to particular tissues during
differentiation (Gluckman et al, 1992; Hill et al, 1989).
IGFBP-1,2 and 6 have been reported to act exclusively as growth inhibitors on IGF
dependent proliferation of growth plate chondrocytes (Kiepe et al, 2002). Amongst these
growth inhibitory proteins, IGFBP-2 is the predominant foetal IGFBP (Gluckman et al,
1992, Green et al, 1994) and may have an inhibitory effect on IGF-I and II activity
(Schnieder et al, 2000). It is the only binding protein that is expressed in the growth plate
of mice (Smink et al 2002, 2003) and it is also a crucial factor in avian skeletogenesis,
where it has been reported to inhibit chondrogenic differentiation and matrix synthesis
(McQueeney & Dealy 2001). Overexpression of IGFBP-2 in mice has been shown to
cause a reduction of somatic growth (Hoeflich et al, 1999). Increased expression of
IGFBP-2 is found after fasting and in other conditions associated with stress (Blum et al,
1993, Strasser-Vogel et al, 1995). Exogenous GC administration is also associated with
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elevated systemic IGFBP-2 levels in children (Crofton et al, 2000) and has been reported
to be associated with increased tissue expression of IGFBP-2 in some tissues such as
human bone marrow stromal cells but not the growth plate (Smink et al, 2002 & 2003,
Cheng et al, 1998).
The aim of this study was to look at the relationship of serum IGF-I, Insulin and IGFBP-2
in the mice offspring who had been exposed to prenatal Dex in the previous experiment
(Expt 6.1) and to look for any perturbations of these in the newborn mice.
6.2.2 Methods
a) Animals
A subset of the offspring either exposed to prenatal Dex or vehicle injections from the
previous experiment (Expt 6.1) had blood samples collected after their physical
characteristics had been ascertained.
b) Serum analysis ofIGF-I, IGFBP-2 and Insulin
Serum from 24 pups (controkDex, 12:12) of the same mother (3 control and 3 Dex treated
mothers) were pooled for the assay of Insulin (DRG diagnostics, Germany), IGF-I (Octeia
rat/mouse; IDS, Boldon, UK) and IGFBP-2 (OBI-DSL, Upper Heyford, UK) by ELISA.
Each sample was assayed in duplicate and followed the manufacturers instructions. Blood
samples were centrifuged at 3000g for 15 min at 4°C and the serum was collected and
stored at -80°C until assayed for IGF-I, IGFBP-2 and insulin.
6.2.3 Statistical Analysis
Results of serum IGF-I, IGFBP-2 and Insulin were not normally distributed and, therefore,
are expressed as median (10th, 90th) centiles. Spearman rank correlations were used to
compare any association between variables and Student's paired t-test or the Mann
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Whitney U test (for data deviating from the normal distribution) were used to compare
differences between groups. Data were analyzed using SPSS software vlO (SPSS Inc.,
Chicago, IL, USA) and Microsoft Excel 2000 SR-2 (Microsoft Corp, Redmond, WA,
USA).
6.2.4 Results
Serum IGF-I, Insulin and IGFBP-2
Median (10th, 90th centiles) serum IGF-I concentration in the control group was 282ng/ml
(281, 291) compared to the Dex-treated groups where it was significantly higher 291ng/ml
(282, 297) (p<0.05). The median serum IGFBP-2 concentration in the Dex-treated group
was also higher than the control values; 3190ng/ml (3001, 3209) and 2982ng/ml (2899,
3282) respectively (p<0.05). No significant differences were noted in the serum Insulin
concentrations in both groups; control 2.82ng/ml (2.74, 2.85) and Dex 2.82 (2.77, 2.95)
(Table 6.1).
6.2.5 Discussion
This study shows that growth retardation following prenatal Dex exposure is associated
with raised levels of IGFBP-2 and IGF-I. IGFBP-2 is the most commonly expressed
IGFBP in the mouse, the most dominant in the foetal circulation and thereafter the second
most abundant IGFBP in the circulation (Rajaram et al, 1997) (Smink et al, 2002, 2003).
Therefore its systemic levels in the newborn mouse were measured to try to understand its
relationship to growth.
The experiments show that Dex-induced growth retardation was associated with raised
levels of IGFBP-2 and IGF-I. Although the IGFBP-2 knockout mouse does not show any
clear growth abnormalities, the transgenic mice that over express IGFBP-2 do show
growth retardation (Hoeflich et al, 1999). Increased IGFBP-2 expression may contribute
147
Chapter six Prenatal GC Exposure
to growth restriction by inhibiting the bioactivity of IGF-I (and IGF-II). Additionally the
increased activity of IGFBP-2 has been shown to 'buffer' the effects of IGF-I
overexpression in transgenic rabbits (Wolf et al, 1997). Direct evidence for an IGF-
inhibitory role of IGFBP-2 comes from in vitro studies where IGFBP-2 inhibits IGF-
dependent growth stimulation of human carcinoma cells but did not affect proliferation of
IGF-resistant cells (Hoflich et al, 1998). Thus, by inducing IGFBP-2 (and thereby
inhibiting IGF-I and/or IGF-II), prenatal Dex may cause a state of IGF resistance.
It is also possible that the raised IGF-I levels that were observed in this study are a
reflection of the raised level of bound IGF-I due to the raised IGFBP-2. The finding of
raised IGFBP-2 is in concordance with the observations of Price et al (1992) who reported
increased hepatic expression of IGFBP-2 in rat foetuses exposed to prenatal GCs. Dex has
also been reported to increase IGFBP-2 expression in human bone marrow stromal cells
(Cheng et al 1998). These two studies showed a negligible to a significant fall in IGF-I
expression, contrary to our finding of a raised IGF-I level. In addition, Cheng et al (1998)
reported raised IGF-II expression following Dex exposure and this elevation was in
proportion to the rise in IGFBP-2. However, as it has not been observed in other non-
skeletal tissues, it is possible that this response may be tissue specific (Beck et al 1988; Li
et al 1993). Interestingly, maternal IGFBP-2 levels also increase in foetal growth
restriction in humans (Holmes et al 1999). Thus, in this model it is also possible that these
raised IGFBP-2 levels in the mother could be reflected in the serum levels of IUGR
offspring. Similarly in rabbits, maternal steroid administration causes a marked increase in
foetal IGF-I mRNA expression and IGF-I protein levels (Thakur et al, 2000). The small
serum sample volumes in the day 1 mice offspring restricted the study of IGFBPs to
IGFBP-2 and gender specific changes could not be investigated as the samples had to be
pooled. The findings would have been further strengthened by the study of the other
IGFBPs as well as IGF-II.
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Although elevated insulin levels have previously been reported in SGA infants (Veening
et al, 2002), no difference in serum Insulin levels was noted in this study. However,
Cianfarani et al (2003) did not demonstrate altered Insulin sensitivity despite a reduction
in glucose concentration in SGA children and this effect may be dependent on variables
such as age, nutrition and the fasting state of the offspring.
A limitation of this study is the relatively small numbers ofmice in each group which then
restricted the ability to look for sexual differences in the IGF-I and IGFBP-2 levels in both
the control and the Dex exposed group. Future studies should attempt to corroborate
whether the small but significant differences in the IGF-I and IGFBP-2 levels remain and
indeed if there is a difference between males and females.
In conclusion this study demonstrates elevated IGF-I and IGFBP-2 levels raising the
possibility of a state of IGF-I insensitivity. This may be due to GC induced IUGR causing
defective IGF-I action which is mediated by an up-regulation of IGFBP-2 and a persistent
defect may explain the growth failure that is observed in a proportion of the offspring who
remain short.
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Table 6.1. Serum concentration (ng/ntl) of IGF-I, Insulin and IGFBP-2 in control and
prenatal Dex exposed mice. IGF-1 and IGFBP-2 levels are significantly increased in the
Dex exposed group compared to their respective control. Results expressed as median ±




IGF-I Insulin IGFBP-2 IGF-I Insulin IGFBP-2
Median 282 2.82 2982 291 * 2.82 3190 *
10th centile 281 2.74 2899 282 2.77 3001
90th centile 284 2.85 3282 297 2.95 3209
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7.1 FINAL DISCUSSION
The rate of longitudinal bone growth is determined by a complex interplay of proliferative
kinetics, size of the proliferative pool, matrix synthesis and hypertrophic chondrocyte
enlargement. The control of these processes is still a matter of debate, however any
perturbation of any of these variables may affect normal bone growth. The benefits ofGCs
often outweigh the risks of potential side effects in the treatment of many diseases in
adults and children. However the growing skeleton is susceptible to the additional growth
impairing effects of the GC. A greater understanding of these effects may influence the
type, duration and dosage schedule that is optimal in controlling disease while minimising
the growth impairment. Therefore, the identification of such changes in the present studies
may provide a better understanding of the mechanisms underlying Dex induced growth
retardation.
GCs regulate many physiological systems and high levels cause growth retardation via
their direct effects on the growth plate. In addition to the effect of primary disease and
stress on growth retardation, GCs also affect the HPA axis, kidneys, muscle, adrenal and
gastrointestinal tract. Many factors interact to cause these negative effects, thus it is
essential that the individual mechanisms are carefully dissected out.
The stimulation for this thesis was the relative lack of any in vivo data on the potencies of
different GC on growth and bone turnover. The clinical findings showed that in children
treated for ALL, Dex and Pred affect short-term growth and bone turnover and that Dex
may be 18 times more potent than Pred at suppressing short-term linear growth and nine
times more potent at suppressing bone turnover. Although the greater potency of Dex had
been demonstrated in other organs systems it was the first time that the varying effects on
linear growth had been substantiated.
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Subsequently these observations were translated into cell culture models and progressed to
increasingly physiological models of bone growth such as the metatarsal explants before
finally completing the cycle to study the impact of prenatal GC exposure on growth in in
vivo mouse models.
Cell culture
Data obtained from the cell culture studies also indicate that Dex has more potent effects
than Pred. In addition it should be highlighted that GC effects appear to be most apparent
during chondrogenesis when the cells are rapidly proliferating - this is an important
observation as this is the first study to characterise a chondrocyte cell line so that the GC
effects can be studied on a homogeneous population of chondrocytes. This observation
could account for the similarities and differences between this data and other investigators,
as the major effects of the GC were dependent on the chondrocyte phenotype. Thus
although Dex and Pred decreased cell proliferation, cell number, proteoglycan synthesis
and increased differentiation these effects were mainly restricted to chondrogenesis with
little effects during terminal differentiation. The cell culture data overwhelming supports
the issue that the negative GC effects on bone growth are mediated via the their anti¬
proliferative effects. An additional effect could be the premature progression to the
differentiated chondrocyte, as indicated by increased ALP activity. In combination, this
decreased proliferation and increased differentiation could account for a net loss of linear
growth.
Further experiments revealed that the ATDC5 chondrocyte cell line expressed the GC,
IGF-I and GH receptors. This information was utilised to show that the antiproliferative
effects of Dex in this cell line could be completely reversed by IGF-I, indeed proliferation
was significantly above control levels, with GH having no beneficial effects, possibly due
to the fact that the GH receptor was expressed later or due to a suboptimal concentration
used. Although Insulin and IGF-I share a high similarity of structure and intracellular
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signalling events (Dupont & LeRoith, 2001), it was interesting to note that at similar
concentrations IGF-I effects on chondrocyte proliferation were much more profound than
insulin.
Metatarsal culture
This thesis has shown that the foetal mouse metatarsal model can closely replicate in vivo
bone growth and this is the first in vitro study to directly demonstrate the pro-hypertrophic
effects of IGF-I, and reversibility ofDex induced growth retardation.
The foetal mouse metatarsals provided an ideal model to study the effects of both GC and
IGF-I. As these bones have a relatively large percentage of cartilaginous growth plate
chondrocytes, maintenance of cellular interactions and a supply of endogenous growth
factors it was possible to culture them in medium devoid of serum, thus removing a
potential confounding variable. Again on direct linear measurements it was ascertained
that Dex and IGF-I have major and opposite effects on longitudinal bone growth with
IGF-I clearly reversing the growth inhibitory effects of Dex. The GC effects were
dependent on duration of exposure whereas IGF-I showed a rapid acceleration in growth.
The mechanism ofDex induced growth retardation in this model appeared to be a decrease
in proliferation and mineralisation.
One of the most important results to stem from this thesis is that the increase in linear
growth achieved by IGF-I is due to a dramatic increase in the size of the hypertrophic
chondrocytes. Although it has been recognised in vivo that the growth retardation in the
IGF-I null mouse is associated with an attenuation of chondrocyte hypertrophy (Wang et
al, 1999), it is the first time this observation has been demonstrated in an in vitro model.
Longitudinal bone growth is a dynamic process, as the chondrocyte undergoes its life
cycle, it is continuously under the influence of a wide and varying range of hormonal
influences. Thus it is imperative that to be sure of the GC and growth factor effects, the
experimentation should allow for the dynamic nature of bone growth. This was shown in
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the cell culture studies undertaken at two distinct time points. In addition the process was
repeated in the metatarsal studies. By studying the two time points at days 4 and 10, it can
be concluded that proliferation is much more marked in all groups at the earlier time point.
Although Dex reduced proliferation at all time points, IGF-I stimulated cell proliferation
early, whereas the reverse was true by day 10, indicating a utilisation of growth factors
associated with the slower rate of linear growth or a change to the predominant
chondrocyte phenotype.
Although IGF-I mRNA has been shown to be concentrated in the murine periosteum and
perichondrium (Shinar et al, 1993; Wang et al, 1995), the observation that cell
proliferation within the perichondrium was more sensitive to inhibition by Dex and
stimulation by IGF-I than chondrocytes within the growth plate, has previously not been
recognised and requires further study, it is possible that the perichondrium could form
another area for the convergence of adverse drug effects.
Cell Recovery
The recovery experiments utilising both the cell culture and metatarsal models had
essentially similar results; that the detrimental effects ofGC are dependent on the duration
of the GC exposure - after a certain period the chondrocytes ability to recover from the
GC effects is impaired. This was demonstrated in the ATDC5 cell line which showed that
cell number and proteoglycans levels gradually decrease with length of exposure, and
ALP levels fail to suppress to control levels with increasing GC exposure. It is postulated
that alternate day GC may not adversely affect final height potential, but they may still
delay puberty and be associated with a delayed growth spurt (Polito et al, 1999). This data
did not reveal any beneficial effect on metatarsal length in continuous versus alternate day
Dex exposure. This could be due to the fact that the high dose of Dex that was used
precluded any beneficial effect being noted. Indeed alternate day exposure with Dex
O 'ft •
10" M as compared with Dex 10" M was associated with less detrimental effects on total
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metatarsal length. Additionally it has been noted that animals with shorter gestations such
as rodents may provide less clinically applicable information than animals of longer
gestations (Jobe, 2003). This would mean that the foetal mouse metatarsal would have had
had a higher net steroid load.
Prenatal GC
Prenatal GCs are extensively used in perinatal medicine to increase the maturation of
various foetal organs in women at risk of premature delivery. Although concerns remain
about the impact of repeated courses of prenatal GC on subsequent childhood growth,
little is known of the prenatal effects of GCs on longitudinal growth at the level of the
growth plate and its relationship to various biochemical markers of GH action. Although
there is a convergence of hormonal, nutritional and environmental effects in the SGA
offspring, the IGFs play a crucial role in prenatal and postnatal growth.
To address this, the bone and biochemical profiles in the offspring of mice exposed to
prenatal Dex were examined. The mouse is particularly suited to study the role of the IGF-
I on prenatal growth as it is known that the foetal growth promoting effects of IGF-I and II
are mediated through the IGF-I receptor (Nakae et al, 2001). Prenatal GC exposure
resulted in a group of SGA mice with reduced weight and length which was greater in the
female offspring. This difference was a surprising but not wholly unexpected finding, as
sexual dimorphisms exist in a number of physical and biochemical measurements at birth.
This sexual dimorphism can exist in birth size as well as other parameters such as the
urinary excretion of GH and IGF-I in children (Fall et al, 2000). Although sexual
dimorphisms are well documented, the association with prenatal GCs and IUGR has not
been previously recognised. It is increasingly recognised that IGF-I action is regulated by
a number of binding proteins, which may also have IGF-I independent effects. This group
of SGA mice had raised levels of IGF-I and IGFBP-2; the latter is the main binding
protein that inhibits IGF-I action. The small sample size did not allow for gender
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differences to be extracted. Together this data indicates the possibility of a state of IGF-I
insensitivity mediated by an up-regulation of IGFBP-2 action. As IGF-2 is the main
prenatal growth factor it is also probable that its regulation is also disrupted.
An issue that arose during this thesis that has not been resolved is the relative contribution
of GH and IGF-I to linear growth. In these experiments IGF-I was consistently shown to
have growth stimulatory effects, over-riding all the Dex effects. However GH had no
effects in the two chondrocyte models. This may have been related to the stage of
differentiation of the chondrocyte or the GH concentration used. As GH is required for
postnatal growth it is also possible that the foetal metatarsals are unresponsive to the GH
effects at the gestation used. It seems likely that local IGF-I production may be the more
important regulator of linear growth (Yakar et al, 1999; Ueki et al, 2000). Although
infusion ofGH into a limb causes an increase in in vivo bone length (Isaksson et al, 1982),
it is postulated that these effects are nonetheless mediated via an elevation in local IGF-I
(Hunziker et al, 1994). Similarly GHR knock out mice show reduced bone growth caused
by premature reduction in chondrocyte proliferation and cortical bone growth at 2 weeks
of age, which is reversed by raising serum IGF-I levels (Sims et al, 2000). In the IGF-I
null mice the hypertrophic zone is shortened but the reserve zone is expanded (Wang et al,
1999). The latter is considered to be due to the increased GH levels, thus supporting the
view that GH expands the pool of chondrocyte progenitors but this contradicts the
hypothesis that IGF-I is responsible for clonal expansion of the proliferating cells. Further
studies have indicated that as well as local IGF-I production there may be a minimal IGF-I
threshold concentration that is necessary for normal growth (Yakar et al, 2002).
In conclusion, this thesis took the clinical observation showing that Dex and Pred have
different potencies on short term linear growth and bone turnover. This was further
investigated in increasingly physiological models of bone growth demonstrating that in
vitro, Dex and IGF-I have opposite effects on direct linear growth and markers of bone
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growth. These effects are dependent on the chondrocyte phenotype, in addition the effects
of Dex are time dependent whereas IGF-I effects are immediate. Dex decreases
proliferation, cell number, matrix production and skeletal mineralisation while IGF-I
markedly stimulates chondrocyte hypertrophy in favour of mineralisation and proliferation
and completely reverses the Dex induced growth retardation. However, IGF-1
administration alters the balance of the different chondrocyte phenotypes and it is unclear
whether this has any long-lasting implications. Recovery after GC exposure is related to
the duration of Dex exposure and alternate-day Dex administration did not have any
growth sparing effects and GH had no beneficial effects at the dose studied. Finally the
thesis completed the cycle back to in vivo data demonstrating that prenatal GC
administration leads to SGA offspring, which is worse in females, and these SGA
offspring may have a state of IGF-I resistance.
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7.2 FUTURE DIRECTIONS
This thesis has opened up some intriguing avenues for further research which in the future
may have clinical significance. In my opinion tackling and understanding the underlying
principles of GC induced bone growth should proceed using a combination of models of
longitudinal growth. It was inevitable that as the work progressed further avenues for
research would be identified.
Observational studies
IGF-II is a key regulator of prenatal bone growth and the circulating levels increase with
gestation. There is little data about the effects of IGF-II in these models of bone growth
and its relative and/or synergistic effects to IGF-I would provide useful additional
information regarding the regulation of longitudinal bone growth.
Once a ligand binds to the GCR, it undergoes a conformation change and the receptor
either causes transcriptional activation or repression (or both events) via different
downstream pathways - the latter is central to GC mediated anti-inflammatory and anti¬
proliferative effects. Selective GCR modulators (SGRM) are in development which have
the same anti-inflammatory activity but without the side effects. The synthetic GC;
Deflazacort (an oxazoline derivative of Pred) was believed to have less impact on growth
and GC induced osteoporosis but fell out of favour as it was subsequently shown to be
little different from standard GC once the anti-inflammatory activity was optimised
(Markham A, 1995). Newer compounds such as AL-438 may have a similar anti¬
inflammatory profile to standard GC but with lesser effects on glucose metabolism and
bone turnover (Rosen & Miner 2005). The models described in this thesis could be used to
corroborate the bone and growth effects of these newer generation of SGRMs.
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Pathophysiology
Dex partially reversed some of the IGF-I effects in both culture systems. The cellular
actions of IGF-I are mediated by a receptor tyrosine kinase (IGF-IR). Binding of IGF-I to
its receptor utilises a family of soluble receptors, known as IRSs which results in the
activation of two distinct signalling pathways, phosphatidylinositol 3-kinase and p42/p44
mitogen-activated protein kinase, leading to proliferative and antiapoptotic effects. These
pathways can be inhibited by LY-294002 and PD-98059 respectively. Therefore the
models could be used to ascertain if the deleterious effects of Dex on chondrocyte
proliferation and linear bone growth are mediated by an inhibition of IGF-1 signalling.
Clinical and in vivo studies
It is unclear which subset of SGA infants do not undergo catch up growth and if a
relationship exists between birthweight and length and future growth potential. Further
studies could ascertain what the spectrum and size reduction is in mice offspring following
GC exposure, that is. A) reduced weight, reduced length, B) reduced weight, normal
length, C) normal weight, reduced length, D) normal weight, normal length. And what the
relationship of the first three phenotypes (A - C) is to the presence or absence of CUG
after repeat measurements in the growing offspring. Differences related to dose and
duration ofGC exposure could be further explored.
Furthermore the models described respond to various factors present in the serum,
including cytokine and growth factors and it is possible that the effects of inflammatory
disease, growth inhibitory or stimulatory agents can be directly measured using a
combination of these models and thus provide information on linear growth regarding the
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Summary
aim To compare the relative potency of prednisolone
(Pred) and dexamethasone (Dex) on short-term growth
and bone turnover.
method Prospective study over 16 weeks of children
randomized to receive Pred (40 mg/m2) or Dex (6-5 mg/
m2) for the first 5 weeks as part of the MRC-ALL97/99
induction chemotherapy for acute lymphoblastic
leukaemia (ALL).
measurements Lower leg length velocity (LLLV) and
weight, serum IGF-I, serum bone alkaline phosphatase
(bALP) levels and creatinine-adjusted, urinary excre¬
tion of deoxypyridinoline cross-links (DPD).
subjects Nineteen children (eight boys, 11 girls) with
a median age of 5-9 years (range 2-6-13) and with a
diagnosis of ALL.
results Atweek 2 of therapy, median LLLV in the Dex
group was -1-5 mm/week (range 0-7 to -2-1) and
significantly lower than the LLLV in the Pred group
which was -0-1 mm/week (range 0-20 to -0-28; P< 0-05).
In the Dex group, LLLV remained lower at week 8 (med
LLLV, -0-3 mm/week, range 0 to -1-3) compared to
LLLV in the Pred group at 0-3 mm/week (range 0-2-1-0;
P< 0-05). Body weight showed an increase after week
2 and reached a peak in both groups of children at
week 6. The change in weight from baseline was
greater in the Dex group than the Pred group reaching
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a maximum change by week 5 of 17-5% (range 5-25)
and 8-7% (range -3 to 18), respectively (P< 0-05). At
presentation, median IGF-I level for the whole group
was 83-5 pg/l (range 31-8-293). IGF-I levels fell mark¬
edly during Dex therapy and continued to remain lower
than baseline. At weeks 4, 6 and 8, median change in
IGF-I from baseline was lower in the Dex group than
the Pred group. From week 1 to week 3, median change
in bALP was 72% (range -8 to 304) in the Pred group,
whereas in the Dex group change in bALP was -1%
(range 23 to -28; P< 0-005). By week 3, median bALP
was higher in the Pred group at 65 U/l (range 36-187)
than in the Dex group at 39 U/l (range 26-60; P< 0-05)
but by week 6 median bALP in the Pred group had
fallen to a similar level to the Dex group. At presenta¬
tion, median DPD was 22 nmol/l (range 17-38) and
20 nmol/l (range 12-26) in the Pred and Dex groups,
respectively (ns), reaching a nadir between weeks 3
and 6. The median percentage change in DPD in the
Pred and Dex group from week 1 to week 3 was -34%
(range -7 to 14) and -53% (range -6 to -69), respect¬
ively (ns). By week 8, DPD excretion had started to rise
more dramatically in the Pred group such that the
median DPD was 35 nmol/l (range 10-53) in the Pred
group and 22 (range 9-30) in the Dex group (P < 0-05).
On average, between weeks 2 and 8, LLLV was three
times lower, percentage gain in weight was three times
higher, bALP was 1-3 times lower and DPD was 1-5
times lower in the Dex group than the Pred group.
conclusion Pred and Dex both affect short-term
growth and bone turnover. The mechanism of the effect
on bone formation may be different between the twodrugs.
Dexmay be about 18 times more potent than Pred at sup¬
pressing short-term linear growth and stimulating weight
gain, and about nine times more potent at suppressing
bone turnover. Glucocorticoids have a variable effect
on different parameters of growth and bone turnover
and the intensity may depend on the steroid used.
Glucocorticoid therapy (GC) is commonly used as anti¬
inflammatory therapy and as part of immunosuppressive regi¬
mens in childhood. It is estimated that 5-10% of children may
require some form ofGC at some time in childhood (Warner, 1995).
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The functional effects of steroids on target tissues is difficult to
predict and their use is hampered in some individuals more than
others because of side-effects such as growth retardation, oste¬
oporosis, hypertension, altered body composition and blood
glucose homeostasis. Impairment ofchildhood growth with long-
term GC was described almost 50 years ago by Blodgett et al.
(1956). Alterations in growth and bone turnover, as assessed by
knemometry and markers ofGH secretion and bone turnover, can
also occur during relatively short periods ofGC therapy (Crofton
etal., 1998; Ahmed etal., 1999). The onset and severity of these GC-
induced effects may be dependent on the duration of therapy and
the nature of the steroid compound, and the comparative biological
potency of GC such as prednisolone (Pred) and dexamethasone
(Dex) may be tissue-specific (Orth & Kovacs, 1998). For instance,
in children and young adults with congenital adrenal hyperplasia,
Dex may be about 25 and 80 times more adrenal suppressive than
Pred and hydrocortisone, respectively (Hansen & Loriaux, 1976;
Hughes & Read, 1982). Dex is also reported to be four times more
potent at suppressing the hypothalamo-pituitary-adrenal axis than
Pred but it may be 16 times more lymphocytotoxic than Pred
(Kaspers etal., 1996). Dex also displays better CNS penetration
(Balis et al., 1987), and this feature and has led to a randomized trial
to look at its efficacy in the treatment ofALL (Gaynon & Carrel,
1999). The relative potency ofdifferent GC on growth and bone
turnover is unclear as there are no in vivo studies in children. The
current study was performed on children entering a national trial
of acute lymphoblastic leukaemia (ALL) therapy in which they
were randomized to receive Pred or Dex as part of induction of
remission and continuing treatment. By accounting for possible
confounding factors such as other concurrent chemotherapy and
the effects of the disease, the randomization process provided a
suitable opportunity to compare the short-term effects ofPred and
Dex on growth and bone turnover by the same methods as
employed in earlier studies (Crofton et ai., 1998; Aluneu et al., 1999).
Patients and methods
Patients
All children presenting to a paediatric oncology centre with a
diagnosis ofALL were eligible for the study. Out of a total of 22
eligible children, one child was excluded because ofCNS disease
at presentation and two children and their families declined
participation in the study. Nineteen children (eight boys, 11 girls)
with a median age of5-9 years (range 2-6—13 years) were recruited.
Design
The children were entered into the national UK trial ofALL -
MRCALL97/99 — and randomized to receive Pred (40 mg/m2,
daily) or Dex (6-5 mg/m2, daily) as induction chemotherapy for
Table 1 Details of Patients who were randomised to receive
Prednisolone (Pred) or Dexamethasone (Dex) as steroid therapy.
Sex Pred Dex
N 12 7
Age (yrs) 5-6 6-3
(range) (2-6, 12-3) (4-3, 13)
Prepubertal 11/12 6/7
Grp A, B, C 7, 4, 1 4, 2, 1
Fig. 1 A flow diagram ofchemotherapy schedule over the first 16 weeks
of MRC-ALL97/99 in children receiving regimen A or B. Children
entering the trial were randomized to receive dexamethasone or
prednisolone. Drugs in the stippled area were only administered to Group
A drugs in the shaded area were only administered to Group B and drugs
in the open area were administered to both groups. Drug doses and route of
administration: prednisolone (Pred), 40 mg/m2/day oral; dexamethasone
(Dex), 6-5 mg/m2/day oral; vincristine, 1-5 mg/m2 i.v.; L-Asparaginase,
6000 U/tn2; cytarabine intrathecal (i.t.) age < 2 years, 30 mg; 2 years,
50 mg; > 3 years, 70 mg;methotrexate (MTX) i.t, age< 2 years, 8 mg; 2 years,
10 mg; > 3 years, 12 mg; methotrexate (MTX) oral, 20 mg/m" weekly;
mercaptopurine (6MP), 75 mg/m2/day oral; 6-Thioguanine (6TG),
40 mg/m2/day oral; Daunorubicin, 25 mg/m2 i.v.; cytarabine (Ara-C),
75 mg/m2/day i.v.; cyclophosphamide (Cyclophos), 1000 mg/m2 i.v.
5 weeks (Table 1). The comparative doses of the GC were chosen
based on previous lymphocytotoxic data. GC were also admin¬
istered as 5-day blocks in weeks 9 and 13. Brief details of the
chemotherapy regimens are outlined in Fig. 1. Seventeen out of
19 children received either Group A or B chemotherapy, which
was determined by their age and white cell count at presentation.
The remaining two children received a more intensive regimen
of chemotherapy as they failed to remit over the first 4 weeks of
induction therapy. Data from the first 4 weeks were analysed up
to 5 weeks in these children. The study was approved by the local
research ethics committee and informed consent was given by
all parents and their children, where appropriate.
Samples and anthropometric measurements
Collection of blood samples coincided with vascular access for
clinical management and were performed every 1-2 weeks at
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approximately the same time in late morning (Fig. 1). Lower leg
length (LLL) was measured weekly by a portable knemometer
using the random zero method (Ahmed et at., 1995). Briefly, the
knemometer consists of two main parts, a rigidmetal frame hold¬
ing a footplate, measuring ruler and a moveable chair that moves
backwards and forwards on the frame. The LLL is measured
while the subject sits on the seat and the right leg is placed on
the footplate and the measuring ruler with its platform rests on
the top of the knee. The measurer moves the chair back and forth
until the maximum length is recorded. The precision of the meas¬
urement was assessed by calculating the technical error (TE),
i.e. 1SD from the mean of a set of triplicate measurements.
The overall mean TE (± 1SD) was 015 mm (0-13). Knemometry
was performed in 13 (six Pred : seven Dex) out of the 19
children. The remainder of the children had a median age of
3T years and were too young to cooperate with the measure¬
ments. Body weight with undergarments was measured by an
electronic scale.
IGF-I
IGF-I concentrations were measured using a two-site immuno-
enzymometric (IEMA) assay incorporating a sample pretreatment
to inactivate binding proteins (Immunodiagnostic Systems Ltd,
Tyne and Wear, UK). The intra-assay and interassay coefficients
of variaton were < 5% and < 8%, respectively, over the sample
concentration range. The detection of the assay was 10 ng/ml.
Bone markers
All samples were analysed in duplicate and samples from each
patient were analysed in a single run to minimize analytical vari¬
ation. Bone alkaline phosphatase (bALP) was measured in plasma
by enzyme-linked immunosorbent assay (ELISA; Alkphase-B, Metra
Biosystems Inc, Mountain View, CA, USA). The sensitivity of
the assay was 0-7 U/l and within-run and between-run coefficients
of variation were < 5% and < 8%, respectively. Deoxypyridinoline
cross-links (DPD) were measured in urine by ELISA (Pyrilink-
D, Metra Biosystems Inc). Assay sensitivity was I T nmol/1 and
within-run and between-run coefficients of variation were < 6%
and < 11%, respectively. The results were expressed in relation
to creatinine measured on the same urine sample.
Statistical analyses
For the knemometry data, lower leg length velocity (LLLV) was
calculated for each time point by subtracting the LLL at that time
point from that measured at the previous time point, and dividing
by the time interval (in weeks) between the two measurements.
LLLV was expressed as mm/week. Change in LLL was also
expressed as a percentage of the previous LLL. Body weight was
expressed as a percentage change in body weight from the
pretreatment body weight. Serum IGF-I, bALP and urinary DPD
were expressed as absolute values as well as percentage change
in IGF-I, bALP and DPD (%IGF-I, %bALP, %DPD). The data
were expressed as medians and ranges and analysed using non-
parametric tests. Comparison between groups was performed
using the Mann-Whitney t/-testm and Spearman rank correla¬
tions were used to compare any association between variables at
each time point. Data were analysed using SPSS software v9 0.0
(SPSS Inc., Chicago, IL, USA) and Microsoft Excel 97 SR-2
(Microsoft Corp, Redmond, WA, USA).
Results
Lower leg length velocity
At week 2 of therapy, median LLLV in the Dex group was
significantly lower than the LLLV in the Pred group (P < 0 05).
During GC therapy, LLLV rose temporarily before falling by week
6 when GC therapy ended. In the Dex group, LLLV remained
lower at week 8 (mod LLLV, -0-3 mm/week, range 0 to —1-3)
compared to LLLV in the Pred group at 0-3 mm/week (range 02-
1 0; P < 005). By weeks 12 and 16 of the chemotherapy protocol,
LLLV was similar in both groups (Fig. 2a). Mean LLLV between
weeks 2 and 8 in the Dex and Pred groups were -0-27 mm/week
and 018 mm/week, respectively. Compared to previous studies
of healthy children where the mean LLLV was 0-39 mm/week
(1SD, 012) (Ahmed et al., 1995), the LLLV in the Dex and Pred
groups were 5-7 SD and 1 -8 SD below the mean.
Body weight
During GC therapy, body weight showed an increase after week
2 and reached a peak in both groups of children at week 6
(Fig. 2b). Although the increase in weight from baseline was
generally greater in the Dex group, the difference did not reach
statistical significance until week 6 when the median change in
weight from baseline in the Dex group was twice that of the Pred
groups at 17-5% (range 5-25) and 8-7% (range-3 to 18), respect¬
ively (P < 0 05). Children in the Dex group continued to remain
at a higher level ofweight gain from baseline until week 16 when
their weight gain became similar to that of the Pred group
(Fig. 2b). The extra weight gain observed in the Dex group in
this study was a transient phenomenon.
IGF-I
At presentation, median IGF-I level for the whole group was
83-5 (ig/1 (range 31 -8—293); median IGF-I level in the Pred and
Dex groups were 69-3 pig/1 (range 33-8-175) and 166 pg/1
(range 39-293), respectively (P = 0-12). During the study period.
© 2002 Blackwell Science Ltd, Clinical Endocrinology, 57, 185-191
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Fig. 2 The effect of prednisolone (■) and dexamethasone (♦) on (a) lower leg length velocity (LLLV, mm/week), (b) percentage change in body
weight from baseline, (c) serum IGF-I concentration (IGF-I, pig/1), (d) serum bone ALP concentration (bALP, U/l), and (e) Urinary DPD excretion
corrected for creatinine excretion (DPD, nmol/L/creat, nmol/1) over the first 16 weeks ofALL97. Glucocorticoid therapy was administered as induction
of remission therapy for 4 weeks at full dose and for an additional week as a tapering dose. Glucocorticoids were also administered as 5-day blocks in
weeks 9 and 13. The results are presented as median and 25th and 75th centile values and measurements at any one time point in the two groups are
clustered in pairs. *P < 0 05.
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median IGF-I levels remained between 100 and 150 fa.g/1 in the
whole group and the absolute values were similar in the Pred and
Dex groups. However, in the Dex group, IGF-1 levels fell much
moremarkedly during the period ofsteroid therapy and continued
to remain lower than baseline (Fig. 2c) At weeks 4, 6 and 8,
median change in IGF-I from baseline was lower in the Dex
group than the Pred group at -16% (range -9 to -45) vs. 19%
(range -50 to 195), -3% (range -58 to 43) vs. 56% (range -43
to 146) and -42% (range -74 to 3) vs. 44% (range -73 to 415),
respectively (P < 0 05).
Bone alkaline phosphatase
At presentation, median bALP concentration was low but similar
in the Pred and Dex groups at 37 U/l (range 17-159) and 46 U/
1 (range 23-69). From week 1 to week 3, change in bALP, as
median %bALP, was 72% (range -8 to 304) in the Pred group,
whereas in the Dex group %bALP was -1% (range -28 to 23;
P < 0-005). By week 3 of therapy, median bALP concentration
was higher in the Pred group (P <005) and, by the end of therapy
at week 6, median bALP concentration had fallen to a similar
level in both groups (Fig. 2d). By weeks 12 and 16, pooled bALP
concentrations had risen to a median value of 80 U/l (range 36-
123) compared to a median pooled value of 44 U/l (range 17—
187) between weeks 1 and 8 (P < 0 005). At weeks 2, 3,4, 6 and 8,
bALP levels were 1, 1-7, 1-4, 1-3 and 1-2 times lower in the Dex
group than the Pred group, respectively. Therefore, on average,
bALP was 1 -3 times lower in the Dex group than the Pred group.
Deoxypyridinoline
At presentation, median DPD excretion was similar in the Pred
and Dex groups at 22 nmol/1 (range 17-38) and 20 nmol/1 (range
12-26). DPD excretion fell in both groups reaching a nadir
between weeks 3 and 6 (Fig. 2c). The%DPD in the Pred and Dex
group from week 1 to week 3 was -34% (range -7 to 14) and
-53% (range -6 to -69), respectively (ns). By week 8, DPD excre¬
tion had started to rise more dramatically in the Pred group, and
subsequently DPD excretion continued to rise but there was wide
variation during this recovery period (Fig. 2e). At weeks 2, 3, 4,
6 and 8, DPD excretion was 1 -4, 1 -6, 1 -4, 1 -2 and 2-2 times lower
in the Dex group than the Pred group, respectively. Therefore,
on average, DPD was 1 -5 times lower in the Dex group than the
Pred group.
Discussion
Pred and Dex are two GCs that are commonly used in immuno¬
suppressive therapy. As Dex has a longer half-life, higher
lymphocytoxicity and penetrates better into the CSF, it may be
better suited for treatment in ALL (Veerman et al., 1990; Kaspers
et al., 1996; Gaynon & Carrel, 1999). The improved CNS
penetration may explain the recent finding of an increased risk
ofneurocognitive late effects in those children who received Dex
rather than Pred during ALL treatment (Waber et al., 2000).
Besides ALL, there may be other conditions where Dex may be
a more suitable drug than Pred but a lack of data on relative effi¬
cacy as well as adverse effects of the two drugs has hindered an
objective choice. By evaluating a number of short-term physical
and biochemical changes, this study has attempted to quantify
the effects of Pred and Dex in children.
The changes documented in short-term growth and bone turn¬
over in this study were generally similar to our previous study
of children undergoing treatment for ALL using Pred during
induction ofremission (Croffon et al., 1998; Ahmed et a/., 1999).
By the end of the induction period there was a reduction in short-
term growth and suppression of markers of bone turnover.
The current study shows that, at the dose used, Dex had a more
profound suppressive effect on bone turnover and short-term
growth than Pred. Short-term growth as assessed by knemo-
metry, and bone formation as assessed by bALP levels, fell lower
in the Dex group. Similar changes were also observed in urinary
DPD excretion, a marker ofbone resorption (Calvo et al., 1996).
Not only did they fall further, bone formation and resorption
remained suppressed for longer in the Dex group. In addition,
the rise in bALP seen over the first 2 weeks of Pred was not
observed in the group who received Dex. This paradoxical rise
in bALP has been attributed to premature maturation of osteo¬
blasts and our data suggest that this effectmay be specific to Pred
(Stein et al., 1990; Canalis, 1996). The rise and subsequent fall
in bALP emphasizes the importance of sequential measurements
of bALP during monitoring of GC effects on bone formation.
These results showing an increased potency ofDex are in keeping
with the recent observation ofan increased cumulative incidence
of fractures in those children who received Dex compared to Pred
during ALL therapy (Strauss et al., 2001).
GC-induced changes in growth may be due to a combination
of factors such as a disruption in the GH-IGF-I axis and direct
effects on the growth plate (Robson, 1999; Mushtaq et al., 2001).
High-dose GC therapy alters pulsatility ofGH secretion through
an elevation of somatostatin tone and may alter GH binding
protein activity (Gabrielsson et al., 1995; Tonshoffet al., 1996). Our
previous studies have suggested that a state ofGH resistance may
exist in children undergoing ALL treatment (Crofton et al., 1998)
and the current study shows thatDex ismore potent at depressing
IGF-I levels than Pred. Absolute IGF-I levels are age-dependent
and may be easier to assess following standardization for age as
standard deviation scores. However, this standardization was not
employed in this study as the age range of children in the two
randomized groups was similar and the aim of the study was to
assess the change in IGF-I levels over a short period of a few
weeks.
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GC promotes food consumption both directly and through
stimulation of NPY and inhibition of CRH release (Tempel &
Leibovitz, 1994; Tataranni et al., 1996). Short-term changes in
energy intake secondary to GC administration during main¬
tenance treatment in children with ALL have recently been
reported by Reilly et al. (2001). This group did not show any
significant differences in energy intake or weight gain between
Dex and Pred and this may have been due to the short, 5-day
period of steroid administration. Our study shows that the
changes in weight gain were more marked in those children who
were randomized to receive Dex for a longer period of4 weeks.
Previous studies of short-term growth by knemometry have
shown that changes in body weight may independently influence
LLL due to the action of gravity on the soft tissues of the lower
leg (Hermanussen et al., 1988; Ahmed et al., 1996). Previous
studies in a pregnant adult subject showed that the increase in
body weight was associated with a reduction in LLL until the
subject developed dependent oedema, at which point LLL started
to increase (Ahmed et al., 1996). Although changes in general
body weight may explain the negative growth or actual shrinkage
that was observed in some children, weight changes cannot solely
account for the observed LLLV differences between the two
groups as some of the major differences in LLLV between the
Pred and Dex groups preceded the major differences in body
weight in the current study. Some of the early shrinkage may be
explained by recent ultrasound studies that show that systemic
steroid therapy may have an early water-depleting effect on
connective tissues and may lead to a reduction in the subcutis
thickness (Schou et al., 2001). This water-depleting affect
may similarly effect the growth plate, which is already known to
be directly susceptible to the effect of corticosteroids by a variety
of mechanisms (Mushtaq & Ahmed, 2002).
The dose of Pred in milligrams was approximately six times
that used ofDex and our studies show that LLLV was about three
times lower in the Dex group over the period of treatment and
the subsequent few weeks. We therefore estimate that, between
weeks 1 and 8 of the 5-week period of GC therapy, Dex was 18
times more potent at suppressing short-term growth. Similar
calculations estimate that Dex was 19 times more potent at raising
body weight and about 8-9 times more potent at suppressing
bone turnover as assessed by serum bALP concentration and
urinary DPD excretion. After 8 weeks all the above parameters,
except change in body weight, were similar in the two groups.
In summary, this study has attempted to quantify the relative
effect of the two corticosteroids, Pred and Dex, on short-term
growth and bone turnover. Compared to Pred, Dex may be almost
20 times more potent at suppressing short-term growth and at
raising body weight and almost 10 times more potent at sup¬
pressing bone turnover. GCs have a variable effect on different
parameters of growth and bone turnover and the intensity may
depend on the steroid used.
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Endocrinology
The impact of corticosteroids on
growth and bone health
T Mushtaq, S F Ahmed
An examination of current evidence
Glucocorticoids (GC) arc impor¬tant regulators of diverse physio¬logical systems and are often
used in the treatment of a number of
chronic inflammatory, autoimmune, and
neoplastic diseases. It is estimated that
10% of children may require some form
of GC at some point in their childhood.1
Impairment of childhood growth with
an approximate cortisone dose of 1.5
mg/kg/day was first described over 40
years ago; osteopenia in children receiv¬
ing a prednisolone dose of less than 0.16
mg/kg/day has also been reported.2' The
maintenance of growth and bone health
is a complex process that can be influ¬
enced not only by drugs, but also by the
nutritional status of the patient and the
underlying disease process. The purpose
of this review is to examine the current
evidence for linking GC to adverse
growth and bone health in childhood
disorders that commonly require GC
therapy.
PATHOPHYSIOLOGY
Loss of bone and deterioration in short
term growth are dependent on the type
and dose of GC and occur most promi¬
nently over the first six months of
treatment.'" Although it is generally
believed that GC affect trabecular bone
more than cortical bone, a recent study
of fractures in children following steroid
exposure as part of acute lymphoblastic
leukaemia (ALL) treatment showed a
high incidence of cortical bone involve¬
ment, suggesting that the disease proc¬
ess may interact with GC usage in influ¬
encing site of bone loss.7 *
GC have a suppressive effect on
osteoblastogcnesis in the bone marrow
and promote the apoptosis of osteoblasts
and ostcocytes, thus leading to decreased
bone formation.' Accumulation of apop-
totic osteocytes may also explain the so
called "osteonecrosis", also known as
aseptic or avascular necrosis. There is
some evidence to suggest that GC may
also increase bone resorption by extend¬
ing the lifespan of pre-existing
osteoclasts.10 GC may also promote cal¬
cium loss through the kidneys and gut,
and this negative calcium balance can
itself lead to increased bone remodelling
and osteoclastic activity due to second¬
ary hyperparathyroidism."
High dose GC therapy can attenuate
physiological growth hormone (GH) se¬
cretion via an increase in somatostatin
tone, and the GH response to GH stimu¬
lation tests may be revcrsibly impaired in
some cases of steroid exposure.1213 How¬
ever, GC induced growth failure may also
be due to direct effects on the growth
plate. Infusion of GC into the growth
Figure 1 Mechanisms of GC induced bone loss and growth retardation.
plate leads to a temporary reduction in
the growth rate of that leg and may dis¬
rupt the growth plate vasculature.1415 GC
exposed chondrocytes show reduced
proliferation rates and a reversible, pro¬
longed resting period. In vitro studies
suggest that local somatotrophic action
of GH and IGF-1 may be affected by a
number of different mechanisms, includ¬
ing alterations in the activity of the GH
binding protein, down regulation of GH
receptor expression and binding capac¬
ity, and a reduction in local IGF-1
production and activity.1"'
GC may also impair the attainment of
peak bone mass and delay growth
through alterations in gonadal function
at the level of the pituitary and through
direct effects on the gonads. Studies in
adults show that GC therapy may be
associated with testosterone deficiency
as well as reversible gonadotrophin
deficiency.20 21 Levels of other sex steroids
such as androstenedione and oestrogen
may also be depressed due to adrenal
inactivity following chronic GC
therapy.22 In addition, there is in vitro
evidence suggesting that GC impair FSH
action, thus reducing oestrogen
secretion.23
Figure 1 summarises the mechanisms
of GC induced bone loss and growth
retardation.
ASTHMA, ECZEMA, AND HAY
FEVER
The increasing incidence and prevalence
of childhood atopy and the more wide¬
spread use of inhaled steroid therapy for
asthma prophylaxis probably accounts
for the largest group of children who are
chronically exposed to steroids. Oral GC
therapy in asthma is associated with a
delay in growth and puberty, and there is
some evidence to suggest that final
height may also be compromised.24 Sys¬
temic exposure to inhaled steroids may
be higher with metered dose inhalers
and dry powder devices where 80% of
the drug is deposited in the oropharynx.
Although earlier studies did not show a
relation between inhaled steroids and
growth, there is now good evidence in
children with relatively mild asthma that
inhaled steroids can temporarily slow
growth and alter bone and collagen
turnover. The magnitude of this effect
may be influenced by the dose delivery
system as well as the systemic bioavail¬
ability of the inhaled steroid used.23 This
effect may be most pronounced over the
first few weeks of treatment.26 Long term
studies are difficult due to a number of
Abbreviations: ALL, acute lymphoblastic
leukaemia; DEXA, dual energy x ray
absorptiometry; GC, glucocorticoid; GH,
growth hormone; JIA, juvenile idiopathic arthritis
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confounding factors including the
plethora of drugs, delivery systems, com¬
pliance, and disease severity, but there is
no clear evidence that final height is
compromised following inhaled GC
therapy in children with asthma. Studies
of bone mineral density in children with
asthma have not shown any significant
abnormality but have only concentrated
on those children who are on relatively
low doses of inhaled steroids.27
Some intranasal GC such as budeso-
nide have a very high level of systemic
absorption when applied directly to the
nasal mucosa; short and intermediate
term studies of children on intranasal
steroids such as budesonide and beclom-
ethasone also show a deterioration in
growth velocity.28 Like asthma, there is
some suggestion that the effects of these
intranasal steroids may be dose depend¬
ent and that the newer forms of intrana¬
sal steroids such as mometasone furoate
may not have these adverse growth
effects.2' Assessment of short term
growth during topical steroid treatment
for eczema has also been studied, but the
results have been inconclusive."
INFLAMMATORY BOWEL DISEASE
Longitudinal studies show that the
growth velocities of children in the year
preceding diagnosis are reduced; growth
retardation frequently complicates the
clinical course in children." There is an
increased recognition of osteoporosis in
adult patients with chronic inflamma¬
tory bowel disease. In children with
inflammatory bowel disease, retardation
of growth and skeletal maturation are
widely reported and may be related to
disease activity as well as to its
treatment.22 Vertebral fractures have also
been described in children with Crohn's
disease with a short or absent history of
steroid usage." 24 A cross sectional study
of bone mineralisation using dual energy
x ray absorptiometry (DEXA) showed
evidence of osteopenia even when cor¬
rected for sex, height, weight, and
puberty.2' In this study, the bone status
was related to steroid usage but had no
relation to disease activity. In a longitu¬
dinal study of 55 children, uncorrected
total body bone mineral density standard
deviation score correlated negatively to
cumulative steroid dosage and positively
to body mass index.28 A reduction in
bone mineral density of the lumbar
spine, femoral neck, and radius may be
more prominent in children with
Crohn's disease and those children who
arc of a pubertal or post-pubertal age.
The recent introduction of budesonide
enemas for treatment of distal colitis has
also been reported to be associated with
suppression of markers of bone
formation.2'
RENAL DISEASE
Impaired linear growth is one of the
major complications of childhood onset
chronic renal insufficiency and its treat¬
ment. Final height may be less than the
third centilc in 50% of children who
enter end stage renal failure in child¬
hood. It is unclear whether such children
who are on appropriate vitamin D
supplements have a poorer bone miner¬
alisation status. Children with a history
of renal insufficiency who receive GC
may grow more slowly, have a poorer
bone mineralisation status, and may not
respond satisfactorily to vitamin D re¬
placement compared to those who do
not receive GC.28 The prolonged use of GC
is also associated with growth failure
and reduced bone mineral density in
other childhood chronic renal disease,
such as nephrotic syndrome." Post¬
transplantation, the cumulative GC dos¬
age may be inversely related to the
change in relative height, but this find¬
ing is not universal." Intcrindividual dif¬
ferences in the handling of GC as
assessed by area under the curve estima¬
tion rather than dose have shown a
stronger association with adverse
growth in post-transplantation patients.
In nephrotic syndrome, it is not clear
whether intermittent GC therapy over a
number of years has an adverse effect on
growth correlates with final height.4'
Following transplantation, a given cu¬
mulative dose of GC has a lower inhibi¬
tory effect on growth velocity, without
compromising graft function, when
given on alternate days.42 Although
alternate day GC may not adversely
affect final height potential, it may still
delay puberty and be associated with a
delayed growth spurt.42 Substitution of
GC with other immunosuppressants im¬
proves growth but leads to a higher rate
of rejection. The effect of these newer
agents on growth and bone health while
reducing the need of GC are unclear.
Alternative forms of GC, such as deflaza-
cort, an oxazoline derivative of pred¬
nisolone, appear to have fewer effects on
growth and corticosteroid induced
osteoporosis, but are not used in com¬
mon practice.44
ARTHRITIS
GC are widely used for treating chronic
connective tissue diseases in children; as
with other inflammatory conditions,
there is considerable overlap between the
inflammatory process and steroid in¬
duced effects on bone health. A failure to
develop adequate bone mineralisation is
virtually universal in children with juve¬
nile idiopathic arthritis (JIA) and is
characterised by a failure of bone forma¬
tion, with a subsequent failure to un¬
dergo the normal increase in bone mass
during puberty.4' The reduction in bone
mineral density and bone mineral gain
may be adversely affected if the child was
on steroids.48 Other studies have not
shown any statistical significance of the
cumulative dose of corticosteroids on
growth, although they did note a reduc¬
tion in the growth velocity during the
first year of treatment which was more
apparent in the polyarticular group.47 It
does appear that good control of disease
activity in systemic onset JIA can be
achieved by high dose alternate day
prednisolone with minimal side
effects.48 The use of high doses of oral
steroids in autoimmune conditions is
associated with a prompt decrease of
bone formation and collagen synthesis,
without any significant changes in bone
resorption; however, these negative ef¬




GC have been a mainstay of the therapy
for childhood ALL. Dexamethasone is
now replacing prednisolone as the drug
of choice because of its greater lym-
phocytotoxicity and higher CNS penetra¬
tion. Recent studies have shown that
bone mineralisation status as assessed
by bone mineral density, corrected as
well as uncorrected for body size, may be
adversely affected immediately after
completion of treatment." " The fracture
incidence during leukaemia treatment
has been reported to be as high as 39%;
this has been recently confirmed by
Strauss et al who have shown a five year
cumulative incidence of 28% for frac¬
tures and 7% for osteonecrosis, with a
median follow up of over seven
years." " '2 The median time from diagno¬
sis to first fracture was 15 months and
most occurred within two years of diag¬
nosis. Older age, pubertal age, the male
sex, and dcxamethasone have been
shown to be independent risk factors for
fractures and reduced bone
mineralisation." Previous studies by our
group have shown alterations in bone
turnover and short term growth of
children during leukaemia treatment;
these changes were most marked during
periods of intensive chemotherapy and
high dose systemic glucocorticoid
administration."'52 More recently, we
have also reported that the biological
potency of dexamethasone in suppress¬
ing growth may be 18 times higher than
that of prednisolone."
MANAGEMENT
A number of childhood conditions that
require chronic GC therapy may them¬
selves predispose the child to abnormali¬
ties of growth and bone health. For
instance, poor linear growth and osteo¬
porosis may be presenting features in a
child with inflammatory bowel disease.
The interaction with other factors such
as inflammatory cytokine production,
diminished physical activity, alterations
in nutritional status, and the use of other
www.archdischild.com
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immunomodulatory agents that may
also have bone adverse effects greatly
increase the risks posed to the growth
and bone health of the child on chronic
GC therapy.
The clinical effects on bone health can
be divided into those occurring in the
short term (fractures and avascular
necrosis) and those that may occur over
the longer term—that is, increased pre¬
disposition for osteoporosis and skeletal
deformity. Current studies and clinical
observations suggest that children who
require long term systemic GC therapy
(for more than three months) have a
higher incidence of fractures during
therapy. For adults, the Royal College of
Physicians has issued guidelines on indi¬
cations for assessing and managing bone
health.54 In the absence of any clear
guidelines for children, it would seem
prudent to monitor susceptible children
carefully with regular review of bone
symptomatology, GC dosage, nutrition
(including calcium and vitamin D sta¬
tus), anthropometry (including sitting
height), pubertal status, and assessment
of bone mineralisation status. Bone min¬
eral status can be assessed by a number
of methods and DEXA is by far the most
popular method. Unlike adults where a
single assessment of bone mineral den¬
sity by DEXA can predict likelihood of
fracture in age related osteoporosis, this
relation is not so clear in children with
GC induced osteoporosis. Children at
risk of GC induced osteoporosis and
those displaying growth failure should,
therefore have serial bone mineral den¬
sity assessment to assess a change in
status; results need to be carefully inter¬
preted in relation to their sex, age,
height, and weight, as well as their
disease and its treatment. Current stud¬
ies of long term follow up of children
treated with chemotherapy only regi¬
mens for ALL do not show disturbances
in final height or bone mineral status,
and there are no data to support or refute
the claim that prolonged GC therapy in
childhood may lead to early osteoporosis
in adulthood.55""
Skeletal disproportion has been re¬
ported as a possible long term effect of
ALL chemotherapy; it is not clear
whether this phenomenon of skeletal
disproportion is observed in other
groups of children requiring chronic GC
therapy.58 In the absence of any convinc¬
ing evidence for or against long term
osteopenia, it would, again, seem pru¬
dent to consider assessing growth and
bone mineral status in all patients with a
past history of prolonged GC exposure
when they reach the end of their second
decade and should have acquired peak
bone mass. Failure to acquire peak bone
mass should prompt longer term moni¬
toring.
Prevention of GC induced growth
retardation and adverse bone health
could be addressed in a number of cases
by judicious use of GC therapy coupled
with improved nutrition and promotion
of weight bearing activities. In addition,
alternate day GC regimens and consid¬
eration of GC sparing drugs at an earlier
stage than before may be possible pre¬
ventive measures but need further evalu¬
ation. For reasons mentioned earlier, cal¬
cium and vitamin D supplementation is
generally recommended in patients on
GC therapy, although there is little
objective clinical evidence to suggest that
this practice prevents GC induced osteo¬
porosis in adults or children. As hypogo¬
nadism may contribute both to poor
growth and impaired bone mineral ac¬
cretion, addressing hypogonadism in
pubertal children on GC therapy should
be an important consideration. Recent
studies show that recombinant GH treat¬
ment may be of benefit in halting the
growth retardation and bone loss ob¬
served in children on chronic GC
therapy."60
In children, the role of the antiresorp-
tive group of drugs, bisphosphonates has
been mostly studied in the field of osteo¬
genesis imperfecta where their use is
associated with a reduction in the
frequency of fractures, improved bone
mass, and mobility.61 Bisphosphonate
therapy is now used regularly in adults
for prevention and treatment of gluco¬
corticoid induced osteoporosis and needs
to be carefully evaluated in the paediatric
setting.62 Acute vertebral fractures can be
a debilitating condition that may be
associated with a prolonged period of
immobility during which the patient
may become increasingly susceptible to
further fractures. An early resumption of
aerobic as well as weight bearing activity,
with good analgesic control will require
the support of a child oriented physio¬
therapy and pain relief service.
GC arc an effective and necessary
form of therapy for a large number of
children. In some children, their use may
be associated with adverse effects; effec¬
tive management of GC induced growth
retardation and bone health will require
improved awareness and better access
for monitoring and managing these chil¬
dren, as well as an improved understand¬
ing of the contributory factors.
Arch Dis Child 2002;87:93-96
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Abstract
Glucocorticoids (GC) are used extensively in children and
may cause growth retardation, which is in part due to the
direct effects ofGC on the growth plate. We characterised
the ATDC5 chondrocyte cell line, which mimics the
in vivo process of longitudinal bone growth, to examine the
effects of dexamethasone (Dex) and prednisolone (Pred)
during two key time points in the chondrocyte life cycle -
chondrogenesis and terminal differentiation. Additionally,
we studied the potential for recovery following Dex
exposure. During chondrogenesis, Dex and Pred exposure
at 10~8M, 10~7 M and 10~6M resulted in a significant
mean reduction in cell number (28% vs 20%), cell
proliferation (27% vs 24%) and proteoglycan synthesis
(47% vs 43%) and increased alkaline phosphatase (ALP)
activity (106% vs 62%), whereas the incidence ofapoptosis
was unaltered. Minimal effects were noted during terminal
differentiation with both GC although all concentrations
ofDex lowered apoptotic cell number. To assess catch-up
growth the cells were incubated for a total of 14 days
which included 1, 3, 7, 10 or 14 days exposure to 10~6 M
Dex, prior to the recovery period. Recovery ofproteogly¬
can synthesis was irreversibly impaired following just one
day exposure to Dex. Although cell number showed a
similar pattern, significant impairment was only achieved
following 14 days exposure. Irreversible changes in ALP
activity were only noticed following 10 days exposure to
Dex.
In conclusion, GC have maximal effects during chon¬
drogenesis; Dex is more potent than Pred and cells
exposed to Dex recover but this may be restricted due
to differential effects of GC on specific chondrocyte
phenotypes.
Journal of Endocrinology (2002) 175, 705-713
Introduction
Glucocorticoids (GC) are commonly used as anti¬
inflammatory therapy and in immunosuppressive regi¬
mens and it is estimated that 5-10% of children may
require some fonn of GC therapy at some time in
childhood (Warner 1995). The functional effects of ster¬
oids on target tissues are difficult to predict and their use is
hampered in some individuals more than others because of
side-effects such as growth retardation and osteoporosis.
Impairment of childhood growth with long-term GC was
described almost 50 years ago but more recent studies have
shown that altered growth and bone turnover also occur
during relatively short periods of GC therapy and that
these effects may vary depending on the type of cortico¬
steroid used (Blodget et al. 1956, Crofton et al. 1998,
Ahmed et al. 1999, 2002).
At the level of the growth plate, local and systemic
factors regulate longitudinal bone growth which involves
the differentiation of committed stem cells into proliferat¬
ing chondrocytes; after a finite number of cell divisions
these cells terminally differentiate into the hypertrophic
phenotype that deposit a matrix which is mineralised and
eventually replaced by bone (Green et al. 1985, Isaksson
et al. 1991). GC-induced growth failure may be due to a
combination of factors such as a disruption of the growth
hormone—insulin-like growth factor-I (GH—IGF-I) axis, a
defect in sex steroid action, a disturbance in calcium and
phosphate homeostasis as well as direct effects on the
growth plate (Crilly et al. 1978, Unterman & Phillips
1985, Baron et al. 1992, Jux et al. 1998).
Studies in children suggest that growth retardation
following a short period of systemic exposure to GC
may be followed by a period of catch-up growth and
that alternate day therapy may be less adverse for
growth (Jabs et al. 1996, Ahmed et al. 1999). Catch-up
growth has also been observed following direct
injection of GC into the growth plate of rabbits (Baron
et al. 1994).
The direct effects ofGC on chondrocytes are not clearly
understood and previous studies that have examined the
effect of GC on primary growth plate chondrocytes have
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Table 1 Primer pairs used for specific gene analysis
Primer sequence Cycles Product size (bp)
Gene
18S Unknown, purchased commercially from Ambion 15 488
Collagen type II TTAGAAAGGGGAGCACAGTCC 35 323
TACACTGCCATGAAGCATGG
Collagen type X CAGAGGAAGCCAGGAAAGC 32 330
GGTGTCCAGGACTTCCATAGC
Ambion, Huntingdon, Cambs, UK.
been unable to examine the effect of GC on the different
stages of the chondrocyte life cycle due to the hetero¬
geneous mixture ofmaturational phenotypes (Robson et al.
1998, Koedam et al. 2000). Recently, the murine ATDC5
chondrocyte cell line has been shown to undergo the
temporal sequence ofevents that occur during longitudinal
bone growth in vivo and thereby provide a good model to
study the molecular mechanisms underlying regulation
of endochondral bone formation (Atsumi et al. 1990,
Shukunami et al. 1997). In this study, this cell line was
used to explore the effects of two commonly used gluco¬
corticoids, dexamethasone (Dex) and prednisolone (Pred),
on cell number, prohferation, differentiation and apoptosis
at key maturational time points (chondrogenesis and ter¬
minal differentiation), within the chondrocyte life cycle.
The effect of the GC on the ability of chondrocytes to
recover following GC exposure was also studied to assess
the potential for catch-up growth.
Materials and Methods
Chondrocyte cell culture
The ATDC5 chondrocyte line was obtained from the
RIKEN cell bank (Ibaraki, Japan) and maintained as
described by Atsumi et al. (1990). Cells were cultured at a
density of 12 000 cells per cm2 in multi-well plates
(Costar, High Wycombe, Bucks, UK) in a maintenance
medium of DMEM/Ham's F12 (Invitrogen, Paisley,
Strathclyde, UK) supplemented with 5% FCS (Invitro¬
gen), 10 pg/ml human transferrin and 3 x 10~8 M sodium
selenite (Sigma, Poole, Dorset, UK) until confluent (day
6). Thereafter, differentiation was induced by the addition
of insulin (10 pg/ml; Sigma) and ascorbic acid (20 pg/ml)
to the maintenance medium (differentiation medium).
Incubation was at 37 °C in a humidified atmosphere of
95% air/5% COz and the medium was changed every
second day.
Gene expression
For the determination of chondrocyte phenotype, cells
were grown for up to 20 days as above and RNA was
Journal of Endocrinology (2002) 175, 705-713
extracted, reverse transcribed and analysed for collagen
type II and collagen type X expression at days 6, 8, 10, 13,
15, 17 and 20 by semi-quantitative RT-PCR.
RNA extraction
Total RNA was extracted from chondrocytes by repeated
aspiration through a 25-gauge syringe needle in 1 5 ml
Ultraspec (Biotecx, Houston, TX, USA). After extraction
with chloroform, RNA in the aqueous phase was precipi¬
tated with isopropanol and bound to RNA Tack resin
(Biotecx) following the manufacturer's protocol. After
washing with 75% ethanol, the RNA was eluted in 100 pi
ribonuclease-free water (Houston et al. 1999). In each case
the 260/280 ratio was 1-9—2 0, confirming the purity of
the RNA. All preparations were diluted to a concentration
of 50 ng/pl and stored at — 70 °C.
Semiquantative RT-PCR
Gene expression was analysed by semiquantitative RT-
PCR (Farquharson et al. 1999, Houston et al. 1999,
Jefferies et al. 2000). Aliquots of 500 ng RNA (or an
equivalent volume of water as a control) were reverse
transcribed in 20-pl reactions with 200 ng random hex-
amers and 200 U Superscript II reverse transcriptase using
the Superscript preamplification protocol (Invitrogen).
PCR was performed in 20-pl reactions containing cDNA
equivalent to 10 ng RNA and 200 nM gene-specific
primers in 111 x PCR buffer (Jefferies et al. 1998) (Table
1). The cycling profile was 1 min at 92 °C (first cycle,
2 min), 1 min at 55 °C, and 1 min at 70 °C. The number
of cycles performed was carefully titrated to ensure that
the reactions were in the exponential phase. Reaction
products were analysed on 1 -5% agarose gels in the
presence of ethidium bromide (250 pg/1), and a digital
image of each gel was captured using a gel documentation
system (Bio-Rad Laboratories, Inc., Hemel Hempstead,
Herts, UK).
Chondrocyte number, proliferation, differentiation and
matrix production
Dex and Pred (Sigma) were added to the cells at a final
concentration of 10~8 M, 10"7 M and 10~6M, in 0-01%
ethanol and compared with control cultures which
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contained 001% ethanol only. Collagen type II and
collagen type X expression was first noted at 10 and 15
days respectively. The GC were added from day 6 or day
11 for the 4 days leading up to the expression of these two
chondrocyte phenotypic markers.
Cell layers were rinsed with phosphate buffered saline
(PBS) and lysed with 0-9% NaCl and 0-2% Triton X-100
and centrifuged at 12 000_g for 15 min at 4 °C. The
supernatant was assayed for protein content and alkaline
phosphatase (ALP) activity as a measure of cell number
and chondrocyte differentiation respectively. The protein
content of the supernatant was measured using the Bio-
Rad protein assay reagent (Bio-Rad Laboratories) based on
the Bradford dye binding procedure, and gamma globulin
was used as standard (Farquharson et al. 1995). Enzyme
activity was determined by measuring the cleavage of
10 mM p-nitrophenyl phosphate (pNPP) at 410 nm. Total
ALP activity was expressed as nmoles pNPP hydrolysed/
min/mg protein (Farquharson et al. 1999). The rate of
chondrocyte proliferation was assessed by incubating the
chondrocytes with 0-2 pCi/nrl [3I 1|thymidine (37 MBq/
ml; Amersham Pharmacia Biotech, Little Chalfont, Bucks,
UK) for the last 18 h of the culture period and the amount
of radioactivity incorporated into trichloroacetic acid-
msoluble precipitates measured (Farquharson et al. 1999).
Proteoglycan synthesis was evaluated by staining with
Alcian Blue as previously described (Shukunami et al.
1997). In brief, cells were washed twice with PBS, fixed
in 95% methanol for 20 min and stained with 1% Alcian
Blue 8 GX (Sigma) in 01 M HC1 overnight and rinsed
with distilled water. Alcian Blue-stained cultures were
extracted with 1 ml 6 M guanidine-HCl for 6 h at room
temperature and the optical density (O.D.) was measured
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Figure 1 Semiquantative RT-PCR analysis of the expression of
chondrocyte marker genes. Collagen type II is expressed from day
10 and collagen type X from day 15. B, blank.
effects in the above experiments. This dose was added to
all cells at confluency (day 6) and subsequently replaced
with differentiation medium without Dex after 1,3,7 and
10 days. All cultures were maintained for a total of 14 days
along with a group that was exposed to Dex for the whole
14 days duration (no recovery period). Additional culture
plates of Dex (10~6 M)-treated cells and their respective
controls (containing 0 01% ethanol) were stopped at the
allocated time points (days 1, 3, 7 and 10) to assess the
impact of Dex prior to the period of recovery. Cell
number, ALP activity and proteoglycan content were
determined as described above.
Apoptosis
Apoptosis of the cells was measured by two complemen¬
tary methods: (1) APOPercentage Apoptosis assay,
(Biocolor Ltd, Belfast, N Ireland), which quantifies dye
uptake by apoptotic cells only after the translocation of
phosphatidylserine to the outer surface of the cell mem¬
brane (Fadok et al. 1992) and (2) Nucleosome ELISA kit
(Oncogene Research Products, Nottingham, Notts, UK),
which allows the quantification ofapoptotic cells in vitro by
DNA affinity-mediated capture of free nucleosomes fol¬
lowed by their anti-histone-facilitated detection. Both kits
were used according to the manufacturers' instructions.
Dex and Pred at concentrations of 10~*M, 1()"7 M and
10 6 M were added to the cell cultures on day 6 or day 13
for a period of 24 h. As a positive control, cells were
incubated as above with 5% ethanol.
Recovery following GC exposure
For these experiments, a single concentration of Dex at
10"° M was used as it was noted to have the most potent
Statistical analysis
All experiments were performed at least twice. Data were
analysed by one way analysis of variance. All data are
expressed as the mean ± s.e.m of four observations within
each experiment and statistical analysis was performed
using Statview (SAS Institute Inc., Cary, NC, USA;
version 5.0.1). P<0-05 was considered to be significant.
Results
Temporal expression of chondrocyte phenotype specific markers
Using gene-specific primers, collagen type II expression
by the ATDC5 cells was first noted after 10 days in culture
indicating that the differentiation of mesenchymal cells
to the chondrocyte phenotype (chondrogenesis) had
occurred. Similarly, collagen type X expression was noted
from day 15 onwards indicating that terminal differentia¬
tion of the chondrocytes occurred from day 10 to day 15
(Fig. 1). This information was used to study the effects of
www.endocrinology.org Journal of Endocrinology (2002) 175, 705-713
708 t mushtaq and others Glucocorticoid effects on chondrocytes
Table 2 Effect of Dex and Pred on cellular protein, proteoglycans and alkaline phosphatase activity during chondrogenesis and terminal
differentiation. All data are expressed as means ± s.e.m.
10"M 10 7M 10" M
Control Dex Pred Dex Pred Dex Pred
Chondrogenesis
Cellular protein (mg) 0-66 ± 0-01 0-54 ± 0 05* 0-59 ± 0-04 0-44 ±0-01* 0-52 ±0-01* 0-45 ± 0 03* 0-46 ± 0-02*
Proteoglycan (O.D.) 0-26 ± 0-02 0-15 ±0-01* 0-17 ±0-005* 0-13 ±0 003*t 0-15 ±0-01* 0-13 ±0-003* 0-12 ±0-002
ALP (nmoles pNPP
hydrol/min/mg protein) 331 ±8 660 ± 32*+ 440 ±15* 723 ± 27*+ 585 ±10* 716 ± 36*f 586±19*
Terminal Differentiation
Cellular protein (mg) 0-92 ±0-01 0-91 ± 0-02 0-85 ± 0-05 0-84 ± 0-03 0-79 ± 0-03* 0-92 ± 0-02t 0-82 ± 0-04*
Proteoglycan (O.D.) 0-82 ± 0-07 0-89 ± 0-05 0-82 ± 0 03 0-7 ± 0-02 0-77 ± 0-04 0-73 ± 0-05 0-72 ± 0-04
ALP (nmoles pNPP
hydrol/min/mg protein) 262 ± 11 265 ± 17 244 ±34 292 ±21 270 ±9 245 ± 10 253 ±23
*P<0-05 compared with control cultures; fP<0 05 Dex cultures compared with equivalent dose of Pred.
Dex and Pred during the periods leading up to the
expression of these maturation markers.
Effects of GC on cell number and proliferation
In comparison with control cultures the addition of Dex
and Pred to cells during the chondrogenic period (days
6—10) caused a significant reduction in cell number as
indicated by cell protein data (Table 2). The reduction in
cell number from control values for the Dex concen¬
trations tested were; 10~8 M, 18-2%; 10~7 M, 33-3%; and
10_<> M, 31-8% (P<0-05). The apparent plateau noted at
10"' M for Dex was not seen with Pred, where a dose-
dependent reduction was observed over the three concen¬
trations tested: 10*8M, 10-6% (not significant); 10"'M,
21-2% (P<0-05); and 10"6 M, 30-3% (P<0-05). The mean
reduction in cell number over the three concentrations
was 28% with Dex and 20% with Pred.
The effect of Dex and Pred on [3HJ thymidine uptake
during the chondrogenesis period is shown in Fig. 2. Both
GC caused a significant concentration-dependent decrease
in cell proliferation from control values — Dex: 1 0~8 M,
11-7%; 10"7 M, 33-8%; and 10"6M, 36-6%; Pred: 10"8 M,
9-6%; 10"7 M, 24-7%; and 10"6 M, 37% (P<0-05). As was
noted for cell number, the apparent plateau noted at
10~7 M for Dex was not seen with Pred, where a
dose-dependent decrease was observed over the three
concentrations tested. The mean reduction over the three
concentrations for Dex and Pred was 27% and 24%
respectively. Dex at 10~7 M was significantly more
antiproliferative than Pred at 10"7 M (P<0-05).
During the terminal differentiation phase (days 10-15)
Dex did not significantly alter cell numbers when com¬
pared with control values (Table 2), whereas Pred caused
a significant reduction (P<0-05) at both 1CT7M (14T%)
and 10"6 M (10-9%). The cell proliferation rate in control
cultures was sixfold less during the terminal differentiation
phase than during the chondrogenic stage and the addition
ofGC led to a significant suppression of proliferation with
Dex at 10"8M (40-9%), 10"7 M (24-1%) and 10"6M
(40'3%) whereas a reduction in proliferation by Pred was
noted at 10~s M (26-3%), with a rise in proliferation at
10"6M (21-6%, P<0-05) (Fig. 2).
Effects of GC on proteoglycan production
In comparison with control cultures during the chondro¬
genesis period, there was a concentration-dependent
reduction in proteoglycan synthesis ranging from 42 to
50% with Dex and 35 to 54% with Pred (Table 2). An
apparent plateau was noted at 10~7 M for Dex which was
not seen with Pred, where a dose-dependent reduction
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Figure 2 Effect of Dex and Pred on cell proliferation as assessed
by [3H]thymidine uptake during chondrogenesis and terminal
differentiation phases. Effect of Dex on chondrogenesis (A and
long dashed lines); effect of Dex on terminal differentiation (A and
short dashed lines); effect of Pred on chondrogenesis (■ and solid
line); effect of Pred on terminal differentiation (A and solid line).
All data are expressed as means ± s.e.m. *P<0-05 compared with
control (Cont); fP<0-05 significance level between Dex and
equivalent dose of Pred.
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Comparing Dex and Pred at equivalent concentrations,
Dex at lO"7 M caused a significantly greater fall in
proteoglycans than Pred at 10~7 M (P<(H)5) (Table 2).
Over the three concentrations, Dex caused a mean reduc¬
tion in proteoglycan synthesis of 47% compared with 43%
with Pred. No significant differences were noted during
terminal differentiation.
Effect of GC on chondrocyte differentiation
The effect ofGC on terminal chondrocyte differentiation
as assessed by ALP activity is shown in Table 2. During
chondrogenesis, enzyme activity in comparison with con¬
trol values was significantly increased with both Dex:
10"* M, 83%; 10"7 M, 118%; and 10"6 M, 116% and Pred:
1(T8M, 39%; 10 7 M, 77%; and 10~6M, 77% (P<0-05).
The mean elevations in ALP with all concentrations of
Dex and Pred were 106% and 62% respectively and at
equimolar concentrations ofGC, Dex caused significandy
larger increases in ALP than Pred. No significant differ¬
ences in ALP activity were noted during the terminal
differentiation phase.
Effects on apoptosis
Using the APOPercentage Apoptosis assay the number of
apoptotic cells was higher in the terminally differentiating
chondrocytes in comparison with cultures in the chondro¬
genesis phase. No evidence was detected for an effect of
Dex and Pred on apoptosis during the chondrogenesis
phase (Fig. 3a), however during terminal differentiation all
Dex concentrations, and Pred at 10"6 M caused a signifi¬
cant decrease in apoptotic cell numbers (P<0-05) (Fig. 3b).
Ethanol acted as a positive control and caused an elevation
in apoptosis at both developmental phases (P<0 05). These
data were confirmed with the use of the nucleosome
ELISA kit (results not shown).
Recovery following GC exposure
Exposure of the ATDC5 cells to Dex for one or more days
resulted in lower cell numbers on day 14. These differ¬
ences, however, did not reach statistical significance unless
the cells were exposed to Dex for all 14 days (P<0-05)
(Fig. 4a and b). There was a significant reduction in
proteoglycan content after 7, 10 and 14 days of GC
exposure (Fig. 4c). After the recovery period (Fig. 4d), all
Dex-exposed cells showed a significant reduction in
proteoglycan content (P<0'05). ALP activity was
increased after Dex treatment at days 7, 10 and 14
compared with control cultures but this increase was
statistically significant only after 7 (65%) and 14 (148%)
days of exposure (Fig. 4e). After the recovery period (Fig.
4f) ALP remained significantly elevated from day 10
(P<0-05).
Discussion
GC are known to exert effects on many physiological
systems and can retard growth in children (Loeb 1976).
While they may do this by altering GH secretion or GH
sensitivity (Luo & Murphy 1989, Lima et al. 1993, Devesa
et al. 1995), it is very likely that they may also exert direct
effects on growth plate chondrocytes (Baron et al. 1992).
In vivo studies in rats and in vitro studies using primary
cultured rat epiphyseal chondrocytes show a down-
regulation of GH receptor mRNA expression after GC
treatment as well as an inhibition of IGF-I production and
secretion into the culture medium (Gabriellsson et al.
1995, Jux et al. 1998). However, Heinrichs et al. (1994)
reported an increase in GH receptor gene expression levels
after treatment of rabbits with Dex. A reduction in rat
growth cartilage width after GC treatment has also been
observed and these authors have suggested that this is a
hkely consequence of the lower chondrocyte proliferation
rate and increased hypertrophic chondrocytes apoptosis
(Silvestrini et al. 2000).
Studies using rat chondrocyte cultures showed that Dex
and Pred reduced both cell proliferation and colony
formation and also that Dex was more potent than Pred at
equimolar concentrations (Dearden et al. 1986, Robson
et al. 1998). This culture data is in accord with in vivo
observations where Dex appears to be more potent than
Pred at causing impairment of normal bone growth
(Strauss et al. 2001, Ahmed et al. 2002).
Our present experiments used the ATDC5 chondro¬
cyte cell line, which has less phenotypic diversity than
cultures containing a heterogeneous population ofprimary
chondrocytes (Robson et al. 1998, Koedam et al. 2000).
Furthermore, it allows the study of two critical events
during cartilage formation: the early differentiation of
committed mesenchymal cells into chondrocytes (chon¬
drogenesis) and the terminal differentiation ofproliferating
to hypertrophic chondrocytes (Cancedda et al. 1995). Cell
numbers were reduced by both Dex and Pred during the
chondrogenesis period, but little effect of either GC was
noted during the terminal differentiation period. Cell
numbers may be reduced by GC by mechanisms such as
loss of proliferative activity, increased apoptosis and cyto-
stasis. Our present data strongly support the proposal that
loss of proliferative activity is, at least in part, responsible
for the decrease in chondrocyte numbers by GC treat¬
ment. We found no evidence of increased apoptosis,
which is in accordance with Mehls et al. (2001). In the
growth plate it is well recognised that apoptotic chondro¬
cytes are most prevalent in the terminally differentiated
zone (Ohyama et al. 1997) and this is also reflected in the
ATDC5 cell line as shown in the present study. Interest¬
ingly, GC reduced apoptosis in the terminally differenti¬
ated cells whilst having no effect on the chondrogenesis
phenotype, suggesting that GC control of chondrocyte
apoptosis is phenotype dependent. This observation
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Figure 3 Effect of Dex and Pred treatment for 24 h on the incidence of apoptosis during (a)
chondrogenesis and (b) terminal differentiation. All data are expressed as means ± s.e.m. *P<0-05
compared with control (Cont). No effects of the CC were observed during the chondrogenesis
phase whereas all concentrations of Dex, and Pred at 10"f' M, caused a significant reduction in
apoptosis during terminal differentiation. Ethanoi (5%) caused a significant elevation in apoptosis at
both developmental time points.
requires further study. Cell proliferation rates and cell
numbers were more greatly affected by Dex and Pred
during the chondrogenesis period when the chondrocytes
were rapidly proliferating. These results extend the data
from cultures containing chondrocytes of various matura-
tional phenotypes (Robson et al. 1998) and are also in
agreement with studies on other bone cell types which
indicate that Dex was more potent than Pred in reducing
osteoblast cell number and DNA synthesis (Kasperk et al.
1995, Davies et al. 2002). Davies and colleagues (2002)
also reported that osteoblast precursor cells (HCC1) were
more chemosensitive to Dex than fully differentiated
osteoblasts and together with our present data suggest that
in bone cells, GC exert their maximum effect at the cell
precursor stage. Over the three concentrations, Dex was
also more potent than Pred as it caused a 44% greater
increase in ALP activity and greater reductions in proteo¬
glycan synthesis, cell number and cell proliferation.
Annefeld (1992) also showed that Dex treatment in rats
results in inhibition of both chondrocyte proliferation and
Journal of Endocrinology (2002) 175, 705-713 www.endocrinology.org
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Figure 4 Effect of 10~6 M Dex on protein (a and b), proteoglycans (c and d) and ALP activity (e and f) either after a
period of no recovery (a, c, e) or where the Dex-treated cells were allowed to recover and were assayed at 14 days (b,
d, f). (a) The cell number increased with time in culture. The only significant reduction was after 14 days Dex treatment
(P<0-05). (b) Protein was reduced at all time points, but this was only significant at day 14 (P<0-05). (c) Proteoglycan
levels were elevated with time in the control group, but there was a significant reduction in proteoglycans (P<0 05) from
day 7 to day 14 in the Dex-treated group as compared with their controls, (d) A significant reduction in proteoglycan
content occurred after 1 day Dex treatment (P<0-05) and this was more pronounced with longer periods of treatment,
(e) There was a gradual elevation in ALP activity (nmoles pNPP hydrolysed/min/mg protein) at each time point with a
significant elevation above the respective control at days 7 and 14. (f) After the recovery period, ALP activity remained
elevated and reached significance at days 10 and 14 (P<0-05). Cont, control.
cartilage matrix production. The pro-differentiating
effects ofDex are in agreement with studies using costo-
chondral cultures, in which Dex promoted ALP activity
(Schwartz et al. 1995). However, the results are at variance
with other studies where Dex lowered enzyme activity in
prehypertrophic chondrocytes but had minimal effects on
hypertrophic or mineralising chondrocytes (Robson et al.
2001). Although these results are in contrast to those
presented here, they do substantiate our own observations
and those of others that the response of chondrocytes to
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Dex is dependent on their stage of differentiation (Yasuda
et al. 1995).
In growth failure, amelioration of the growth retarding
insult results in a period of supranormal linear growth
described as catch-up growth (Prader et al. 1963). Two
underlying mechanisms for this phenomenon have been
suggested — a neuroendocrine model which adjusts the
growth rate to an age appropriate set point, and a local
mechanism intrinsic to the growth plate (Prader et al. 1963,
Baron et al. 1994). Baron et al. (1994) demonstrated a 77%
reduction in the growth rate of 5-week-old rabbit limbs
that had Dex infused into the proximal tibial growth plate.
Following cessation ofDex, catch-up growth was observed
in the affected growth plate and not in the contralateral
tibia. It is postulated that this is due partly to a delay in
growth plate senescence by Dex (Gafni et al. 2001).
The ATDC5 cell line allowed us to study this recovery
phenomenon in greater detail. No differences were
observed in proteoglycan content in the culture plates
stopped prior to recovery at 24 and 72 h of treatment.
However, after the recovery period a reduction in proteo¬
glycans was apparent at all treatment lengths. This would
indicate that Dex-induced suppression may take some
time to manifest itself even though the stimulus for
suppression has been removed. Longer treatments with
Dex of 7 and 10 days duration showed unchanged levels
of proteoglycans compared with the 14-day treated group
and indicates that within the timescale of this experiment
the ability to recover after 7 days of Dex treatment was
irreversible. Longer periods of recovery allowed the ALP
activity to be suppressed towards control levels, although
after 10 days there was no further recovery noted as
compared with the 14-day Dex-treated group. It cannot
be ruled out, however, that longer periods of recovery
could result in suppression ofALP activity back to control
levels. It is possible that catch-up growth is never complete
and merely falls below the statistical detection limit of a
study (Silverstein et al. 1997).
In conclusion, Dex and Pred reduce cell number, cell
proliferation and proteoglycan content whilst stimulating
chondrocyte differentiation. The GC have maximal effects
during chondrogenesis with minimal effects during termi¬
nal differentiation. The ability to recover is related to the
length of Dex exposure and possibly the chondrocyte
phenotype. Our studies suggest that the potential for
recovery of different events of the chondrocyte life cycle
may vary. Our findings in the ATDC5 cell line will allow
a more focussed approach towards studying the mecha¬
nisms underlying GC-induced growth retardation as well
as investigating the potential benefit of growth-promoting
therapy.
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Insulin-Like Growth Factor-I Augments Chondrocyte
Hypertrophy and Reverses Glucocorticoid-Mediated
Growth Retardation in Fetal Mice Metatarsal Cultures
T. MUSHTAQ, P. BIJMAN, S. F. AHMED, and C. FARQUHARSON
Bone and Endocrine Research Group (T.M., S.F.A.), Royal Hospital for Sick Children, Glasgow G3 8SJ; and Bone Biology
Group (T.M., P.B., C.F.), Roslin Institute, Edinburgh EH25 9PS, United Kingdom
The study aims were to improve our understanding of the
mechanisms of glucocorticoid-induced growth retardation at
the growth plate and determine whether IGF-I could amelio¬
rate the effects. Fetal mousemetatarsals were cultured for up
to 10 d with dexamethasone (Dex; 10-6 m) and/or IGF-I and GH
(both at 100 ng/ml). Both continuous and alternate-day Dex
treatment inhibited bone growth to a similar degree, whereas
IGF-I alone or together with Dex caused an increase in bone
growth. GH had no effects. These observations may be ex¬
plained at the cellular level; cellproliferationwithin the grow¬
ing bone was decreased by Dex and increased by IGF-I and
these effects were more marked in the cells of the perichon¬
drium than those in the growth plate. However, the most
prominent observation was noted in the hypertrophic zone
where all treatments containing IGF-I significantly increased
(3-fold) the length of this zone, whereas Dex alone had no
significant effect. In conclusion, Dex impaired longitudinal
growth by inhibiting chondrocyte proliferation, whereas
IGF-I stimulated chondrocyte hypertrophy and reversed the
growth-inhibitory Dex effects. However, the IGF-I-mediated
improvement in growth was at the expense of altering the
balance between proliferating and hypertrophic chondro¬
cytes within the metatarsal. (Endocrinology 145: 2478-2486,
2004)
CLINICAL STUDIES BY our own group, as well as oth¬ers, have shown that growth and skeletal development
are impaired during treatment with prednisolone and dexa¬
methasone (Dex) (1, 2). Most children who require systemic
glucocorticoids (GCs) also suffer from chronic inflammatory
disease, and in the clinical scenario, it can be difficult to
clearly assess the relative contribution of disease and drugs
on growth. In these children, maintenance of growth is a
complex process that is influenced by a number of different
mechanisms that influence the GH/IGF-1 axis by disrupting
GH secretion or altering GH/IGF-1 sensitivity (3, 4). Al¬
though catch-up growth often follows cessation of GC ther¬
apy, children with systemic chronic inflammatory diseases
who are on long-term GCs may have reduced final height (5,
6). Concomitant high-dose recombinant GH therapy may
prevent a further deterioration in height velocity, but there
is no evidence that it can normalize height in this group of
children (7-9). Alternate-dayGC treatmentmay have a lesser
impact on childhood growth velocity than continuous GC
treatment, but permanent growth impairment has also been
noted in children receiving this form of therapy (10, 11).
Optimization of growth-promoting therapy requires an im¬
proved understanding of the biological effects of GCs and
GH/IGF-1 at the level of the growth plate.
The dual-effector theory ofGH/IGF-1 action at the growth
plate proposes that GH acts directly on germinal zone pre¬
cursors of the growth plate to stimulate the differentiation of
Abbreviations: ALP, Alkaline phosphatase; BrdU, bromodeoxyuri-
dine; Dex, dexamethasone; GC, glucocorticoid.
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chondrocytes and then amplify local IGF-I synthesis, which,
in turn, induces the clonal expansion of chondrocyte columns
in an autocrine/paracrine manner (12). Although liver-
derived IGF-I is the main determinant of serum IGF-I levels,
it is not as important for postnatal growth as locally derived
IGF-1 (13, 14).
In the ATDC5 chondrogenic cell line, our group's recent in
vitro studies show that GC effects may be dependent on the
stage of chondrocyte maturation with maximal effects dur¬
ing chondrogenesis and minimal effects during terminal dif¬
ferentiation (15). It also seems that, although the progenitor
cells may become quiescent when exposed to GC, their ca¬
pacity to undergo chondrogenesis is maintained and the
program is reactivated when the GC is removed (16). These
data are consistentwith the in vivomodel of catch-up growth
that is observed after cessation of GC administration directly
into the growth plate (17).
The complex effects and physiological mechanisms of GC
on growth plate chondrocytes are difficult to study solely in
live animals where effects cannot be localized to specific cell
types. The fetal mouse metatarsal explant culture is a highly
physiological model for studying growth as the growth rate
of fetal bones in culture is similar to that found in vivo,
whereas bones harvested postna tally from 2-d-old rats arrest
in culture after 2 d in vitro (18,19). In addition, the metatarsal
culture model maintains cell-cell and cell-matrix interac¬
tions, and the direct assessment of bone growth and histo¬
logical architecture can be determined. By using the fetal
mouse metatarsal assay, the aims of the present study were
to obtain a clearer understanding of the cellular events un¬
derlying GC-induced growth retardation and, in addition,
determine whether IGF-I can ameliorate the effects of GC on
bone growth. This model has also allowed a comparison of
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the effect of continuous vs. alternate-day GC exposure. Our
studies reveal that the fetal mouse metatarsal model can
replicate in vivo bone growth, and these experiments repre¬
sent the first in vitro study to demonstrate the prohypertro-
phic effects of IGF-I and reversibility of Dex-induced growth
retardation.
Materials and Methods
Fetal metatarsal organ culture
The middle three metatarsals were aseptically dissected from 18-d-
old embyronic Swiss mice. Bones were cultured at 37 C in a humidified
atmosphere of 95% air/5% CO, individually in 24-well plates (Costar,
High Wycombe, UK) for up to 10 d. Each well contained 300 p.1 of
ff-MEM without nucleosides (Invitrogen, Paisley, UK) supplemented
with 0.2% BSA Cohn fraction V (Sigma, Dorset, UK), 0.1 mmol/liter
^-glycerophosphate (Sigma), 0.05 mg/ml l-ascorbic acid phosphate
(Wako, Fukuoka, Japan), 0.292 mg/ml l-glutamine (Invitrogen), 0.05
mg/ml gentamicin (Invitrogen), and 1.25 pg/ml fungizone (amphoter¬
icin B) (Invitrogen). Dex (Sigma), IGF-I (Bacham, St. Helens, UK), and
GH (Bacham) were added at a final concentration of 10~6 m, 100 ng/ml,
and 100 ng/ml, respectively, to the cultured bones. In addition, the
effects of continuous Dex 1CT6 m vs. alternate-day Dex 10~6 m exposure
on total metatarsal length was also studied. The control and experi¬
mental groups contained six metatarsals each, and the experiment was
repeated at least two times.
Morphometric analysis
Images were taken of the metatarsals every second day of culture
using a digital camera (COHU, San Diego, CA) attached to an Olympus
M081 microscope. The total length of the bone and width through the
center of the mineralizing zone was determined using Image Tool (Im¬
age Tool version 3.00, University of Texas Health Life Science Centre,
San Antonio, TX). All results are expressed as a percentage change from
harvesting length, which was regarded as baseline to demonstrate the
rate of growth over time. For the determination of the size (in the
direction of longitudinal growth) within the growth regionof the distinct
chondrocyte maturational zones, the 4- and 10-d-old metatarsals were
fixed in 70% ethanol, dehydrated, and embedded in paraffin wax (20).
Wax sections (10 pm in thickness) were reacted for alkaline phosphatase
(ALP) activity (21) for the demarcation of the hypertrophic and prolif¬
erating zones. Serial sections were stained with von Kossa and hema¬
toxylin and eosin using standard protocols to identify the zone of car¬
tilage mineralization. Images of the stained metatarsals were captured
using Tmage Tool (University of Texas), and the size of the combined
(distal and proximal) ALP-negative proliferating zone was determined:
proliferating zone = total length - (hypertrophic zone + mineralizing
zone. Similarly, the size of the combined ALP-positive hypertrophic
zone located at either side of the mineralizing zone was determined:
hypertrophic zone = (hypertrophic zone + mineralizing zone) - min¬
eralizing zone. The size of the mineralizing zone was determined di¬
rectly from the von Kossa-stained sections.
ALP enzyme activity
At the end of the culture period (d 10), ALP activity within the
metatarsals was determined as previously described (22). Briefly, each
metatarsal was permeabilized in 100 pi of 10 mmol/liter glycine (pH
10.5) containing 0.1 mmol/liter MgCl2, 0.01 mmol/liter ZnCl2, and 0.1%
Triton X-100 by freeze-thawing three times. The extract was assayed for
ALP activity by measuring the rate of cleavage of 10 mm p-nitrophenyl
phosphate. Total ALP activity was expressed as nanomoles p-nitrophe¬
nyl phosphate hydrolyzed per minute per metatarsal. Each group con¬
tained threemetatarsals, and the experiment was repeated at least twice.
Cell proliferation and dry weight determination
[3H]Thymidine uptake. On d 4 and 10 of culture [3H]thymidine (Amer-
sham Biosciences, Little Chalfont, UK) was added (final concentration,
10 pCi/ml) to each metatarsal culture for the last 6 h of culture. After
washing in PBS, the metatarsals were extracted in trichloroacetic acid
(twice for 30 min), acetone (twice for 30 min), and ether (three times for
30 min) and air dried overnight at room temperature. After the deter¬
mination of dry weight (Sartorious Micro, Gottingen, Germany) the
tissue was solubilized (NCS-II tissue solubilizer, Amersham) and the
DNA incorporating [3H]thymidine was determined using a scintillation
counter (20). The cell proliferation data were expressed as [3H]thymidine
(dpm) per metatarsal. Each group contained three metatarsals, and the
experiment was repeated at least two times.
Histological assessment of bromodeoxyuridine (BrdU) uptake. BrdU (Sigma)
was added (final concentration, 1 mg/ml) to the culture medium of the
metatarsals for the last 6 h of culture on d 4 and 10 as described pre¬
viously (20). At the end of the incubation period, the tissue was washed
in PBS and fixed in 70% ethanol, dehydrated, and embedded in paraffin
wax. Sections, 10 p.m in thickness, were cut along the longitudinal axis,
and chondrocyte nuclei with incorporated BrdU were detected using an
indirect immunofluorescence procedure as detailed previously (23).
Briefly, sections were denatured with 1.5 m HC1 for 30 min before
incubationwith an antibody to BrdU (Dako, Ely, UK) diluted 1:50 in PBS
for 1 h. After washing, the sections were incubated for an additional 1 h
in fluorescein isothiocyanate-labeled goat antimouse IgG (Sigma) di¬
luted 1:50 in PBS. The sections were finally mounted in PBS/glycerol
(Citifluor, Agar Scientific, Essex, UK). Sections were examined using a
Leica BMRB fluorescent microscope, and the total number of BrdU-
positive chondrocytes within both the proximal and distal growth re¬
gions was determined. BrdU-labeled cells located to the perichondrium
were also counted. Three sections from each of six bones from each
treatment group at both time points were examined to obtain an ag¬
gregate value.
Statistics
All data are expressed as the mean ± sem, and statistical analysis
was performed using an ANOVA (GenStat, sixth edition, VSN In¬
ternational Ltd., Hemel Hempstead, UK). P < 0.05 was considered to
be significant.
Results
All fetal mice metatarsals grew in culture and displayed a
central core ofmineralized cartilage juxtaposed on both sides
to a translucent area representing the hypertrophic chon¬
drocytes (Fig. 1, B-D). The localization of ALP reactivity
within metatarsal sections was restricted to the mineralizing
and hypertrophic chondrocytes and thus clearly delineated
the boundary between the proliferating and hypertrophic
zones (Fig. 1E) whereas von Kossa staining was specific to the
mineralizing zone (not shown).
Longitudinal bone growth
All experiments were done on metatarsals from 18-d-old
embryos that were cultured for intervals for up to 10 d.
Dex-treated bones paralleled control bone growth rate until
d 8 when their rate of growth decreased resulting in a total
length that was significantly reduced from controls at d 8
(P < 0.05) and 10 (P < 0.05), (Fig. 2A). IGF-I and combined
IGF-I plus Dex (IGF-I+Dex)-treated bones showed a rapid
acceleration in growth from d 2 that was significantly higher
than the control group (P < 0.05), and this increased growth
rate was maintained throughout the duration of the exper¬
iment. At d 10, mean increase from baseline in total length
of control, Dex, IGF-1, and IGFl+Dex bones was 50 ± 3%,
42 ± 2% (P < 0.05), 99.3 ± 5%, (P < 0.05), and 87 ± 4% (P <
0.05), respectively. Compared with the IGF-I-treated bones,
the length of the bones treated with IGF-I+Dex was also
significantly lower at d 8 (P < 0.05) and 10 (P < 0.05). The










Fig. 1. Measurements ofdigital images of fetal mousemetatarsal bones in culture with clearly delineated mineralizing zones (B-D) were taken
using a calibrated ruler (A). These images demonstrate the harvesting day length (B) and the increased longitudinal growth at d 4 (C). An
IGF-I-exposed metatarsal at d 10 is illustrated in D. Section of an IGF-I-treated metatarsal at d 10 reacted for ALP activity showing staining
within both the mineralizing and hypertrophic zone. The proliferating zone is negative (E). The location of the proliferating (PZ), mineralizing
(MZ), and hypertrophic (HZ) zones are also illustrated in E.
ability ofGH to directly influence bone growth in this model
system was also studied (Fig. 2B). In contrast to the growth-
promoting effects of IGF-1 (Fig. 2A), GH was found to have
no significant effects on total bone length compared with
control metatarsals. We also determined whether alternate-
day Dex had a lesser deleterious impact on growth rate than
continuous Dex treatment (Fig. 2B). Both modes of Dex treat¬
ments resulted in a significant reduction in total length from
d 8 (P < 0.05). By d 10 in the continuously treated Dex group
there was a 27 ± 2% (P < 0.05) reduction in total length vs.
a 21 ± 3% decrease in the alternate-day Dex group (P < 0.05)
when compared with the control metatarsals. No significant
differences were detected between the continuous and al¬
ternate-day Dex lengths.
In control bones, there was a significant increase in the
length of the mineralizing zone by d 6, and by d 10 the mean
increase in length from baseline was 122 ± 2% (P < 0.05) (Fig.
2C). The mineralizing zone length of the IGF-I-treated bones
changed little throughout the culture period and by d 10 it
had increased from baseline by only a mean of 10 ± 2% (P <
0.05). Also by d 10 the length of the mineralizing zone in the
Dex-treated metatarsals had increased by a mean of 79 ± 19%
(P < 0.05) from baseline, significantly less than in the control
metatarsals (P < 0.05). The growth rate of the mineralizing
zone in the IGF-I+Dex-treated metatarsals was also less than
control, and Dex-treated metatarsals with the mineralizing
zone length significantly decreased at d 6 (11 ± 5%; P < 0.05),
d 8 (32 ± 8%; P < 0.05), and d 10 (33 ± 10%; P < 0.05) from
the control bones. Overall, these data suggest the existence
of an inverse relationship between the length of the miner¬
alization zone and total bone length (Fig. 2, A and C).
The thickness of the control and Dex-treated metatarsals
did not change with time in culture and were not signifi¬
cantly different from each other at any of the time points
examined (Fig. 2D). In comparison with controls, both the
IGF-I and IGF-I+Dex-treated bones were significantly
thicker from d 4 (P < 0.05) and 6, respectively (P < 0.05). At
d 4, the thickness of the IGF-I-treated bones was significantly
different from the IGF-I +Dex-treated bones. At d 10, the
thickness of the IGF-I and IGF-I+Dex-treated bones were,
respectively, 51 ± 10% (P < 0.05) and 35 ± 14% (P < 0.05)
greater than that of their harvesting lengths.
With the exception of the results shown in Fig. 2B, the data
presented in Fig. 2, A, C, and D (and all subsequent results),
were obtained from metatarsals of embryos from the same
mother. The differing growth rates shown in Fig. 2, A and B,
are likely to be due to variability between the embryos se¬
lected for each experiment. The inhibition of growth rate by
Dex was observed in both studies.
Assessment of chondrocyte maturational zone sizes
In many of the metatarsal rudiments, the boundary be¬
tween the proliferating and hypertrophic zone of chondro¬
cytes was difficult to delineate while in culture; therefore,
measurements of the size of these individual maturational
zones was performed on histological sections of 4- and 10-
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Fiu. 2. A, Continuous Dex at 10~° M caused a significant decrease in linear growth from 8 d, whereas IGF-I and IGF-I+Dex had significant
stimulatory effects from 2 d. B, Effects of GH (100 ng/ml) and continuous and alternate-day Dex on total length. GH had no significant effects
on total length. However, both continuous and alternate-day Dex caused a significant decrease in length from d 8 (P < 0.05). C, Effects of Dex,
IGF-I, and IGF-I+Dex on the length of the mineralized zone. In the control metatarsals, mineralization increased from 4 d. All treatments caused
a significant reduction in mineralization from d 6. IGF-I-treated bones were the least mineralized, whereas Dex and IGF-I+Dex effects were
intermediate. D, Effects of Dex, IGF-I, and IGF-I+Dex on metatarsal thickness. Both IGF-I and IGF-I+Dex caused a significant increase in
the metatarsal thickness from d 4 and 6, respectively. Results shown in A, B, and D were obtained from the same cultures, whereas the data
shown in B were from a separate experiment. All data are expressed as the mean ± SEM; *, P < 0.05 compared with control; t, significance
of IGF-I compared with IGF-I/Dex (P < 0.05); A, continuous Dex; ▲, alternate-day Dex; ■, IGF-I (100 ng/ml); □, combined IGF-I+Dex; O, GH
(100 ng/ml); •, control cultures.
d-old metatarsals. The lengths of the proliferating, mineral¬
izing, and hypertrophic zones are shown in Table 1.
Although Dex decreased and IGF-I increased the length of
the proliferating zone, these changes did not reach statistical
significance. However, IGF-I+Dex treatment resulted in a
significant increase in the length of the proliferating zone at
d 4 (P < 0.05), which was not sustained by d 10. The length
of the mineralizing zone was significantly reduced with all
treatments at both time points (P < 0.05) compared with the
controls. At d 4, there was a 10% reduction with all treat¬
ments; this decrease became larger by d 10, with Dex, IGF-I,
and IGF-I+Dex causing a 16, 51, and 42% reduction, respec¬
tively, in the length of the mineralizing zone compared with
the control bones (P < 0.05). Dex caused a nonsignificant
increase in the length of the hypertrophic zone at d 4 and 10.
In contrast, IGF-I led to a marked increase in the length of the
hypertrophic zone at d 4 (98% increase; P < 0.05), which
became more pronounced by d 10 (346% increase; P < 0.05)
(Table 1; Fig. 3, A and B). The combined effects of IGF-I+Dex
were similar to IGF-I exposure alone, resulting in a 74% and
233% increase in length at d 4 and d 10, respectively (P < 0.05)
(Table 1). The size of the individual hypertrophic chondro¬
cytes in the 10-d IGF-I-treated metatarsals was also much
larger than those of the control metatarsals (Fig. 3, C and D).
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TABLE 1. Lengths of the proliferating, mineralizing and hypertrophic zones
Treatment
Proliferating zone Mineralizing zone Hypertrophic zone
d 4 d 10 d 4 d 10 d 4 d 10
Control 140 4 + 3.0 122.6 ± 7.0 53.7 ± 1.3 102.0 ± 3.4 38.2 ± 1.7 36.7 ± 4.4
Dex 129.0 ± 2.4 120.3 ± 4.2 48.5 ± 1.9° 84.2 ± 7.4° 42.6 ± 4.0 40.2 ± 15.1
IGF-I 150.6 ± 5.6 123.8 ± 5.0 48.8 ± 1.5° 49.3 ± 2.2° 75.6 ± 1.4° 163.4 ± 7.6°
IGF-I + Dex 159.8 ± 8.9* 137.0 ± 4.7 48.5 ± 1.5° 57.8 ± 3.5° 66.6 ± 8.4° 122.0 ± 3.1"
Data are expressed in micrometers ± sem.
" P < 0.05 compared with controls.
Metatarsal ALP enzyme activity
The enlargement of the hypertrophic zonewi th IGF-I treat¬
ment after 10 d in culturewas further studied by determining
ALP activity in the metatarsals at the end of the culture
period The ALP activity (nmoles hydrolyzed per minute per
metatarsal) expressed as mean ± sem was as follows: control,
0.0187 ± 0.009; Dex, 0.0117 ± 0.009; IGF-1,0.038 ± 0.0061 (P <
0.05); and IGF-I+Dex, 0.026 ± 0.0044. In agreementwith the
increase in hypertrophic zone length (Table 1; Fig. 3B), IGF-I
treatment resulted in significantly elevated levels of ALP
activity within the metatarsals (103% increase; P < 0.05)
compared with the control bones. Combined IGF-I+Dex
caused an increase and Dex treatment alone a reduction in
ALP activity, although these results were not significantly
different from the control values. It was of interest to note
that the data from the IGF+Dex-treated cultures are consis¬
tent with the metatarsal length data (Fig. 2A) where the
presence of Dex partially reduced the effects of IGF-I.
Cell proliferation: [3H]thymidine incorporation and
BrdU staining
The incorporation of [3H]thymidine into the metatarsals
was determined at d 4 and 10, representing two distinct
phases of varying growth rates. There was a tailing off in the
linear growth curve from d 6 in all bones (Fig. 2A), and this
was reflected in a lower [3H]thymidine incorporation rate in
the control metatarsals at d 10 (75131 ± 5864 dpm) compared
with the control bones at d 4 (98608 ± 6732 dpm) (Table 2).
In comparison with control bones, Dex treatment for 4 d
resulted in a significant reduction (50%; P < 0.05) in [3H]thy-
midine incorporation, whereas both IGF-I and IGF-I+Dex
treatment resulted in significant increases of 43 and 57%,
respectively (P < 0.05). After 10 d, there was a significant
reduction in [3H]thymidine incorporation in all treatment
groups compared with the control cultures (Table 2). How¬
ever, this reduction, from control bone values, was greater
with Dex (80%; P < 0.05) than that observed with IGF-I (64%;
P < 0.05) or IGF-I+Dex (53%; P < 0.05).
To further refine the [3H]thymidine uptake data we de¬
termined the localization of the proliferating cells (BrdU
positive) and quantified their number in both the growth
plate and the perichondrium (Figs. 3 and 4). The total number
of proliferating cells in all control metatarsal groups was
higher at d 4 than d 10, which is in agreement with the
[3H]thymidine incorporation data and indicative of slower
linear growth with time in culture (Table 2 and Fig. 2A).
Compared with d 4 control metatarsals, Dex significantly
reduced the number of BrdU-positive cells located in the
growth plate (42% decrease; P < 0.05) and perichondrium
(76% decrease; P < 0.05) and therefore also the total number
of dividing cells within the whole metatarsal (56% decrease;
P < 0.05), (Figs. 3, E and F, and 4A). In contrast, IGF-I
treatment significantly increased the number of BrdU-posi¬
tive cells in the perichondrium (76% increase; P < 0.05) but
not those within the growth plate (Figs. 3G and 4A). Com¬
bined IGF-I+Dex treatment had no significant effect on BrdU
incorporation in the perichondrium and growth plate com¬
pared with the control metatarsals at d 4.
Compared with d 10 control metatarsals (Fig. 3H), treat¬
ment with Dex alone (Fig. 31) or in combination with IGF-I,
significantly reduced the number of BrdU-positive cells
within the perichondrium (Dex, 96% decrease, P < 0.05;
IGF-I+Dex, 71% decrease, P < 0.05) (Fig. 4B). Similarly,
treatment with IGF-I alone (Fig. 3J) or in combination with
Dex resulted in a reduction in BrdU-positive cells within the
growth plate chondrocytes (IGF-I, 63% decrease, P < 0.05;
IGF-I+Dex, 57%, P < 0.05) (Fig. 4B). No cells outside of the
perichondrium and growth plates showed any BrdU-posi-
tive staining. These results indicate that in comparison with
chondrocytes within the growth plate, the cells within the
perichondrium are more sensitive to stimulation by IGF-I
during rapid growth (d 4) and inhibition by Dex at both time
points.
Dry weights
At d 4 and 10, there was no significant difference between
the weights of the control and Dex-treated metatarsals They
were, however, significantly lighter (P < 0.05) than the IGF-I
and IGF-I+Dex-treated bones, which were themselves sim¬
ilar in weight to each other at both time points (Table 3).
Discussion
The rate of longitudinal bone growth is determined by a
complex interplay of proliferative kinetics, size of the pro¬
liferative pool, matrix synthesis, and hypertrophic chondro¬
cyte enlargement (24, 25). The control of these processes is
still a matter of debate, and the individual contribution of
each variable to bone growth differs with growth rate and is
not uniform for all bones (26). Any perturbation of these
synchronized variables may underlie the growth-modula-
tory effects of both Dex and IGF-I. Therefore, the identifica¬
tion of such changes in this present study will provide a
better understanding of the mechanisms underlying Dex-
induced growth retardation.
Our results unequivocally show that Dex and IGF-I have
major and opposite effects on longitudinal bone growth with
IGF-I clearly reversing the growth-inhibitory effects of Dex.
However, the potential for Dex to inhibit bone growth was
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Fig. 3. Histological assessment of
chondrocyte hypertrophy (A-D) and
proliferation (E-J) in metatarsals
treated with Dex and IGF-I. A-D, He¬
matoxylin- and eosin-stained sections
of 10-d-old cultures of control (A and C)
and IGF-I-treated (B and D) metatar¬
sals. There is an increase in the size of
the hypertrophic zone of the IGF-I-
treated metatarsals (B) compared with
controls (A). The chondrocytes ofthe hy¬
pertrophic zone of the metatarsals in A
and B are shown in higher magnifica¬
tion in C and D. The chondrocytes jux¬
taposed to the von Kossa-positive min¬
eralized cartilage are larger in the IGF-
I-treated (D) than in the control
metatarsals (C). Note the micrographs
shown in A and B are taken at different
magnifications to accommodate the in¬
creased length of the IGF-I-treated
metatarsals. P, Proliferating chondro¬
cytes; H, hypertrophic chondrocytes.
The dashed line marks the boundary
between the proliferating and hypertro¬
phic zones. E-J, BrdU-labeled cells in
control (E and H), Dex-treated (F and I),
and IGF-I-treated (G and J) metatar¬
sals cultured for 4 d (E-G) and 10 d
(H-J). Note the decreased number of
proliferating cells in the Dex-treated
metatarsals and in particular the lack
ofstainingwithin the perichondrium (F
and I). Increased perichondria! stainmg
is observed in the 4-d-old IGF-I-treated
cultures. Bars, 100 pm (A and E—J), 200
fim (B), and 25 pm (C and D).
still present in the IGF-I+Dex cultures where the growth
rates d id notmatch those of bones cultured with IGF-I alone.
The Dex-induced reduction in total metatarsal length from d
8 was due to reduced chondrocyte proliferation and a re¬
duction in the growth of the mineralizing zone. Similar ef¬
fects with other GCs have previously been reported by
Picherit et al. (27) who demonstrated that hydrocortisone
induced growth retardation in fetal rat metatarsals. Interest¬
ingly, our present data did not reveal a significant growth-
sparing effect of alternate-day glucocorticoids. The growth-
sparing effect of alternate-day steroids is not a universal
observation, and it may be influenced not only by the du¬
ration of therapy but also by the underlying disease process
and the sex of the patient (4). In addition, most clinical reports
refer to the use of prednisolone or hydrocortisone, whereas
our studies employed the use of Dex, which has markedly
more potent effects on growth in vivo and in vitro (2, 15).
In contrast to the effects of Dex, IGF-I rapidly stimulated
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linear bone growth by increasing both the size of the hyper¬
trophic zone and the chondrocyte proliferation rate during
the early phase of bone growth. Stimulation of bone growth
by IGF-I has also been reported by Scheven and Hamilton
(18), but they further demonstrated that the stimulation of
cell proliferation in cultured rat metatarsals by IGF-I was not
sustained with IGF-I over time. This may indicate the rapid
use of endogenous growth factors needed to support longi¬
tudinal growth. However, these workers (18) reported GH
stimulatory effects on metatarsal length, which is in contrast
to the data of this present study. Although GH is well rec¬
ognized to stimulate longitudinal bone growth in vivo (28,29)
its effects in vitro are less clear (30, 31). Other studies have
strongly suggested that GH effects in vivo may be indirect
and that IGF-I effects are more pervasive in vitro (32, 33).
To understand the cellular mechanisms underlying the
opposite effects ofDex and IGF-I on bone length we analyzed
the distribution of BrdU-positive cells within metatarsals
treated by both Dex and IGF-I alone and in combination. The
number of dividing cells within the perichondrium was
greatly reduced by Dex at both 4 and 10 d of culture. In
contrast, at 4 d, the number ofBrdU-positive cells was greater
in the perichondrium of IGF-I-treated bones. Stimulation of
cell proliferation was not observed in the IGF-I-treated 10-
TABLE 2. Cell proliferation: effect of Dex, IGF-I, and IGF-I +
Dex on [3H] thymidine uptake at d 4 and 10
Treatment
[3H]thymidine (dpm)
d 4 d 10
Control 98608 ± 6732 75131 ± 5864
Dex 49521 ± 1124° 15000 ± 1612°
IGF-I 140547 ± 9821° 27631 ± 2594°
IGF-I + Dex 154941 ± 3695° 35470 ± 1339°
Data are expressed as mean ± sem.
" P < 0.05 compared with controls.
d-old metatarsals, and this may be due to the observed slow¬
ing of growth in these rapidly growing bones. In 4-d-old
rapidly growing metatarsals, IGF-I completely reversed the
inhibitory effects of Dex on cell proliferation within the peri¬
chondrium and growth plate. This reversal of the negative
effects ofDex by IGF-I coincubation was also observed, albeit
to a lesser extent, in the perichondrial cells of 10-d-old cul¬
tures. These results extend the [3H]thymidine incorporation
data and also confirm the ability of IGF-I to reverse the
deleterious effects of Dex on cell proliferation. Our obser¬
vation that cell proliferation within the perichondrium was
more sensitive to inhibition by Dex and stimulation by IGF-I
than chondrocytes within the growth plate has previously
not been recognized. The perichondrium is vital to the en¬
dochondral process through its role in mediating the para¬
thyroid hormone-related peptide-indian hedgehog (PTHrP-
Ihh) signaling cascade, and it is possible that the marked
Dex-induced inhibition of proliferation within cells of the
perichondrium has a more direct effect on the bone growth
process (34-36). The differential sensitivity of cells to Dex
treatment within the perichondrium and within the growth
plate requires additional study.
A morphometric analysis was completed to further char¬
acterize the response of metatarsals to both Dex and IGF-I
with respect to the size of the individual maturational zones
TABLE 3. Dry weights (microgram) of all bones at d 4 and 10
Treatment
Dry weights (pg)
d 4 d 10
Control 34 ± 3 84 ± 2
Dex 33 ± 2 82 ± 5
IGF-I 48 ± 2° 152 ± 5°
IGF-I + Dex 59 ± 5° 147 ± 2°
Data are expressed as mean ± sem.
" P < 0.05 compared with controls.
















cont Dex IGF IGF-I+Dex
Drug treatment
Fig. 4. Effect ofDex, IGF-I, and IGF-I+Dex on the number ofBrdU-positive cellswithin the growth plate (black bars), the perichondrium (white
bars), and the combined number within the growth plate and perichondrium (hatched bars) at d 4 (A) and d 10 (B). Cell proliferation is higher
at d 4 than d 10 with all treatments. At d 4, Dex causes a significant reduction in cell proliferation in the growth plate and perichondrium (P <
0.05), whereas IGF-I increases the number ofproliferating perichondrial cells (P < 0.05). By d 10, Dex sustains the decrease in cell proliferation,
which is significant in the perichondrium (P < 0.05). Both IGF-I and IGF-I+Dex also cause a decrease in the number of the positive
immunofluorescent cells at this time point. All data are expressed as the mean ± sem; *, P < 0.05 compared with controls.
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within the growth plate. The reduction in length of the min¬
eralization zone with Dex was consistent with metatarsals
treated with hydrocortisone (27). However, the absence of an
increase in the length of this zone after IGF-I is at variance
to others who have demonstrated an increase in mineraliza¬
tion zone length with IGF-I in a rat metatarsal model system
(19). Dex also led to a small, nonsignificant increase in the
length of the hypertrophic zone, which is similar to the find¬
ings of Smink and colleagues (37) who demonstrated an
increase in the hypertrophic zone length in mice treated with
Dex. They further postulated that this was a likely conse¬
quence of an acceleration of the chondrocyte differentiation
rate as observed in PTHrP null mice (34, 37). Alternatively,
due to the restriction of cartilage mineralization, the in¬
creased size of the hypertrophic zone may be in part due to
a simple buildup of nonmineralized hypertrophic chondro¬
cytes. A similar, more pronounced process may explain the
more marked reduction in the mineralization zone observed
in the IGF-I-treated metatarsals.
Within the maturational zones of the growth plate, the
major effects of IGF-I were clearly on the length of the hy¬
pertrophic chondrocyte zone and also the size of the cells
within. This result is in accord with the hypothesis that it is
the size of the hypertrophic zone rather than chondrocyte
proliferative kinetics that is the single major determinant of
bone growth rate (26, 38). Although IGF-I is expressed by
chondrocytes situated in all maturational zones of the
growth plate, IGF-I mRNA expression ismainly restricted to
the hypertrophic zone, and the infusion of IGF-I into hy-
pophysectomized rats showed that IGF-I stimulated growth
plate chondrocytes at all stages of differentiation including
those in the hypertrophic zone (29, 37, 39). The growth re¬
tardation in the IGF-I null mouse is associated with an at¬
tenuation of chondrocyte hypertrophy and no significant
changes in proliferation (40), and our data further strengthen
the hypothesis that the predominant role of IGF-I in growth
promotion is in augmenting chondrocyte hypertrophy rather
than proliferation. This effect of IGF-I can reverse GC-
induced growth retardation, but this apparent ameliorative
effect results in an alteration of the relative proportion of
proliferative, hypertrophic, and mineralized chondrocytes.
The opposite effects of IGF-I and Dex on cell proliferation
and bone growth and the ability of IGF-I to reverse the
growth-inhibitory effects of Dex have not been previously
reported. Its clinical significance is unclear, but an up-
regulation of chondrocytes expressing IGF-I after GC expo¬
sure has been reported previously, and it is possible that
IGF-I is an important local growth factor that counteracts the
effect of GCs at the tissue level (37, 41, 42). Besides GH and
IGF-I, GC exposure may also alter the GH and IGF binding
proteins that modulate tissue exposure to these growth fac¬
tors, and this requires additional study, especially now that
a complex of IGF-I and IGFBP3 is available for treatment of
GH insensitivity (37, 43-45).
In conclusion, we have shown that Dex and IGF-I have
opposite effects on linear bone growth. The effects of Dex
were time dependent, whereas IGF-I effects were immediate.
During the phase of rapid growth, Dex decreased and IGF-I
increased cell proliferation. The alteration in proliferation
rate by both Dex and IGF-I weremostmarked within the cells
of the perichondrium. Dex decreased skeletal mineralization,
whereas IGF-I markedly stimulated chondrocyte hypertro¬
phy in favor ofmineralization and completely reversed Dex-
induced growth retardation. However, the potential for Dex
to inhibit bone growth was still present in the IGF-I+Dex
cultures where growth rates did not match those of bones
cultured with IGF-I alone. In addition, the IGF-I-mediated
improvement in growth was at the expense of altering the
balance between proliferating and hypertrophic chondro¬
cytes within the metatarsal. Alternate-day Dex administra¬
tion did not have a growth-sparing effect, and GH had no
beneficial effect on metatarsal growth at the dose studied.
The fetal mouse metatarsal model can replicate in vivo bone
growth, and this is the first in vitro study to demonstrate the
prohypertrophic effects of IGF-I and reversibility of Dex-
induced growth retardation.
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